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ABSTRACT
Background: Pre-exposure prophylaxis (PrEP) is a daily pill that can reduce a person’s chances
of acquiring HIV. HIV testing and counseling is a critical point during which non-clinical staff
could intervene, discuss and/or refer clients for PrEP. However, not all HIV testing/counseling
staff take part in PrEP implementation in the same way. This study investigated: 1) the
underlying PrEP implementation subgroups of staff who perform HIV testing and 2) PrEP
implementation as a function of key constructs from the Consolidated Framework for
Implementation Research (CFIR).
Methods: This study was a mixed methods concurrent triangulation design, in which qualitative
and quantitative data were collected concurrently and data were triangulated during analysis
and interpretation. Latent Class Analysis (LCA) was performed using MPlus.v.8 on a sample of
150 HIV testing/counseling staff in Florida. The LCA technique groups participants based on
similarities in how they answer a predetermined set of questions (here, five items related to
PrEP-implementation behaviors). The final LCA model and corresponding latent classes were
determined based upon fit indices and theoretical interpretation. Two generalized linear mixed
models were conducted to estimate PrEP implementation as a function of key variables from the
CFIR. A total of 22 interviews were completed and data were analyzed thematically.
Results: A LCA with four models was conducted–containing 1, 2, 3 or 4 classes, respectively.
Based on consideration of fit statistics and theoretical relevance, a 3-class LCA was selected.
Class one (labeled “Universal”; 42%; n=62) includes HIV testing/counselors who were PrEP
advocates; “Universal” participants were likely to talk about PrEP with clients, regardless of
client eligibility, and likely to share physical information about PrEP (e.g. brochures). Class two
vii

(labeled “Eligibility Dependent”; 33%; n=48) includes staff who were most likely to discuss PrEP
if they believed their client met the indications for PrEP. Staff in Class 3 (labeled “Limited”; 25%;
n=37) spoke to clients about PrEP inconsistently. Several variables under the CFIR have a
statistically significant association with PrEP implementation among HIV testing staff, including
race, sexual orientation, relative priority, and available resources. Qualitative data revealed the
importance of available resources, cosmopolitanism, and leadership in PrEP implementation
within community-based HIV testing sites.
Conclusions: Not all HIV testing and counseling staff discuss PrEP with clients. Some staff
differentially discuss PrEP based on eligibility, or inconsistently talk to clients about PrEP.
Understanding implementation subgroups can assist in training and program development.
Furthermore, understanding the factors that could affect PrEP implementation (e.g. availability
of PrEP-related resources) may help organizations to better prepare HIV testing staff to more
seamlessly implement PrEP education and referrals.
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SECTION 1: INTRODUCTION
Statement of Problem
HIV as a Public Health Problem
Recent estimates from the Centers for Disease Control and Prevention (CDC) suggest
that approximately 1.2 million people in the United States are living with HIV (CDC, 2015).
Although the annual number of newly diagnosed HIV cases has declined in the last decade,
there were still nearly 40 thousand people newly diagnosed with HIV in 2014 (CDC, 2015).
These new diagnoses have disproportionately affected Black (44% of new diagnoses) and
Hispanic (23% of new diagnoses) Americans, women (19% of new diagnoses), and gay,
bisexual, and other men who have sex with men (MSM; 67% of new diagnoses) (CDC, 2015).
Florida has particularly alarming rates of HIV – consistently ranking among the top states
for both new HIV infections and cumulative number of people living with HIV (CDC, 2017;
FDOH, 2016a). As with the nation, Blacks and Hispanics, as well MSM, have a higher incidence
and prevalence of HIV in the state than other demographic groups (FDOH, 2018b). Such high
rates of HIV incidence and prevalence make Florida an important location for HIV prevention
work.
Although HIV can now be well controlled by active engagement in care and medication
adherence, it is still an incurable infection with significant consequences to the immune system
(CDC, 2015). Moreover, when left untreated, HIV can progress to Acquired Immune Deficiency
Syndrome (AIDS) – marked by a decreased CD4 count (i.e. under 200 cells/mm) or the
presence of an AIDS-defining opportunistic infection (i.e. an infection such as tuberculosis or
Kaposi sarcoma that takes opportunity of the body’s weakened immune system) (CDC, 2015;
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NIH, 2017). An HIV diagnosis also means taking daily medications for the duration of life –
which can be further complicated by changing insurance policies and social benefits, medication
resistance, and medication side effects (CDC, 2015). Such health effects and the alarming rates
of HIV act to remind us that HIV prevention is still an important public health problem that needs
to be addressed.
The State of HIV Prevention
HIV prevention has long been categorized into structural, social-behavioral, and
biomedical approaches. In a large-scale review, Rotheram-Borus and colleagues (2009) found
that more than 140 interventions were available, and efficacious, in promoting HIV risk-related
behavior change; however, some interventions may only be designed for niche populations or
available within certain regions of the United States. Biomedical prevention methods include the
non-behavioral methods of HIV prevention, such as those directly affecting the biological
transmission of the virus. Until recently, biomedical HIV prevention was largely centered around
prevention of mother to child transmission and treatment as prevention (TasP). Although these
methods have been effective at reducing the incidence of HIV over the past several decades,
more is needed to completely eliminate the spread of the virus.
Pre-exposure Prophylaxis for HIV Prevention
Daily use of emtricitabine/tenofovir disoproxil fumarate (TDF/FTC; often referred to by its
brand name, Truvada®) used for PrEP (henceforth, PrEP) has been introduced as an innovative
way to curb the spread of HIV. This method of HIV prevention includes daily use of antiretroviral
medication by HIV-negative individuals who are at high risk of acquiring HIV (CDC, 2014,
2016d). Researchers tend to agree that combination prevention – including biological, structural,
and socio-behavioral prevention methods – is the key to furthering the success of HIV
prevention (Kippax & Stephenson, 2012; Koblin, Andrasik, & Austin, 2013; McNairy & El-Sadr,
2014; Rotheram-Borus, Swendeman, & Chovnick, 2009; Underhill, Operario, Skeer, Mimiaga, &
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Mayer, 2010). This is because, even with the evolution of efficacious biomedical prevention
options, there exists a social side of prevention – including promoting initiation and adherence to
the biological methods, partner-based communication, and the need for behavioral counseling
or interventions (Rotheram-Borus et al., 2009; Underhill, Operario, Skeer, et al., 2010).
PrEP Efficacy
Pharmacological efficacy studies investigating PrEP have included tenofovir disoproxil
fumarate (referred to as TDF), a combination of tenofovir-emtricitbine (referred to as TDF/FTC);
some studies have also compared these two formulations for the use of PrEP (Jiang et al.,
2014; Spinner et al., 2016). This study refers to TDF/FTC as PrEP and its use as a daily, oral
dose, as this is the formulation currently approved by the Food and Drug Administration (FDA).
Studies of on-demand, or intermittent, PrEP use (PrEP used only immediately before and after a
potential HIV exposure) and other drug formulations used as PrEP are ongoing (Spinner et al.,
2016) and are not yet approved by the United States’ FDA; as such, their implementation is not
directly studied in this dissertation.
PrEP efficacy has varied across studies, with systematic reviews reporting efficacy to be
between 44 to 86%; when adjusted for adherence (and thus, concentration of the drug actually
in the blood), reported efficacy has been higher, varying between 74 to 92% (Spinner et al.,
2016). This has led many governmental agencies to market PrEP as up to 92% effective (CDC,
2016f). Some agencies also refer to 99% efficacy, the highest possible efficacy when PrEP is
taken every day as intended (Anderson et al., 2012).
Through the current dissemination of PrEP (as a daily, oral pill), studies have found that
drug concentrations are greatest in the rectal tissue, followed by blood and vaginal/cervical
tissue (Anderson et al., 2012); and thus, PrEP may have a greater protective effect for anal sex
when compared to vaginal sex. It is also important to note that studies vary in their findings of
PrEP efficacy – with at least one study reporting that PrEP use was not efficacious
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(Marrazzo et al., 2015). These studies, and the researchers’ rationale for low PrEP efficacy, will
be reviewed in the following paragraphs, and have led to important guidelines regarding the
level of adherence needed to achieve the maximum effect of HIV risk reduction (Murnane et al.,
2013). Although a comprehensive literature review can be found in Appendix A, key efficacy
results by risk category are briefly described below.
Efficacy among Men who have Sex with Men and Transgender Women
Perhaps one of the best known and most commonly cited PrEP efficacy trials is the
iPrEx study, which occurred over four continents, enrolling 2499 MSM and transgender women
in a randomized control trial (Grant et al., 2010). This study reported that Truvada reduced the
incident rate of HIV by 44% (Grant et al., 2010). In a secondary data analysis, Anderson et. al.
(2012) reported the rate of risk reduction varied based upon the number of PrEP doses
participants took each week; when PrEP was taken twice a week participants were 76% less
likely to contract HIV, when taken four times a week participants were 96% less likely to contract
HIV, and when taken seven days a week – as recommended – participants were 99% less likely
to contract HIV (Anderson et al., 2012). These researchers also reported that the rate of efficacy
in the iPrex trial would likely have been greater if participant had better rates of adherence.
Efficacy among Heterosexuals and Opposite-Sex Partners
A recent systematic review indicated that several randomized control trials have
investigated PrEP efficacy among heterosexual men and women (Jiang et al., 2014). These
studies included sexually active women, heterosexual couples, and serodiscordant couples
(Jiang et al., 2014). The efficacy achieved across these studies ranged widely, including rates of
65% (high risk women), 62% and 73% (heterosexual discordant couples), 6% (women), and
63% (heterosexual men and women). Some studies have reported lower rates of efficacy for
PrEP. The FEM PrEP study among African women found PrEP to not be efficacious
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(Marrazzo et al., 2015). The study cites low adherence as a possible reason for the findings, but
points to an important need to better understand adherence of PrEP in real-world scenarios.
The Partners PrEP study was a randomized, double-blind, placebo controlled clinical
trial of nearly 5000 serodiscordant heterosexual couples throughout Kenya and Uganda,
examining the use of TDF/FTC and TDF alone as PrEP (Baeten et al., 2012). This study
resulted in such significant efficacy results (overall 67% protection with TDF; 75% efficacy with
TDF/FTC) (Baeten et al., 2012; Donnell et al., 2014) that the placebo arm of the study was
discontinued (Donnell et al., 2014). These protective results were found in both men and
women. In subsequent analyses, Donnell et al. (2014) examined the treatment arm of the study,
comparing the 29 cases in which seroconversion occurred with 196 randomly chosen
participants from those who did not seroconvert. Researchers found that the concentration of
PrEP in the blood of those who did not convert was consistently high; among those who
seroconverted the concentration of PrEP in the blood was only high in 5 of the 29
seroconverters. Thus, in the majority of participants who converted to a positive HIV serostatus,
adherence to PrEP was likely low (Donnell et al., 2014).
Efficacy among Injection Drug Users
There is limited clinical data available assessing the efficacy of PrEP among injection
drug users. Only one clinical trial (a randomized, double-blind, placebo-controlled trial), the
Bangkok Tenofovir Study, assessed the efficacy of PrEP among injection drug users
(Choopanya et al., 2013). The trial was conducted in Thailand among 2413 men and women
who had injected drugs in the past year (Choopanya et al., 2013). Findings resulted in a nearly
50% reduction in HIV incidence; 17 participants (of 1204 in the study arm) and 33 participants
(of 1209 in the control arm) seroconverted during the study. When participants with low (or not
present) levels of PrEP were removed from efficacy analyses, the efficacy in the treatment arm
increased to 73.5%.
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Guidance and Recommendations for PrEP Use
PrEP is supported by a wide array of international and governmental agencies – such as
the WHO (Hodges-Mameletzis, Dalal, Msimanga-Radebe, Rodolph, & Baggaley, 2018; World
Health Organization, 2015) and CDC (CDC, 2014; The White House Office of National AIDS
Policy, 2015; U.S. Public Health Service, 2014, 2015). These agencies are similar in that they
support, or provide suggested guidelines, for PrEP implementation. As in all public health
implementation, guidelines are a great start, but only the beginning of creating systematic
organizational change (Bhattacharyya, Reeves, & Zwarenstein, 2009). It is also important to
note that PrEP is not the right choice for everyone. These guidelines suggest indications for
beginning PrEP, but this is just one option for HIV prevention.
Early guidance from the WHO in 2012 found PrEP clinical trials to be promising, and
encouraged demonstration projects for serodiscordant couples, MSM, and transgender women
– populations with particularly high rates of HIV and with a higher than average chance of being
exposed to HIV (World Health Organization, 2012b). The WHO officially recommended PrEP for
MSM in 2014, following the successful efficacy trials within this population, and expanded this
recommendation to all high risk populations in 2015 following more comprehensive efficacy
trials (World Health Organization, 2015). The WHO recommendations, much like the CDC
recommendations described in the next paragraph, emphasize that PrEP is recommended only
when combined with other prevention methods, such as condom use and behavioral
counseling. PrEP has also been included as an important option within the WHO report
Guidance on couples HIV testing and counselling including antiretroviral therapy for treatment
and prevention in serodiscordant couples: recommendations for a public health approach
(World Health Organization, 2012a).
In 2011, the CDC published interim guidelines for PrEP use (Smith et al., 2011),
followed by comprehensive guidelines recommending the use of PrEP, alongside condom use
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and other prevention methods, for individuals at high risk for acquiring HIV (CDC, 2014; The
White House Office of National AIDS Policy, 2015; U.S. Public Health Service, 2014, 2015).
U.S. Population Meeting PrEP Indications and Using PrEP
Recent data suggest that over one million people in the U.S meet the clinical indications
for PrEP (Smith et al., 2015). This includes nearly 25% of sexually active MSM, 19% of injection
drug users, and 0.5% of heterosexual adults (Smith et al., 2015). However, far fewer adults are
accessing PrEP. Although there is no comprehensive database of PrEP users, estimates
suggest that at least 77,000 (AIDSvu & Emory University Rollins School of Public Health, 2018),
or even upwards of 100,000 (Mera Giler, 2017) people are using PrEP – a number that has
continued to rise since the FDA approval of PrEP in 2012 (AIDSvu & Emory University Rollins
School of Public Health, 2018). In Florida, these rates are estimated to be 32 per every 100,000
people (AIDSvu & Emory University Rollins School of Public Health, 2018). While this is a great
start, PrEP has yet to reach many communities. Available data suggests that those most likely
to be using PrEP are middle and older aged adults who are White and male (Snowden, Chen,
McFarland, & Raymond, 2016). This may be because, although PrEP is now recommended
among a variety of HIV prevention options for at-risk populations (Liu et al., 2014; Mayer et al.,
2013), many individual, structural, and community-level barriers limiting the success of PrEP
initiatives still exist.
Current State of PrEP Research
To date, many aspects of social-behavioral PrEP research have been investigated. Such
studies have examined: client willingness to use PrEP (Goedel, Halkitis, Greene, & Duncan,
2016; Gredig, Uggowitzer, Hassler, Weber, & Niderost, 2016; Grov, Rendina, Whitfield,
Ventuneac, & Parsons, 2016; Hoots, Finlayson, Nerlander, & Paz-Bailey, 2016; Karuga et al.,
2016; Kesler et al., 2016; Kuo et al., 2016; Levy et al., 2017), adherence (Daughtridge,
Conyngham, Ramirez, & Koenig, 2015; Hosek et al., 2013; Marcus et al., 2014; Shrestha &
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Copenhaver, 2018; Tangmunkongvorakul et al., 2013; Underhill, Operario, Skeer, Mimiaga, &
Mayer, 2010; Ware et al., 2012), and stakeholder views of PrEP (Arnold et al., 2012; Brooks et
al., 2011; Newman & Rubincam, 2014; Tellalian, Maznavi, Bredeek, & Hardy, 2013). This
research has yielded several findings important to the field of HIV prevention.
Willingness to Use, and Acceptability of, PrEP
Studies have found that many people who meet the indications for PrEP are willing to
consider using it. In one study of nearly 2,000 people considered possible candidates for PrEP
across seven countries, willingness to use PrEP was found to be at least moderately high
(Eisingerich et al., 2012). Additionally, such willingness has increased with time for many
populations at greatest risk of acquiring HIV (Patrick et al., 2017). However, knowledge of, and
willingness to take, PrEP varies based on demographic and behavioral factors. These factors
will be discussed in greater detail below.
MSM and Transgender Women. The majority of social-behavioral PrEP research has
focused on MSM and transgender women, due to the disparate rates of HIV that occur in these
populations. Knowledge and acceptance of PrEP among MSM and transgender women has
increased over time, as noted in a systematic review of 33 studies conducted between 2008 and
2012 (Young and McDaid, 2014). Since this systematic review was published, similar trends of
increasing knowledge and acceptability of PrEP have been found (Grov, Rendina, Whitfield,
Ventuneac, & Parsons, 2016; Patrick et al., 2017). Of course, gay, bisexual, and other men who
have sex with men, as well as transgender women, are not a homogenous group; neither is
their acceptance and knowledge of PrEP. Studies have noted varied acceptability of PrEP ranging from 28 to 80% among MSM, as stated in a systematic review by Young & McDaid
(2014). Among MSM and transgender women, studies have yielded mixed results regarding the
role demographic characteristics (e.g. race) may have on willingness to take PrEP (Young &
McDaid, 2014). For example, in an analysis based on 2011 data collected in New York City,
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interest in taking PrEP varied significantly based upon race and ethnicity: Latino men expressed
the most interest in PrEP (over 70% interested), followed by Black men (just under 70%
interested), and lastly White men (less than 40% interested) (Mantell et al., 2014). Golub,
Gamarel, Rendina, Surace, and Lelutiu-Weinberger (2013) noted a different trend when
measuring racial differences in the acceptance of PrEP. These findings suggest that men who
were Black and Latino rated the concerns and barriers to PrEP use higher than their White
counterparts. Various other studies have highlighted mixed findings about the role race, and
other demographic characteristics, have in PrEP awareness, acceptance, and knowledge (Metz
et al., 2017). More research is needed to better understand the role demographic characteristics
may have on these factors (Hannaford et al., 2018). Regardless of awareness, acceptance, or
knowledge, as stated earlier, available data suggests White middle and older aged men are the
most likely to be prescribed and taking PrEP (Snowden et al., 2016). This variation in PrEP
uptake by race and ethnicity may further exacerbate the disparities in HIV rates in minority
populations (Galindo et al., 2012; Snowden et al., 2016).
Women and Heterosexual Couples. Lower rates of PrEP awareness among women,
compared to MSM, have been cited throughout the literature (Auerbach, Kinsky, Brown, &
Charles, 2015; Garfinkel, Alexander, McDonald-Mosley, Willie, & Decker, 2016) . Data have
suggested that despite this limited knowledge of PrEP, women in the U.S. may find PrEP an
acceptable and worthwhile intervention after being informed about the risks and benefits of its
use (Auerbach et al., 2015; Flash et al., 2014; Rubtsova, Wingood, Dunkle, Camp, &
DiClemente, 2013; Sales et al., 2018). PrEP also provides another method of safe conception
for serodiscordant couples, sometimes referred to as PrEP-C (Heffron, Pintye, Matthews,
Weber, & Mugo, 2016; Lampe, Smith, Anderson, Edwards, & Nesheim, 2011; Mack, Odhiambo,
Wong, & Agot, 2014; Matthews, Baeten, Celum, & Bangsberg, 2010; Matthews et al., 2014;
Matthews, Smit, Cu-Uvin, & Cohan, 2012; Ngure et al., 2016; Whetham et al., 2014) or
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PrEPception (Auerbach, Kinsky, Brown, & Charles, 2015; Lampe, Smith, Anderson, Edwards, &
Nesheim, 2011; Mmeje, Cohen, & Cohan, 2012).
Injection Drug Users. Compared to other risk groups, limited research has been
conducted on PrEP and injection drug users. This dearth of research was noted in a 2014
review of PrEP implementation among injection drug users, citing limited empirical research on
the topic beyond the initial efficacy trials (Escudero, Lurie, Kerr, Howe, & Marshall, 2014).
Injection drug users are perhaps the population least aware of PrEP. A Washington, D.C. based
study found that out of over 300 participants surveyed in 2012, only 13% had heard of the use
of ARVs to prevent HIV (Kuo et al., 2016). Other studies have also found low rates of
willingness to use PrEP, averaging about 30% (Escudero, Kerr, Wood, et al., 2015).
Demographic characteristics may also play a role in willingness to use and acceptance of PrEP
among people who inject drugs. Page et al. (2015) suggest that women who are injection drug
users are told about, or screened for, PrEP less often than their male counterparts. Additionally,
Des Jarlais et al. (2015) call for a need to address injection drug users who are from minority
groups, as this population is most at risk for HIV transmission via injection drug use.
Facilitators of, and Barriers to, PrEP Use
Common facilitators of and barriers to PrEP use exist across all populations. Reasons
for interest in PrEP have included desires to: protect oneself against HIV, reduce the associated
fears of contracting HIV, and have condomless sex with less fear (Young & McDaid, 2014). The
most salient barrier to PrEP use is cost, or anticipated cost (Auerbach et al., 2015; Falcao et al.,
2016; Flash et al., 2014; Geary & Bukusi, 2014; Kuo et al., 2016). However, several studies of
MSM actively engaged in PrEP care found that medication costs are not a significant barrier to
its continued use (Chan et al., 2016). Awareness of the availability of free or low-cost
medication, as well as access to healthcare and HIV testing, has also been noted as a facilitator
of PrEP use (Golub et al., 2013). Additional concerns noted in the literature have included fear
of the related side effects (Auerbach et al., 2015; Brooks et al., 2011; Falcao et al., 2016; Flash
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et al., 2014; Geary & Bukusi, 2014; Golub et al., 2013; Idoko et al., 2015; Mack et al., 2014;
Mantell et al., 2014; Scholl, 2016; Young & McDaid, 2014) and related stigma associated with
using PrEP (Auerbach et al., 2015; Flash et al., 2014; Geary & Bukusi, 2014; Idoko et al., 2015;
Mack et al., 2014). Concerns related to the pharmacodynamics of PrEP have also emerged in
the literature, including doubts regarding the efficacy of PrEP (Auerbach et al., 2015; Falcao et
al., 2016; Golub et al., 2013) and fear of potential for drug resistance if a person was to acquire
HIV after using PrEP (Golub et al., 2013). Although drug resistance has been noted as a
concern from people meeting the indications for PrEP, research has found that the contribution
of PrEP to drug resistance is low (Dimitrov et al., 2016; Hurt, Eron, & Cohen, 2011; Parikh &
Mellors, 2016; van de Vijver & Boucher, 2010; van de Vijver et al., 2013; Weis et al., 2016). Use
of PrEP by someone who is unknowingly living with HIV is a contributor to this low, but notable,
resistance development (Abbas, Hood, Wetzel, & Mellors, 2011; Parikh & Mellors, 2016).
Barriers and facilitators that are unique to particular risk populations have also been
noted in the literature. For example, men have noted specific concerns with the availability of
PrEP (Brooks et al., 2011; Hannaford et al., 2018; Young & McDaid, 2014) – a concern reaching
beyond cost and related to the concern about who can, or will, prescribe PrEP. This concern
was not noted in other populations, perhaps because other populations are less likely to be
aware of PrEP. Additional unique concerns have emerged from serodiscordant couples. Some
studies have found concerns within serodiscordant partnerships regarding the possible stigma
brought not only to the individual, but to the relationship, due to PrEP use (Idoko et al., 2015;
Mack et al., 2014); for example, PrEP use may “out” the partner living with HIV or cause others
to judge the partner taking PrEP. Additionally, promoting PrEP use within the injection drug use
population comes with a unique set of challenges. Given that some injections drug users are
transient or experience time in jail or prison, adherence may be a particularly important barrier
to regular PrEP use (Martin et al., 2015). Preliminary results have indicated that PrEP
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adherence may differ based on the type of injection drug being used (Martin et al., 2015); thus,
programs may need to be tailored to specific populations within the injection drug use
community. Stakeholders have also noted concerns regarding how PrEP may affect the uptake
of other harm reduction activities, by limiting the conversation about other HIV prevention
strategies for injection drug users- such as rehabilitation or needle exchange programs
(Escudero et al., 2014; Kuo et al., 2016).
Provider Knowledge of PrEP
Provider awareness, knowledge, and prescribing practices regarding PrEP have varied
across specific types of clinical providers. Several studies have found that, compared to doctors
specializing in HIV or infectious diseases, general medical providers were less aware, less
informed, and less likely to prescribe PrEP to their clients (Krakower & Mayer, 2016; Krakower
et al., 2015; Mimiaga, White, Krakower, Biello, & Mayer, 2014). It has been suggested that,
although HIV care providers primarily serve people living with HIV, these providers may be
important in disseminating PrEP to people who are at a high risk of HIV infection with a negative
serostatus - largely because they are already familiar with the medication, side effects, and
speaking openly about HIV with clients. However, HIV care providers may not see many people
not known to be living with HIV, thus limiting their available reach for PrEP dissemination (Pinto,
Berringer, Melendez, & Mmeje, 2018). This juxtaposition of 1) HIV care providers being a wellinformed outlet for PrEP dissemination, yet not seeing clients who would be eligible for PrEP
and 2) primary care doctors seeing clients who might be eligible, but not being comfortable
prescribing PrEP has been coined the “purview paradox” (Pinto et al., 2018). Beyond HIV care
providers, other provider types have also been studied to assess PrEP awareness and
knowledge. A study of over 1000 infectious disease doctors not specializing in HIV found that
while most had heard of PrEP, the majority (91%) had never prescribed it (Karris, Beekmann,
Mehta, Anderson, & Polgreen, 2014). Moderate rates of PrEP knowledge were found in studies
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of generalist in several U.S. based states (Krakower & Mayer, 2012; Krakower, Oldenburg, et
al., 2015; White, Mimiaga, Krakower, & Mayer, 2012). Lower rates of PrEP knowledge have
been reported in military-based healthcare providers (Hakre et al., 2016) and family planning
providers (38% of providers being able to define PrEP) (Seidman, Carlson, Weber, Witt, & Kelly,
2016). Therefore, clients may, or may not, be hearing about PrEP from their doctor, depending
on the provider(s) they see.
Acceptance and awareness of PrEP have appeared to increase in providers since the
release of the CDC PrEP Guidelines in 2014 (Krakower & Mayer, 2016; Smith, Mendoza,
Stryker, & Rose, 2016). However, despite this general increase acceptance and awareness,
there may be differential prescribing practices of PrEP (Adams & Balderson, 2016; Calabrese et
al., 2017; Krakower & Mayer, 2016). For example, some prescribers are more comfortable
addressing PrEP for HIV risk associated with sex than for HIV risk associated with injection drug
use (Adams & Balderson, 2016; Krakower & Mayer, 2016). A 2015 study found that providers
may differentially offer PrEP to clients within certain risk populations, such as prescribing to only
those at highest possible risk for HIV transmission – MSM in serodiscordant partnerships
(Adams & Balderson, 2016; Smith et al., 2015), or have biases in prescription by race – such as
greater willingness to prescribe PrEP to White, compared to Black, patients due to a belief that
Black men would engage in condomless sex if prescribed PrEP (Calabrese, Earnshaw,
Underhill, Hansen, & Dovidio, 2014). Moreover, there are mixed findings regarding if PrEP
awareness and knowledge alone result in increased prescribing practices, with some
researchers finding that PrEP knowledge was associated with a greater likelihood of prescribing
PrEP (Blumenthal et al., 2015) and others noting that PrEP knowledge was unlikely to result in
an increase in prescribing practices (Krakower & Mayer, 2016). Therefore, it is important to
examine other factors that may affect prescribing practices. These findings may also suggest
the importance of promoting PrEP outside of providers’ offices (Smith et al., 2015; Underhill et
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al., 2014; Underhill, Operario, Mimiaga, et al., 2010; Underhill, Operario, Skeer, Mimiaga, &
Mayer, 2010).
Increasing the Reach of PrEP
To best reach the populations in need, researchers have suggested that PrEP
information delivery and referral (i.e. PrEP implementation) should occur in a diverse array of
settings, including emergency room departments, primary care doctors, and infectious disease
specialist sites (Smith et al., 2015; Underhill et al., 2014; Underhill, Operario, Mimiaga, et al.,
2010; Underhill, Operario, Skeer, Mimiaga, & Mayer, 2010); however, not all of these settings
have been extensively explored for PrEP implementation. A notable amount of research has
been conducted within sexually transmitted disease clinics, as well as an array of nongeneralists’ sites. A study of Lesbian-Gay-Bisexual-Transgender (LGBT) clinics in Boston
suggests that PrEP referral and prescription may be higher in LGBT focused settings than in
generalist offices (Krakower, Maloney, Grasso, Melbourne, & Mayer, 2016). Smith et. al. (2016)
conducted a study of 175 community-based organizations (CBOs), both clinical and non-clinical
in nature, and examined the knowledge and infrastructure for PrEP implementation at these
sites. While the organizations were knowledgeable about PrEP, non-clinical CBOs felt illequipped for PrEP, with some indicating they did not know where they would refer a client if the
client was interested in talking to a clinical provider about PrEP (Smith et al., 2016). Participants
indicated that informational materials for clients and a financial resource guide would assist
them in such implementation. Although few non-clinical CBOs in the study were actively
participating in PrEP implementation, these agencies were still interested in being involved via
referral, community education, or interventions (Smith et. al., 2016). There remains a need to
further explore PrEP implementation outside of providers’ offices, specifically in sites accessible
to a variety of at-risk populations. One potentially underutilized time to promote the discussion of
PrEP, and possible referral for a prescriber visit, is during HIV testing.

14

Theoretical Considerations
Theory and HIV Prevention
Theory is important in public health to guide both research and practice. Prestwich et al.
(2014) noted in a meta-analysis that few researchers apply specific theoretical constructs when
evaluating or conceptualizing interventions; instead, they may not use theory at all, or only
mention the theory as a guiding framework. Yet, interventions driven by theory are statistically
more likely than those not driven by theory to have large effect sizes (Prestwich et al., 2014). In
public health, theory is often organized by the levels of Social Ecological Model, noting the
interplay between the different levels: intrapersonal, interpersonal, organizational, community,
and societal (Coreil, 2010). Fishbein (2000) suggests that despite the numerous theories
available, there are a limited number of constructs that truly affect behavior change, among
them: beliefs, skills, intentions, attitudes, norms, and self-efficacy. However, these constructs
are used across a large number of theories, and all of these constructs have been previously
applied within the field of public health.
Theory has long been applied to HIV prevention and care. Many of these theories have
been used to investigate HIV prevention and sexual health behavior change. In 2007, Noar
identified 13 theories that were most commonly used to predict HIV-related behavior change:
Health Belief Model, Theory of Reasoned Action, Theory of Planned Behavior, Integrated
Model, Social Cognitive Theory, Transtheoretical Model, AIDS Risk Reduction Model,
Information Motivation, Behavioral Skills Model, Multiple Domain Model, Extended Parallel
Process Model, Protection Motivation Theory, Theory of Gender and Power, and Precaution
Adoption Process Model. The similarities between many of these theories can often make it
difficult to select a single theory to use. Researchers suggest several steps to select which
theory to apply: examine the aims of the study, relevant literature, inapplicable theories, and
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investigate what theories have been applied to the population being studied in the past (Noar,
2007).
PrEP Implementation and Existing Theories and Frameworks
PrEP is relatively novel to HIV prevention and entered research as a biomedical
innovation. This is likely why much of the available PrEP research is driven by pharmaceutical
and biomedical schemas, rather than theories common in public health research and practice.
Now that the efficacy of PrEP has been well established, social science is bridging the gap to
address behavior change, initiation, adherence, and a number of other behaviorally driven
concepts that must be understood in order for PrEP implementation to be successful.
PrEP implementation is broad - encompassing many aspects of PrEP. Implementation
here consists of factors affecting the initiation and success of PrEP programs, as well as the
barriers and facilitators to running such programs. This study addresses the implementation of
PrEP within HIV testing sites. Of the constructs included in the HIV prevention literature, and
those already applied to PrEP implementation research, two major themes emerge
organizational characteristics relevant to PrEP implementation within HIV testing sites and the
behavior change process among staff performing HIV testing, with regard to PrEP knowledge
and implementation practices.
Some theories have already been applied to the study of PrEP and PrEP
implementation. In a study of nearly 1500 African American and White women, Rubtsova,
Wingood, Dunkle, Camp, and DiClemente (2013) applied the Health Belief Model to examine
participants’ willingness to use PrEP, and possible barriers that may affect PrEP use. The
strength in this theoretical application is the identification of intrapersonal level barriers and
beliefs regarding PrEP, but its weaknesses lie in the lack of consideration regarding the
organizational and contextual factors critical to implementation. Other researchers have applied
theory to the behaviors and prescribing practices of providers. As part of the Adolescent
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Medicine Trials Network, researchers investigated providers’ attitudes toward adolescent PrEP
use (PrEP for adolescents was not yet approved by the FDA at the time of the study) (Mullins et
al., 2015; Mullins, Zimet, Lally, & Kahn, 2016). These researchers used semi-structured
interviews guided by the Theory of Planned Behavior and Diffusions of Innovations, largely
noting the adaptations that providers would make to the adolescent application of PrEP,
compared to how they disseminated PrEP-related information to adults (Mullins et al., 2015;
Mullins, Zimet, Lally, & Kahn, 2016). Through application of these theoretical frameworks,
researchers were able to identify barriers at the client, provider, organizational, and community
levels; however the discussion of organizational and community level barriers were limited and
specific to youth, and may not be experienced by organizations serving adults (Mullins et al.,
2015; Mullins et al., 2016). These findings were further limited because the relationship between
the theoretical constructs,the study results and discussion are not explicitly stated (Mullins et al.,
2015; Mullins et al., 2016). Krakower and Mayer (2016) conducted a systematic review guided
by the Diffusion of Innovations to describe the diffusion of PrEP throughout the healthcare field.
This review focused on identification of early adopters in the implementation of PrEP. Although
the researchers used the Diffusion of Innovations to discuss adopter categories and to
hypothesize the uptake of providers prescribing PrEP, they did not utilize the other variables
within the Diffusion of Innovations, such as attributes of the innovation (including the constructs
of relative advantage, compatibility, complexity, trialability, and observability), communication
channels, the innovation decision process, and the social system (Rogers, 2010). The
theoretical application most relevant to this study is that of Walsh & Petroll (2016). Their
outcome was measured both as prescription, and discussion about PrEP – the latter of which is
most relevant to the role HIV testers could provide in PrEP promotion. These researchers
applied the Information-Motivation-Behavioral Skills Model to examining the factors affecting
PrEP implementation among primary care providers. Among providers in 10 major U.S. cities,
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they found that knowledge and motivation could predict providers’ discussion and prescription of
PrEP; and that these factors were mediated by the self-perceived level of skill that the provider
has to discuss and prescribe PrEP (Walsh & Petroll, 2016). Other studies, although not explicitly
using a theory, have relied on terminology reminiscent of theoretical constructs. For example,
Krakower, Oldenburg, et al. (2015) describe their PrEP related survey items as covering
“awareness, knowledge of normative guidance, prescribing practices and intentions, and
perceived barriers to providing PrEP” (p. 4), which could be perceived as some of the constructs
within the Theory of Planned Behavior and Health Belief Model, but the researchers do not
describe the relationships between these constructs.
Implementation, Organizational, and Community Theories and Frameworks Applied to
PrEP
Theories addressing organizational, community, and societal factors may have an
important role in PrEP implementation, but to date are only briefly mentioned in the literature
and used in the research. These factors include the organizational readiness to adopt such an
innovation, community acceptance of PrEP, related health communication campaigns, and
policies. Jaspal and Nerlich (2016) applied Social Representation Theory to address the hope
and risk that PrEP represents in the media, particularly when advertised to MSM. Social
Representation Theory posits that people create schemas for new, unfamiliar, ideas; these
schemas then affect how ideas are perceived by others; in short, societal views of new ideas
can either make the ideas more concrete or dichotomize them to create conflicting sides of an
issue (Jaspal & Nerlich, 2016; Rateau, Moliner, Guimelli, & Abric, 2011). Social Representation
Theory was used to guide data collection and analyses, but the study was also specific to the
United Kingdom culture in which the study took place, and its application was not relevant to
barriers occurring within organizations or during HIV testing (Jaspal & Nerlich, 2016).
Similarly, Spieldenner (2016) examined social representation of PrEP use among MSM by
applying Queer Theory and Quare Theory to examine the operationalization of the term “PrEP
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Whore,” which has been used in the MSM community to describe men using PrEP. This
stereotype stigmatizes men who took PrEP as overtly sexual and only engaging in condomless
sex; however, more recently, the term has turned into a term of empowerment emphasizing that
PrEP enables sexual expression (Spieldenner, 2016). A few researchers have also applied
social justice theories to PrEP research. Researchers have used the Public Health Stewardship
Framework (which includes both public health and equity outcomes) to examine the ethical
issues in providing ARV medication for PrEP and TasP (Haire & Kaldor, 2013).
The application of a specific implementation theory (beyond the Diffusion of Innovations,
which can be applied at both the organizational and intrapersonal levels of the Social Ecological
Model) is a missing component in the literature. Specifically, no studies have used theory to
investigate real world implementation or to identify the organizational characteristics necessary
for successful PrEP implementation within publicly funded HIV testing sites. Although the need
to study PrEP through an implementation lens is clear, there is still an entire field of theories,
models, and frameworks from which to choose. Several researchers have attempted to provide
guidance on selecting the most appropriate implementation framework to use in a given
scenario (Hanson, Self-Brown, Rostad, & Jackson, 2016; Nilsen, 2015; Tabak, Khoong,
Chambers, & Brownson, 2012). Nilsen (2015) describes five types of models, frameworks, or
theories that could address the various phases of implementation research, including process
models, determinant frameworks, classic theories, implementation theories, and evaluation
frameworks. Both process models and evaluation frameworks have a temporal significance, and
are most appropriately applied at the onset (process models) or conclusion (evaluation
frameworks) of a particular phase of implementation (Nilsen, 2015). The remaining theory types
(determinant frameworks, classic theories, implementation theories) are collectively used to
describe the factors that may affect implementation. Implementation theories are those newly
developed by implementation researchers, while classic theories are applications of more
established theories – such as Social Cognitive Theory or the Information Motivation Behavioral
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Change Model – applied to implementation. While both provide a foundation for the study of
implementation, the former (implementation theories) are novel and often lack well defined
constructs. On the other hand, classic theories often lack the ecological perspective needed for
implementation in an organizational setting. Nilsen (2015) describes determinant frameworks
as:
Types (also known as classes or domains) of determinants and individual determinants,
which act as barriers and enablers (independent variables) that influence implementation
outcomes (dependent variables). Some frameworks also specify relationships between
some types of determinants. The overarching aim is to understand and/or explain
influences on implementation outcomes, e.g. predicting outcomes or interpreting
outcomes retrospectively (Table 1).
Hanson et al. (2016) typifies implementation theories differently, and perhaps more broadly, as:
stages of implementation frameworks; consolidation and core component frameworks;
organizational support frameworks; and planning frameworks. Stage frameworks and planning
frameworks are often temporal in nature and may be best suited for studies that investigate the
entire range of the diffusion, dissemination, and implementation spectrum (e.g. EPIS).
Consolidation and core component frameworks may address a broad range of determinants and
factors affecting implementation, as derived from prior implementation science theories, models,
and frameworks; however, this classification also includes frameworks designed for evaluation
(e.g. REAIM). Furthermore, Tabak et al. (2012) explain that while some theories, models, and
frameworks can be applied across the dissemination to implementation spectrum, others are
best suited for a specific phase of the process (i.e. dissemination only or implementation only).
These researchers suggest that additional consideration in model selection should include
which level(s) of the Socioecological Model the study intends on examining; the development or
flexibility of the model constructs; and the field from which the study originates.

20

The Consolidated Framework for Implementation Research (CFIR) is a synthesis of
nearly 20 implementation theories and frameworks (Damschroder et al., 2009). CFIR guides the
study of real-world implementation by providing a framework and underlying constructs that
commonly affect implementation. CFIR could be classified as a determinant framework (Nilsen,
2015) and consolidation and core component framework (Hanson et al., 2016) – which are
thought to be helpful when examining the facilitators and barriers to an implementation
outcome. The framework addresses the implementation phase of the diffusion-disseminationimplementation spectrum – such as the PrEP implementation outcomes occurring within HIV
testing sites. The CFIR has five overarching domains: Intervention Characteristics, Inner
Setting, Outer Setting, Characteristics of Individuals, and Process (Damschroder et al., 2009) –
each containing constructs found in the literature to influence implementation in other settings
(i.e. settings which are not specifically HIV testing sites). A full description of the rationale for the
use of CFIR domains and constructs can be found in Appendix C and below under Application
of CFIR to HIV Prevention.
Review of CFIR
CFIR has been described as a meta-theory drawing upon many constructs within the
field of implementation science (Damschroder et al., 2009). The framework is comprised of five
overarching domains: Intervention Characteristics, Inner Setting, Outer Setting, Characteristics
of Individuals, and Process of implementation – each with its own associated constructs (see
Table 1.1).
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Table 1.1. Domains and constructs of the Consolidated Framework for Implementation
Research (CFIR; Damschroder, 2009)
Domain
Constructs
Intervention
Characteristics

Inner Setting

Outer Setting

Characteristics of
Individuals
Process

Intervention Source; Evidence Strength and Quality; Relative
Advantage; Complexity; Design Quality and Packaging; Cost;
Structural Characteristics; Networks and Communications; Culture;
Implementation Climate (Tension for Change; Compatibility; Relative
Priority; Organizational Incentives and Rewards; Goals and Feedback;
Learning Climate); Readiness for Implementation (Leadership
Engagement; Available Resources; Access to Knowledge and
Information)
Needs and Resources of Those Served by the Organization;
Cosmopolitanism; Peer Pressure; External Policy and Incentives
Knowledge and Beliefs about the Intervention; Self-efficacy; Individual
State of Change; Individual Identification with Organization; Other
personal attributes
Planning; Engaging (Opinion Leaders; Formally Appointed Internal
Implementation Leaders; Champions; External Change Agents; Key
Stakeholders; Intervention Participants); Executing; Reflecting and
Evaluating

CFIR aligns well with measures of theoretical evaluation. The framework is clear and,
although it contains a large number of domains and constructs, was created with the intention of
providing a succinct framework for implementation research. Strengths of the framework include
its application to implementation science and the synthesis of preexisted constructs which have
already been defined. Clarity of precision is measured by the conceptual and operational
development of the framework (Goodson, 2010). Conceptually, CFIR was developed to provide
a concise framework for implementation research (Damschroder et al., 2009). The constructs
were drawn from implementation theories that provide a foundation for their use and
development. The development of operationalization of CFIR is ongoing in the literature
(Damschroder, 2016). The CFIR technical assistance team (Damschroder, 2016) has created a
qualitative interview guide template, touching on the specific constructs of each CFIR domain.
Quantitative measurement is less developed, although many CFIR constructs have been
mapped to Organizational Readiness for Change Assessment (ORCA) for measurement
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purposes (Helfrich, Li, Sharp, & Sales, 2009). Although the development of additional CFIR
quantitative measures is considered ongoing (Damschroder, 2016; Liang et al., 2015),
researchers have not defined relationships between constructs. This weakness is
acknowledged by Damschroder (2016). However, the researchers also suggest that domains
and constructs of the framework can be used in part or whole as appropriate, suggesting there
may not be a need for defined ties between measures. Testability measures the ability and ease
of which replication of the theoretical application can be tested (Goodson, 2010). The degree to
which the framework can be consistently tested across studies is strongly related to the
operationality of its constructs. As the constructs are further operationalized, so will the
framework’s ability to be tested. Abstraction level and explanatory power are two inter-related
constructs that describe the applicability of the theory to a variety of phenomenon,
circumstances, and populations (Goodson, 2010). Due to the nature of the framework, rooted in
implementation, it is applicable to the implementation of a variety of phenomenon. Similarly, the
framework is meant to take context into account, making it applicable to a variety of situations
and populations. Parsimony describes the degree to which the framework simply explains its
constructs and theoretical basis (Goodson, 2010). Perhaps due to the complexity of
implementation, the framework contains numerous domains and constructs, making it lack
parsimony in the strictest sense. However, the framework was rooted in the need to synthesize
existing constructs and provide common terminology. This may suggest that compared to other
implementation science frameworks and theories, CFIR could be considered parsimonious.
Formal development of a theory is described as how well a theory has been articulated and
tested in its application (Goodson, 2010). In the case of CFIR, the framework was developed in
2009 and is relatively novel (Damschroder et al., 2009). The heuristic value of the framework is
rooted in its ability to generate additional research (Goodson, 2010). CFIR is meant to be
applied to implementation research and, as such, may develop and improve new ways to
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implement programs (in this case discussing PrEP during HIV testing). It may also help to refine
new research and assist in determining the best way to implement intervention programs in the
real world, as well as the best way to assess potential implementation challenges and
strategies.
Theoretical Application
Application of CFIR to HIV Prevention
Little is known about the context of PrEP implementation specifically during HIV testing.
To investigate this unique setting for PrEP implementation, the CFIR will be used, including the
domains: Intervention Characteristics, Inner Setting, Outer Setting, Characteristics of
Individuals, and Process; these domains and constructs can be viewed in full in Table 1.1.
Because PrEP is relatively novel compared to other HIV prevention methods, little is known
regarding how the characteristics of PrEP (CFIR domain Intervention Characteristics) may affect
its institutionalization. Additionally, PrEP is rooted in a history of biomedical development, which
has the potential to lend itself to distrust if not marketed successfully. Characteristics of the
organizations providing HIV testing (CFIR domain Inner Setting) and the political climate
surrounding HIV prevention (CFIR domain Outer Setting) may also be critical to real world PrEP
implementation. Characteristics of the Individuals performing HIV testing, such as their age,
understanding of PrEP, and personal values may also cause variation in PrEP implementation.
Although guidelines to determine clinical indications of PrEP now exist, provider views may still
be biased. Furthermore, although external PrEP guidelines have been developed by the CDC,
internal policies may not have been developed at community clinics or AIDS Service
Organizations (ASOs) involved in performing HIV testing. Information is needed regarding the
factors that affect PrEP implementation, as well as the perceived barriers to, and facilitators of,
PrEP implementation in this setting. Such information will assist in planning the rollout of PrEP
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implementation in HIV testing locations, and in overcoming obstacles to providing access to HIV
prevention via PrEP.
Although the strengths outweigh the weaknesses, there are some weaknesses of
utilizing the CFIR as the guiding framework for this study. The theory focuses on specific
constructs, but not the relationship between these constructs; this also limits the ability for the
theory to be empirically tested (Damschroder et al., 2009). Additionally, CFIR is a framework
and not an explicit theory, limiting the explanatory nature of the constructs (Nilsen, 2015).
However, relationships between the domains and constructs may not be necessary in this
study, as this is one of the first studies to investigate the facilitators and barriers specific to the
staff providing HIV testing. Preliminary information, as collected in a study such as this, may be
needed before relationships are drawn between the variables to better understand the state of
PrEP implementation within HIV testing sites.
Aims and Research Questions
There is a paucity of research regarding the specific role staff who perform HIV testing
may have in PrEP implementation. Existing studies have only utilized HIV testing sites for
recruitment of clients who may be eligible for PrEP (Flash et al., 2018; Gallagher et al., 2014;
King, et al. 2014), and have not focused on the role that staff performing HIV tests have in PrEP
implementation. Publicly funded HIV testing sites are an ideal location for PrEP implementation
because these sites often provide services free of charge, regardless of if a person has health
insurance - unlike many other health care services. Additionally, such locations routinely collect
information on sexual risk behavior during the testing process, and may provide an easy outlet
for PrEP implementation. A study of providers who were early adopters of PrEP (in this study
identified by peer referral for working in PrEP implementation during 2014 to 2015) found that
support staff were an important part of PrEP implementation – citing their ability to educate,
counsel, and assist with financial resources (Calabrese et al., 2016). Staff performing HIV
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testing could be one group of support staff to bridge the gap between PrEP information delivery
and clinical prescription. Additionally, researchers examining practice viewpoints of PrEP
implementation also suggested the possibility of providing PrEP linkages during HIV testing
campaigns (Jay & Gostin, 2012; King et al., 2014; Mayer, Grinsztejn, & El-Sadr, 2016).
CFIR provides unique insight into the implementation of PrEP. Although provider and
client views have been examined in research, there are few studies that examine the
implementation of PrEP with a theoretical basis (Krakower, Beekmann, Polgreen, & Mayer,
2016; Mullins, Lally, Zimet, & Kahn, 2015; Mullins, Zimet, Lally, & Kahn, 2016; Rubtsova et al.,
2013; Walsh & Petroll, 2016). Unlike other theories used in the literature thus far, CFIR focuses
specifically on implementation and the context in which it occurs.
To address this paucity, this study explores the facilitators of and barriers to PrEP
implementation via community-based publicly funded HIV testing sites in Florida, as well as key
characteristics associated with implementing PrEP within this setting. To do this the following
aim and research questions were explored:
Study Aim: Describe the context of PrEP implementation/non-implementation in organizations
providing HIV testing in Florida.
Research Question #1: What, if any, PrEP implementation subgroups exist among staff
providing HIV testing in Florida?
Research Question #2: What characteristics of the individual are associated with PrEP
implementation during HIV testing, as guided by the constructs of CFIR?
Research Question #3: What inner and outer setting factors are associated with PrEP
implementation during HIV testing, as guided by the constructs of CFIR?
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Table 1.2. Research Questions, Hypotheses, and Related Analyses
Research Question
Hypotheses
Research question 1:
Within the population of HIV testing staff,
What, if any, PrEP
subpopulations exist based on PrEP
implementation subgroups Implementation behaviors.
exist among staff providing
HIV testing in Florida?

Research question 2:
What characteristics of the
individual are associated
with PrEP implementation
during HIV testing, as
guided by the domain of
CFIR (i.e. characteristics
of the individual)?

Research question 3:
What inner and outer
setting factors are
associated with PrEP
implementation during HIV
testing, as guided by the
domains of CFIR?

High levels of PrEP knowledge, PrEPrelated self-efficacy, prior/current PrEP
use, and positive personal PrEP
motivations and beliefs will be associated
with high levels of PrEP implementation,
when controlling for key organizational
factors. Low levels of PrEP knowledge,
PrEP-related self-efficacy, and negative
personal PrEP motivations and beliefs will
be associated with low levels of PrEP
implementation when controlling for key
organizational factors.
A belief that clients need the option for
PrEP (patient needs and resources),
cosmopolitanism; pro-PrEP internal policy
and incentives, structural characteristics,
networks and communications, culture,
tension for change, compatibility, relative
priority; a positive learning climate; and
PrEP-related available resources, and
access to knowledge and information will
be positively associated with high levels of
PrEP implementation; while a belief that
clients do not have a need for the option of
PrEP (patient needs and resources);
limited cosmopolitanism; anti-PrEP internal
policy and incentives, structural
characteristics, networks and
communications, culture, tension for
change, compatibility, relative priority; a
negative learning climate; and a lack of
PrEP-related available resources, and
access to knowledge and information will
be negatively associated with high levels
of PrEP implementation.
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Related Analyses
Descriptive
Statistics
Latent Class
Analysis
Thematic Analysis
Descriptive
Statistics
Generalized Linear
Mixed Model
[Distribution:
Multinomial; Logit
Link]
Thematic Analysis

Descriptive
Statistics
Generalized Linear
Mixed Model
[Distribution:
Multinomial; Logit
Link]
Thematic Analysis

Overview of Study Design
This study utilized a mixed methods concurrent triangulation design (Creswell, 2013), in
which the qualitative data and quantitative data were collected concurrently to fully understand
the study aim, to describe the context of PrEP implementation/non-implementation in
organizations providing HIV testing in Florida. A concurrent strategy was used for both feasibility
and to allow concurrent data interpretation. This approach included the advantages of both
qualitative and quantitative methods – providing a holistic view of PrEP implementation during
HIV testing. Collecting both qualitative and quantitative data was particularly important in this
study because PrEP implementation research is relatively novel compared to other HIV
prevention methods; thus, the literature providing insight to interpret the findings is limited.
This study consisted of a quantitative assessment with staff who provide publicly funded,
community-based, HIV testing in Florida. The quantitative assessment was used to determine
the most common facilitators of, and barriers to, PrEP implementation, as well as the factors
associated with PrEP implementation during HIV testing. The quantitative assessment utilized
the CFIR domains of Intervention Characteristics, Inner Setting, Outer Setting, and
Characteristics of Individuals. Semi-structured qualitative interviews were used to further
describe the most salient implementation constructs, focusing on the facilitators of, and barriers
to, PrEP implementation within each CFIR domain. The results were examined through an
integrated analysis.
Dissertation Format
The following dissertation is written in a manuscript format. The following sections are included:
Section 1: This section contains an introduction to the dissertation and the theoretical
underpinnings of the research. A brief overview of the study methodology is also included.
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Section 2: This section consists of Manuscript 1, “I'm obligated as somebody who's doing HIV
prevention and testing to talk to somebody about this”: A latent class analysis identifying the
underlying PrEP implementation behaviors of staff performing HIV testing in community-based
HIV testing sites in Florida. The primary research question addressed in this manuscript is:
Research question 1: What, if any, PrEP implementation subgroups exist among staff providing
HIV testing in Florida?
Section 3: This section consists of Manuscript 2, “It's sort of all falling into place … before I felt
like educating people about PrEP was like talking about the tooth fairy”: A mixed methods study
examining the intrapersonal, organizational and external factors affecting PrEP implementation
within community-based HIV testing sites in Florida. This manuscript answers two research
questions: 1) What characteristics of the individual are associated with PrEP implementation
during HIV testing, as guided by the construct of CFIR (Characteristics of the Individual)? and 2)
What inner and outer setting factors are associated with PrEP implementation during HIV
testing, as guided by the constructs of CFIR?
Section 4: This section consists of additional analyses not directly related to the research
questions presented, but rather the larger context of PrEP implementation within HIV testing
sites.
Section 5: This section consists of an overarching discussion, conclusion, and public health
implications of the research presented.
To assist in ease of reading, a list of acronyms and terms used throughout the dissertation are
included in Table 1.3 below.
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Table 1.3 List of Acronyms and Terms
AIDS
ARV
ASO
CBO
CDC
CFIR
FDA
FLDOH
HIV
LGBT

Acquired Immune Deficiency Syndrome
Antiretroviral Medication
AIDS Service Organization
Community-based Organization
Centers for Disease Control and Prevention
Consolidated Framework for Implementation Research
Food and Drug Administration
Florida Department of Health
Human Immunodeficiency Virus
Lesbian-Gay-Bisexual-Transgender

MOU

NIH

Memorandum of Understanding
Men who have sex with men; In the HIV literature this term
encompasses gay, bisexual, and other men who have sex
with men
National Institutes of Health

NNT

Number need to treat

ORCA

Organizational Readiness for Change Assessment
Promoting Action on Research Implementation in Health
Services Framework
Post-exposure prophylaxis; PEP is a 28 day medication that
can be started within 72 hours after HIV exposure to prevent
HIV
Pre-exposure Prophylaxis; The proposed study refers to
combination TDF/FTC (either Truvada® or generic
formulation) as PrEP, and its use as a daily, oral dose, as
this is the prescription currently approved by the Food and
Drug Administration (FDA)
Sexually transmitted infection

MSM

PARHIS
PEP

PrEP

STI
TasP

Treatment as Prevention; A method by which people living
with HIV are on medication and become virally suppressed,
resulting in a substantially decreased likelihood of HIV
transmission

TGW

emtricitabine/ tenofovir disoproxil fumarate – the formulation
of the medication used for PrEP
A brand name medication used in the treatment and
prevention of Human Immunodeficiency Virus; composed of
the formulation Tenofovir/ Emtricitabine Disoproxil Fumarate
Transgender women

U.S.
WHO

United States
World Health Organization

TDF/FTC
Truvada
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SECTION 2: “I'M OBLIGATED AS SOMEBODY WHO'S DOING HIV PREVENTION AND
TESTING TO TALK TO SOMEBODY ABOUT THIS”: A LATENT CLASS ANALYSIS
IDENTIFYING THE UNDERLYING PREP IMPLEMENTATION BEHAVIORS OF STAFF
PERFORMING HIV TESTING IN COMMUNITY-BASED HIV TESTING SITES IN FLORIDA
Introduction
Pre-exposure prophylaxis (PrEP) has been approved by the Food and Drug
Administration (FDA) , and is recommended by the Centers for Disease Control and Prevention
(CDC) (CDC, 2014; The White House Office of National AIDS Policy, 2015; U.S. Public Health
Service, 2014, 2015) and World Health Organization (WHO) (World Health Organization, 2012b,
2015) as one method to assist in the prevention of HIV. By taking a daily pill of Tenofovir/
Emtricitabine Disoproxil Fumarate (often referred to by the brand name, Truvada ®), a person
can reduce his or her risk of HIV by up to 92% (CDC, 2016f; Spinner et al., 2016). Despite the
development and recommended use of this prevention method for at risk populations, many
people are still unaware of PrEP (Chapman Lambert, Marrazzo, Amico, Mugavero, & Elopre,
2018; Eaton et al., 2017; Garnett et al., 2018; Walters, Reilly, Neaigus, & Braunstein, 2017).
In the complicated United States healthcare system, it is unclear who is responsible for
ensuring patients are informed about HIV prevention and PrEP. Partnering with medical
providers may be a natural first step to disseminate information related to PrEP. Acceptance
and awareness of PrEP has appeared to increase in medical providers since the release of the
CDC PrEP Guidelines in 2014, but many providers are still unaware of PrEP (Krakower &
Mayer, 2016; Smith, Mendoza, Stryker, & Rose, 2016). Additionally, factors beyond awareness
affect whether medical providers talk to their clients about, or prescribe, PrEP. Studies have
found that some medical providers may differentially discuss PrEP based on how at-risk they
perceive their patient to be (Adams & Balderson, 2016; Calabrese et al., 2014; Krakower &
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Mayer, 2016). Additional research has shown that providers may not be fully aware of their
patients’ sexual histories or behaviors (Krakower & Mayer, 2012; Thrun, 2013). For instance,
studies among MSM have found that some men may not be “out” to their provider (i.e.
voluntarily open with their provider about their sexual orientation) (Arrington-Sanders et al.,
2016; Mehta et al., 2011). This is particularly important because some findings have suggested
that being “out” to a provider about sexual orientation is associated with awareness of PrEP
(Raifman, Flynn, & German, 2016; Watson, Fish, Allen, & Eaton, 2018). Patients not being “out”
to their providers about their sexual orientation may further complicate PrEP implementation
because providers may not be aware of the HIV-related risk behaviors in which these patients
engage. Therefore, providers may not adequately assess which patients would most benefit
from PrEP and may not provide adequate counseling. Given these shortcomings, locations
outside of providers’ offices must also be utilized to increase knowledge and awareness of PrEP
(Mayer, Chan, R, Flash, & Krakower, 2018; Smith, Dearing, Sanchez, & Goldschmidt, 2013;
Underhill et al., 2014; Underhill, Operario, Mimiaga, Skeer, & Mayer, 2010; Underhill, Operario,
Skeer, et al., 2010).
Although it is clear a multi-faceted approach is needed to successfully implement PrEP
(Mayer et al., 2018; Smith et al., 2013; Underhill et al., 2014; Underhill, Operario, Mimiaga, et
al., 2010; Underhill, Operario, Skeer, et al., 2010), locations outside of traditional medical
provider offices have been underexplored. Alternative locations such as community-based
organizations, pharmacies, and clinics specializing in treating sexually transmitted infections
have been suggested as possible locations to expand PrEP implementation. Depending on the
location and clinical availability, these sites could participate in at least one or more of the
following: education, counseling, referral, or screening for a possible prescription (Mayer et al.,
2018; Mayer et al., 2016; Smith et al., 2013; Underhill et al., 2014; Underhill, Operario, Mimiaga,
et al., 2010; Underhill, Operario, Skeer, et al., 2010). Moreover, studies investigating the role of
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non-clinical staff in PrEP implementation have found that such staff may be important to
education and counseling efforts (Calabrese et al., 2016; Smith et. al., 2016), as well as
navigating the available resources for PrEP-related financial assistance (Calabrese et al., 2016).
A recent systematic review even suggested the need to study the integration of PrEP education
into routine HIV testing procedures (Mayer et al., 2018). However, the perspectives of staff
performing HIV testing have not yet been studied.
Counseling during the HIV testing process could be a critical point during which nonclinical staff could intervene and discuss PrEP as an option for HIV prevention, or refer people
to organizations providing PrEP, (Mayer et al., 2018). HIV testing sites are focused on serving
people who are uninfected, or do not yet know they are living with HIV. Staff at such sites
already ask sensitive questions about sexual risk behavior during pre-test counseling. For
example, in Florida, the DH1628 Laboratory Request Form completed with each publicly funded
HIV test requires that counselors ask clients about risk factors, including both sexual risk factors
and risks associated with injection drug use (FDOH, 2012). Yet, little is known about the specific
factors affecting PrEP implementation (i.e. discussing PrEP or referring clients to an
organization providing PrEP) during the HIV testing process.
It is likely that many HIV testing staff discuss PrEP with their clients, but such staff may
not discuss PrEP in the same way, and some staff may not include PrEP in their counseling
discussion. Building on prior research examining the role of non-clinical staff in PrEP
implementation (Calabrese et al., 2016; Smith et. al., 2016), this study investigates the role that
staff performing HIV testing have in PrEP implementation, answering the research question:
What, if any, PrEP implementation subgroups exist among staff providing HIV testing in Florida?
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Methods
Study Design
This study utilized a mixed methods concurrent triangulation design (Creswell, 2013) to
investigate the unobserved subgroups of staff who provide HIV testing in Florida, and how these
characteristics impact the role of staff in PrEP implementation. In this study, PrEP
implementation is described as the degree to which PrEP is discussed and/or a referral to a
prescriber occurs during HIV testing. Data were collected and analyzed concurrently and
triangulated during data analysis and interpretation. The study was approved by the Institutional
Review Board of the University of South Florida (Appendix G). A waiver of written informed
consent was received and participants provided informed consent within the electronically
delivered survey.
Data collection
Participants were recruited via email to complete an online assessment administered
through Qualtrics that lasted approximately 15-20 minutes. Contact information for publicly
funded HIV testing sites in Florida is freely available on the Internet. Each community-based
(i.e. not located within the department of health) publicly funded testing site was contacted via
email with a request to share the survey with staff who perform HIV testing and counseling.
Unsuccessful attempts and requests for no further contact were logged daily. Organizations
were contacted up to four times (i.e. a pre-notice, followed by up to 3 additional contacts that
include the survey link) (Dillman, 2011). At the end of the quantitative assessment, participants
were asked if they would like to enter a raffle for one of three $50 gift cards, and if they would be
willing to be contacted for the qualitative portion (i.e. in-depth interviews) of the study. Interview
participants were selected from those who indicated interest by quota sampling to ensure
inclusion of participants with a diverse range of PrEP implementation experiences. Participants
who took part in the qualitative interview received a $20 gift card.
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Measures
The study outcome was PrEP implementation, with PrEP implementation categories
determined by a Latent Class Analysis (LCA). The LCA was based upon how clients answered
a pre-determined set of questions regarding multifaceted PrEP implementation, with specific
questions to follow: Overall, how often do you talk to clients about PrEP when testing/counseling
for HIV?;I talk to clients about PrEP every time I test for HIV; I talk to clients about PrEP when I
think they might be eligible (meet the indications to start taking PrEP); I give physical
information about PrEP (such as pamphlets, flyers, and written contact information for PrEP
friendly providers) to clients during HIV testing/counseling; Overall, how often do you give
clients physical information about PrEP (such as pamphlets, flyers, and written contact
information for PrEP friendly providers) during HIV testing/counseling? All items were
categorical in nature and measured in a 5-point scale (see Table 2.3 in results). The in-depth
interview guide was based on CFIR guidance provided on the CFIR technical assistance
website (Damschroder, 2016). [A full list of quantitative and qualitative items can be found in
Appendices C and E.]
Sample Size
A total of 150 participants from 48 organizations were included in quantitative analysis.
The qualitative sample size was based on thematic saturation, when no new themes emerge
from the data (Guest, Bunce, & Johnson, 2006). Saturation was reached at 22 participants.
Data analysis
Quantitative data were exported from Qualtrics (Qualtrics, 2017) into SPSS v.24 (SPSS,
2011). Data were cleaned and examined for suspicious and repeat responses. Forty-nine
participants were excluded from analysis: 12 did not meet inclusion criteria, thus were unable to
continue on to the survey and an additional 18 did not proceed past the consent. Nineteen
participants completed between 34-55% of the survey. These participants had not yet
completed demographic questions, so it was not possible to compare their demographic
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information to those who completed the survey in its entirety. However, when comparing key
variables (e.g. existence/non-existence of a PrEP policy), these participants did not appear to
be drastically different than the analytic sample. Additionally, 21 IP addresses were listed more
than once. This was expected based upon internet configuration, as some organizations may
have a shared IP address between their employees. These responses were determined to be
from unique participants based upon investigation into survey answers and demographic
characteristics. Additionally, no names, phone numbers, or emails of participants who entered
the gift card raffle, or agreed to future contact, were duplicated. Descriptive statistics of the
remaining analytic sample were conducted.
Latent Class Analysis (LCA) (Heck, Thomas, & Tabata, 2013; McCutcheon, 1987) was
used to determine PrEP implementation groups. The LCA was performed using MPlus v.8
(Muthén & Muthén, 2015). All other analyses were performed using SPSS v.24 (SPSS, 2011).
The LCA technique groups participants based on similarities in how they answer a
predetermined set of questions. Five items were included in the LCA (full items depicted in table
2.3 under “results”), asking participants to rank the degree to which they participated in a
number of dissemination activities related to PrEP. These activities included referring clients to
a place where they could learn more about PrEP and/or providing clients with resources about
PrEP. All items were categorical and were each measured on a 5-point scale. The final LCA
model and corresponding latent classes were determined based upon fit indices (BIC [Bayesian
Information Criterion] and LMR [Lo-Mendell-Ruben]) and theoretical interpretation (Nylund,
Asparouhov, & Muthén, 2007). In interpreting BIC, the lower the score the better fit of the model.
For LMR, it is suggested that researchers find the model which produces a non-significant LMR
value, and use one less class (k-1) (Nylund et al., 2007). Theoretical interpretation (i.e.
consideration of how participants responded to the items in the LCA, as they relate to the
existing literature) was also considered (Nylund et al., 2007).
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Qualitative interviews were transcribed, verified by the primary author to ensure correct
transcription, imported into MaxQDA (Kuckartz, 2007) and analyzed thematically (Guest,
MacQueen, & Namey, 2011). The primary author segmented all transcripts based on topic. An
initial codebook was created based on the CFIR guidelines and emerging codes that arose
while conducting the interviews listening to the audio and verifying transcription accuracy. Two
researchers trained in qualitative data analysis coded the same transcript independently before
discussing revisions and edits for the codebook. The same researchers coded an additional
transcript to refine the codebook. Following agreement on the codebook, four transcripts were
independently coded to calculate interrater reliability (IRR). At this first attempt the overall
Kappa was K=.75. The same two coders reviewed these transcripts, discussed interpretation
and clarification of codes, and again attempted IRR with 4 new transcripts. IRR was reached,
with an overall K=.86. The remaining transcripts (n= 12) were coded by the primary author.
Trustworthiness of the qualitative data was examined using Guba’s model of trustworthiness of
qualitative research (Guba, 1981; Krefting, 1991; Lincoln & Guba, 1986).
Integration of the qualitative and quantitative findings was performed. During data
collection and analysis, connecting occurred via using the quantitative data to identify
participants for the qualitative phase (Creswell, 2013; Creswell, Klassen, Plano Clark, & Smith,
2011). Data were also merged after data collection, a technique that involves combining the
quantitative and qualitative data sets (Creswell et al., 2011; Fetters, Curry, & Creswell, 2013).
During data interpretation a narrative approach (where integration of the two data sources was
woven throughout the interpretation), and utilization of joint display of data (displaying the
quantitative and qualitative portions of the study within the same section and noting how they
build upon each other) were used to integrate the data (Fetters et al., 2013).
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Results
Participant Characteristics
A total of 150 staff
providing HIV testing
(participants) from 48
organizations were included in
analysis. Participants were an
average of 41.4 years old,
ranging in age from 20 to 73
years (Table 2.1). The sample
was fairly diverse in terms of
gender (53.7% male; 43.6%
female) and sexual orientation
(48.3% heterosexual; 40.9%
homosexual). Just over half of
participants indicated their race
as White, while just over 20%
indicated being Black. While
most participants worked
fulltime at their organization
(78.1%), some worked part time
(10.1%) or volunteered (11.8%).
Notably, nearly 20% (19.3%) of

Table 2.1
Participant Characteristics (N=150)
Age (range)
Gendera
Male
Female
Transgender female to male
Another gender
Sexual Orientation b
Heterosexual (Straight)
Homosexual (Gay/Lesbian)
Bisexual
Another Sexual Orientation
Racec
White
Black/African American
Asian
American Indian/Alaskan Native
Native Hawaiian/Pacific Islander
Hispanic ethnicity
Employment Status
Full time
Part time
Volunteer
Prescriber (employed in position that
involves prescribing medicine)d
Ever taken PrEPe
Currently on PrEPf
HIV statuse
Living with HIV (HIV positive)
Not living with HIV (HIV negative)
a No

n (%)
41.4±14.1 (20-73)
80 (53.7)
65 (43.6)
2 (1.3)
1 (0.7)
72 (48.3)
61 (40.9)
7 (4.7)
5 (3.4)
77 (51.3)
35 (23.3)
6 (4.0)
4 (2.7)
1 (0.7)
50 (33.3)
118 (78.7)
13 (8.7)
19 (12.7)
4 (2.7)
20 (13.4)
14 (9.6)
29 (19.5)
120 (80.3)

participant identified as transgender male to female. One participant
selected “prefer not to answer”. One participant skipped the question.
N=149
b Two participants indicated “not sure” and two indicated “prefer not to
answer”. One participant skipped the question. N=149
c Participants could select all races/ethnicities that applied. Some
participants did not select a race, and only selected Hispanic ethnicity
d. One participant skipped the question N=149
e. One participant selected “prefer not to answer” N=149
f. One participant selected “prefer not to answer”. Three participants
skipped the question N=146

participants were living with HIV.
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Qualitative interview participants (N=22) were similar to the larger sample, with slight
variations. These participants were slightly younger, and more likely to be White and/or male
than the full sample. The average qualitative participant was 37.4 years (range: 21-64), 63.6%
White, 63.6% male, 54.5% heterosexual, and 18.2% living with HIV.
Classes of PrEP Implementation
A total of four models were conducted using LCA– each containing 1, 2, 3 or 4 classes,
respectively (Table 2.2). The 1 class and 4 class models each had higher BIC values than the 2
class and 3 class models, respectively; the 2 class and 3 class models were further
investigated. Although the 2 class model had the best model fit as determined by the BIC
criteria, the 3 class model had the better fit when considering LMR and theoretical interpretation.
Based on consideration of fit statistics and theoretical relevance, a 3 class LCA was selected
and used for all further analyses.
Table 2.2. Comparison of latent class models
Number of
AIC
BIC
classes
1
1967.987
2027.796
2
1798.022
1920.629
3b
1750.482
1935.889
4
1733.269
1981.475

aBIC

LMR p value

Entropya

1964.505
1790.883
1739.687
1718.818

NA
p < .001
p=0.0098
p=0.1392

NA
0.961
0.914
0.938

aEntropy
bModel

was not considered for fit or the decision of the number of latent classes, but is here for reference.
adopted

As a model approaches 1.0, it approaches full delineation of latent classes, referred to
as entropy (Celeux & Soromenho, 1996); entropy for the LCA was .914. After reviewing the
classes, or grouping of participants, each group was assigned a label to be used throughout
analysis and data reporting. The name of each label was determined based on the
characteristics of their latent class. The class labeled Universal was labeled as such because
this group indicated talking about PrEP with all or most of the clients they see, as well as
handing out PrEP-related materials regularly. Thus, class one (42%; n=62) included staff
performing HIV testing who were PrEP advocates; these participants were highly likely to talk
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about PrEP with their clients, regardless of client eligibility. This group was also most likely to
give their clients physical information about PrEP – such as pamphlets, flyers, and written
contact information for PrEP friendly providers. Class two (33%; n=48) were staff who often
talked to clients about PrEP, but were most likely to discuss the prevention method if they felt
their client was eligible, thus referred to as Eligibility Dependent. This group also provided
physical materials to clients, but not as consistently as participants in the Universal group. Class
3 (25%; n=37) was the most discriminate group with regards to PrEP implementation – they
sometimes spoke to clients about PrEP, but not as systematically as those in the Universal or
Eligibility Dependent groups. This group will be referred to as Limited. This group was also the
least likely group to provide physical information about PrEP, such as brochures or referral
cards.
The latent classes were often triangulated via qualitative data. In qualitative interviews,
some members of the Universal group stated that they believed everyone should be aware of
PrEP, regardless of their current level of risk. Participants in the Universal group often confirmed
discussing PrEP with clients on a frequent basis, such as “I'm obligated as somebody who's
doing HIV prevention and testing to talk to somebody about this [PrEP]. (Participant 113)” or “I
think is great because it's a resource that everyone should know about. Regardless if you don't
use it [PrEP] or use it, you know, if you know someone that can use it, you can always
recommend them to it (Participant 116)”. This theme was less present in the Eligibility
Dependent group and not present in the Limited group.
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Table 2.3. Categorical distribution of final latent class model
Survey Question

Overall, how often do you talk to clients about PrEP
when testing/counseling for HIV?

I talk to clients about PrEP every time I test for HIV

I talk to clients about PrEP when I think they might be
eligible (meet the indications to start taking PrEP)

I give physical information about PrEP (such as
pamphlets, flyers, and written contact information for
PrEP friendly providers) to clients during HIV
testing/counseling
Overall, how often do you give clients physical
information about PrEP (such as pamphlets, flyers, and
written contact information for PrEP friendly providers)
during HIV testing/counseling?

Response Categories

I never do this
Very rarely
Some of the time
Most of the time
Every time
Strongly disagree
Disagree
Neither
Agree
Strongly agree
Strongly disagree
Disagree
Neither
Agree
Strongly agree
Strongly disagree
Disagree
Neither
Agree
Strongly agree
I never do this
Very rarely
Some of the time
Most of the time
Every time
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Latent Class 1
Universal
62 (42%)
0.000
0.000
0.018
0.019
0.963
0.050
0.000
0.000
0.243
0.708
0.080
0.016
0.048
0.181
0.674
0.064
0.024
0.091
0.337
0.483
0.000
0.064
0.165
0.256
0.515

Latent Class 2
Eligibility
Dependent
48 (33%)
0.000
0.021
0.114
0.780
0.085
0.000
0.079
0.221
0.700
0.000
0.000
0.021
0.000
0.337
0.642
0.000
0.054
0.088
0.609
0.249
0.041
0.022
0.398
0.539
0.000

Latent Class 3
Limited
37 (25%)
0.055
0.164
0.532
0.249
0.000
0.107
0.527
0.366
0.000
0.000
0.000
0.055
0.165
0.479
0.301
0.027
0.326
0.415
0.152
0.079
0.055
0.328
0.590
0.000
0.027

Eligibility Dependent participants often brought up concerns regarding the side effects of
PrEP that seemed to highlight the need for a more selective discussion of PrEP based on risk
criteria, such as “Like I said, if you're married and you have one partner, then you're taking PrEP
to damage your liver or your kidneys, and so on and so on. It doesn't make sense [to use PrEP].
(Participant 103)” or “We have many people that we know are in serodiscordant relationships,
so we want to help them (Participant 107).” In essence, these participants weighed the pros and
cons of PrEP for their client and determined if PrEP should be discussed based upon their
client’s level of risk.
In LCA the Limited group was found to have inconsistent discussions about PrEP. This
lack of systematic rationale for PrEP implementation was captured by the varied qualitative
responses within this group. This group discussed concerns regarding PrEP but did not have
salient qualitative rationale for why they did, or did not, discuss PrEP with clients.
Discussion
This study sought to understand PrEP implementation at community-based HIV testing
locations in Florida. A latent class analysis revealed three distinct classes of PrEP
implementation– Universal, Eligibility Dependent, and Limited. Entropy was found to be 0.914
(approaching 1), indicating delineation between classes (Celeux & Soromenho, 1996).
Qualitative data were triangulated with quantitative data, and provided additional information
and characterization of these classes.
While staff who provide HIV testing may share some similar characteristics, they are a
heterogenous population with regards to the specific ways that they take part in PrEP
implementation. Using the LCA approach (Heck et al., 2013; McCutcheon, 1987) allowed for the
grouping of participants into mutually exclusive sub-groups within the larger population of staff
who provide HIV testing. This approach takes the complex nature of PrEP implementation into
account; unlike other approaches that may split participants based on a score or percentage
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ranking, the LCA considers the specific combinations of PrEP-related implementation activities
(Heck et al., 2013; McCutcheon, 1987).
Participants in the Limited group were inconsistent in their PrEP implementation
behaviors, despite the state of Florida HIV testing manual describing the importance of linkage
to prevention resources, including PrEP (FDOH, 2018a). These findings may also speak to the
need for targeted interventions for HIV testing staff with characteristics of the Limited group.
From a public health perspective, there is a need for these participants to change their PrEP
implementation behaviors to those similar to the Eligibility Dependent or Universal groups.
Participants in both the Universal and Eligibility Dependent groups meet the standards of the
Florida Department of Health testing procedures in that they are able to provide linkages and
may be able to provide client-centered risk assessments during the counseling process (FDOH,
2018a). The understanding of what it means to provide client-centered risk assessments could
be one differentiating factor between these groups. Participants in the Eligibility Dependent
group may feel that discussing PrEP with clients they believe would not meet the indications for
PrEP diverts from the recommendation of client-centered counseling. It is also important to note
that the level of risk HIV testing staff perceive a client to have may not always be accurate.
Clients may not be fully truthful with the staff providing the HIV testing service (Sheon, Lee, &
Facente, 2010); similarly, the staff providing testing may make assumptions about the client
based on the way he or she presents themselves or demographic characteristics (Adams &
Balderson, 2016a; Calabrese et al., 2014; Calabrese & Underhill, 2015). Thus, while some
participants in the Eligibility Dependent group may be accurately determining which clients could
benefit from knowing about PrEP, other HIV testing staff within the Eligibility Dependent group
may be missing the opportunity to tell clients about a potentially valuable prevention method.
While the Universal participants may be sharing information about PrEP with those who do not
meet the indications, (unlike the Eligibility Dependent participants) they are not missing clients
who may benefit from the innovation. By sharing this information with all clients, participants in
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the Universal group are also increasing the general community-level knowledge of PrEP, which
in turn may reduce associated stigma.
This study is not without limitations. The study was limited to community-based
organizations within one state in the southern United States. Some aspects of PrEP
implementation may vary geographically, as studies have found slower PrEP uptake among
some populations (Elopre, Kudroff, Westfall, Overton, & Mugavero, 2017) and high rates of HIVrelated stigma in the southern United States (Darlington & Hutson, 2017). The lack of validated
scales measuring PrEP implementation led to a literature driven development of relevant items;
however, use of latent class analysis provided some strength to the outcome variable.
Literature-driven development of items used in LCA has been used in other understudied
contexts (Laska, Pasch, Lust, Story, & Ehlinger, 2009).
There are many strengths in this study. The study is rooted in an implementation science
framework that has been used extensively in the literature (Birken et al., 2017; Damschroder et
al., 2009); however, has been underutilized the field of PrEP implementation. Additionally, it is a
mixed methods study that triangulates the quantitative and qualitative findings to provide a
comprehensive look at PrEP implementation during HIV testing. This study may have
implications for training and program development related to PrEP implementation, such as
providing targeted skill-based training for participants in the Limited group or additional
resources to Eligibility Dependent participants. Finally, this study also took place in a state with
high HIV prevalence and incidence, Florida (FDOH, 2016a). Much can be learned from PrEP
implementation in Florida, as it is geographically and ethnically diverse, as well as entering a
statewide push for PrEP implementation. This study is among the first to examine PrEP
implementation from the perspective of staff who provide HIV testing to the clients. These
findings may help organizations in determining the best way forward in providing training for
PrEP implementation in the future.
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SECTION 3: “IT'S SORT OF ALL FALLING INTO PLACE … BEFORE I FELT LIKE
EDUCATING PEOPLE ABOUT PREP WAS LIKE TALKING ABOUT THE TOOTH FAIRY”: A
MIXED METHODS STUDY EXAMINING THE INTRAPERSONAL, ORGANIZATIONAL AND
EXTERNAL FACTORS AFFECTING PREP IMPLEMENTATION WITHIN COMMUNITYBASED HIV TESTING SITES IN FLORIDA
Introduction
Pre-exposure prophylaxis (PrEP) has been found to effectively reduce HIV acquisition by
approximately 90% (Anderson et al., 2012; CDC, 2016f; Spinner et al., 2016). Following
successful efficacy trials, PrEP was approved by the Food and Drug Administration and
recommended for at-risk populations by several key public health entities, including the Centers
for Disease Control and Prevention (CDC) and World Health Organization (WHO) (CDC, 2014;
The White House Office of National AIDS Policy, 2015; U.S. Public Health Service, 2014; World
Health Organization, 2012a, 2012b, 2015). However, to date, there has been slow uptake of
PrEP (Scholl, 2016). There has been a focus on the role that medical providers have in PrEP
implementation (Krakower & Mayer, 2016; Smith, Mendoza, Stryker, & Rose, 2016), and for
good reason. A medical provider is needed to prescribe PrEP. Yet, there are some limitations to
relying on medical providers as the only staff responsible for PrEP implementation, among them
the struggle or disinterest some medical providers have in discussing sexual health with their
patients (Krakower & Mayer, 2012; Thrun, 2013). However, additional sites – such as STI
clinics, pharmacies, and community-based organizations - could be utilized to disseminate
PrEP-related education and support (Mayer et al., 2018; Smith et al., 2013; Underhill et al.,
2014; Underhill, Operario, Mimiaga, et al., 2010; Underhill, Operario, Skeer, et al., 2010).
HIV testing sites offer alternative locations in which PrEP implementation could occur
(Mayer et al., 2018); in these settings PrEP implementation is conceptualized as PrEP
education and/or referral to a place where a PrEP prescription could take place. Many HIV
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testing sites can be accessed regardless of insurance coverage and operate on a walk-in basis.
Additionally, staff providing HIV testing already speak with clients about their sexual risk
behaviors and HIV prevention. Thus, PrEP implementation at HIV testing sites may be important
for reaching clients who may meet the indications for PrEP.
Research regarding HIV testing and PrEP has focused on the client – the person
receiving the HIV testing and counseling (Hevey, Walsh, & Petroll, 2018; Kwan & Lee, 2018;
Parsons, John, Whitfield, Cienfuegos-Szalay, & Grov, 2018; Wilton et al., 2016). For example,
studies have examined the frequency in which clients already on PrEP have continued to get
tested for HIV; testing for HIV every three to six months is suggested per the CDC guidelines for
PrEP. (Hevey et al., 2018; Parsons et al., 2018). Researchers have recruited clients from within
HIV testing sites and investigated the interest these clients have in PrEP (Kwan & Lee, 2018).
One study assessed the role of HIV testing sites in linkage to PrEP, but again this study focused
only on the perspective of the clients being served (Flash et al., 2018). Several researchers
have noted the possible utility of PrEP referrals during HIV testing (Hammack, Meyer, Krueger,
Lightfoot, & Frost, 2018) However, to our knowledge, studies focusing on the role staff who
provide HIV testing have in PrEP implementation (i.e. inclusion of PrEP in counseling and/or
PrEP referrals) are limited.
Damschroder et al. (2009) synthesized implementation theories and frameworks and
identified five overarching domains affecting implementation: intervention characteristics, outer
setting, inner setting, characteristics of individuals, and process. Collectively, these domains
and their related constructs make up the Consolidated Framework for Implementation Research
(CFIR). The CFIR helps researchers and practitioners to understand the implementation
process and where key changes could be made to improve PrEP implementation.
Understanding the constructs within the CFIR domain Characteristics of Individuals may help to
explain how intrapersonal characteristics of the staff performing HIV testing may impact PrEP
implementation within HIV testing sites. The CFIR domain Characteristics of Individuals covers
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a range of intrapersonal constructs regarding the staff implementing the intervention; among
these constructs are PrEP-related knowledge and beliefs, self-efficacy, and personal attributes
of the staff performing HIV testing (e.g. prior personal experience with PrEP). Understanding
how Characteristics of Individuals affect PrEP implementation during HIV testing could help
organizations to plan program and training development. The Inner Setting describes the
organizational characteristics that may affect implementation of an intervention (e.g. the culture
of an organization or the resources available to those who implement the intervention)
(Damschroder, 2016). Thus, the CFIR domain Inner Setting could provide guidance on what
organizational attributes are associated with successful PrEP implementation. The Outer Setting
describes factors external to the organization that may impact implementation of an intervention
(e.g. the needs of the clients the organization serves or the degree to which an organization is
networked with other organizations) (Damschroder, 2016). Given that organizations exist in
communities, the Outer Setting may provide important context to understanding implementation.
This study examined how the intrapersonal characteristics of HIV testing staff
(Characteristics of Individuals), organizational (Inner Setting) and community (Outer Setting)
characteristics impact PrEP implementation as performed by staff performing HIV testing. Two
research questions were addressed: 1) What characteristics of the individual are associated
with PrEP implementation during HIV testing, as guided by the domain of CFIR (i.e.
characteristics of the individual)? and 2) What inner and outer setting factors are associated
with PrEP implementation during HIV testing, as guided by the domains of CFIR?
Methods
Study Design
This study utilized a mixed methods concurrent triangulation design (Creswell, 2013) to
examine the factors affecting PrEP implementation during HIV testing in Florida. Participants
included staff who conduct HIV testing, as they are most aware of the daily activities of PrEP
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implementation/non-implementation during the HIV testing process. Eligibility criteria included:
1) working or volunteering at an organization that provides community-based publicly funded
HIV testing in the state of Florida; 2) having provided HIV testing/counseling within the past
three months and 3) being at least 18 years old. Participants were ineligible if they were unable
to complete a computer-based survey without assistance. The guiding framework for the study
was the Consolidated Framework for Implementation Research (CFIR).
Human Protections
This study was approved by the Institutional Review Board of the University of South
Florida (Appendix G). All participants were provided with an electronic informed consent prior to
initiating the survey.
Data Collection
Quantitative data were collected using an online survey (approximately 15-20 minutes in
length) via Qualtrics (Qualtrics, 2017). Contact information for publicly funded HIV testing sites
is freely on the internet. The primary investigator of the study contacted each publicly funded
testing site via email with a request to share the survey with staff who perform HIV testing and
counseling. A log was kept listing all recruitment attempts. Following the Dillman methodology
(2011), organizations were contacted up to four times (i.e. a pre-notice, followed by up to 3
additional contacts that include the survey link) (Dillman, 2011).
After completing the online survey, participants had the option to provide their name and
contact information; three of the 150 participants received a $50 gift card. Participants were also
asked if they were willing to be contacted to complete a semi-structured interview. A subset of
participants who agreed to be contacted were considered for the qualitative interview. These
participants were purposefully sampled to ensure data from participants with a wide range of
experiences in PrEP implementation. Participants who took part in the qualitative interview
received a $20 gift card. A total of 22 participants completed the semi-structured interviews.
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Measures
Quantitative Measures
Quantitative study measures were related to constructs within the CFIR domains
Characteristics of Individuals, Inner Setting, and Outer Setting, as well as PrEP implementation
behaviors occurring within HIV testing sites. [A full list of items can be found in Appendix D and
rationale for domain and construct inclusion can be found in Appendix C.] The study outcome
was PrEP implementation. In this setting, PrEP implementation is conceptualized as the
inclusion of PrEP in counseling and/or PrEP referrals. PrEP implementation was determined
based on a latent class analysis (Manuscript 1). Briefly, five items were used in a latent class
analysis, and a three-class model was determined to be the most appropriate model to describe
implementation. The three groups of PrEP implementation were defined as: 1) Universal (42%
of the sample; participants who were highly likely to talk about PrEP with their clients and
provide physical materials regarding PrEP, regardless of if the client was at a high risk for HIV);
2) Eligibility Dependent (33% of the sample; participants who were likely to discuss PrEP only if
they felt their client was at a particularly high risk for HIV; they may also give out physical
material, but not consistently); and 3) Limited (25% of the sample; participants who sometimes
discuss PrEP with clients, but not systematically; least likely to give clients physical materials
regarding PrEP).
Model 1. Three constructs within the CFIR domain Characteristics of Individuals were
included in analysis: 1) knowledge and beliefs about the intervention; 2) self-efficacy; and 3)
other personal attributes. Knowledge and beliefs about the intervention were measured using
two composite variables. Knowledge was measured using an adapted version of the 5-item
PrEP knowledge scale (α=.66) developed by Walsh and Petroll (2016), with the addition of an
item measuring the frequency in which participants should get tested for side effects related to
taking PrEP (Blumenthal et al., 2015). This scale was originally used to measure provider
knowledge, and adapted for this study by replacing the word “patient” with the word “client”.
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Additionally, an item measuring knowledge of the antiretroviral medicine used for PrEP was
simplified for a nonmedical audience. Beliefs about the intervention were measured using a 10item scale on personal beliefs related to PrEP (α =.78), originally intended to measure attitudes
towards PrEP (Walsh & Petroll, 2016). Self-efficacy was measured as a composite variable
derived from a six item scale (Walsh & Petroll, 2016) that measured how comfortable
participants were with a variety of behaviors related to PrEP implementation within HIV testing
sites (α =.88). Other personal attributes included key participant characteristics: gender, age,
race, HIV status, and prior personal experience with PrEP.
Model 2. Within the CFIR domain Outer Setting, three constructs were included in the
analysis: patient needs and resources, cosmopolitanism, and external policies and incentives.
Patient needs and resources was measured as a composite score of four items adapted from
the Organizational Readiness for Change Assessment (ORCA) (Helfrich et al., 2009). These
items are suggested as proxy measures based on the CFIR technical assistance website
(Damschroder, 2016). In this setting (i.e. HIV testing sites), patient needs and resources
measured the degree to which clients would benefit from increased opportunities for HIV
prevention, including PrEP. This construct also measured how the needs of clients are
prioritized by the organization in which the participant (i.e., staff performing HIV testing) works.
Cosmopolitanism was measured as a composite score of three items. CFIR guidance does not
suggest proxy measures for this construct; as such, items were created based on the provided
definition of cosmopolitanism, “The degree to which an organization is networked with other
external organizations” (Damschroder, 2016). Cosmopolitanism was measured based on
attendance at local, statewide, or national meetings that discuss HIV prevention and knowledge
of local clinics or organizations to which they could refer clients if the client was interested in
PrEP. External policy and incentives was measured as a composite score of three items. CFIR
guidance suggests that external policy and incentives is similar to item 8a in the Organizational
Change Manager (OCM) (Gustafson et al., 2003), which asks about external pressures to
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implement an intervention (Gustafson et al., 2003). As such, three items were developed to
assess the influence of external recommendations and guidelines, such as those from the CDC
and WHO.
Within the CFIR domain Inner Setting, the constructs structural characteristics, culture,
tension for change, compatibility, relative priority, learning climate, and available resources were
included. Structural characteristics describe the structure of an organization. Three items were
used in analysis: size of the organization, if the organization has offices in more than one county
or state, and if the organization specializes in serving Lesbian, Gay, Bisexual, and/or
Transgender (LGBT) populations. Culture was measured by a composite score determined by
five items adapted from the ORCA (Helfrich et al., 2009), as suggested by CFIR technical
assistance (Damschroder, 2016). Culture describes organizational norms and values. Tension
for change is defined as “the degree to which stakeholders perceive the current situation as
intolerable or needing change (Damschroder, 2016);” this was measured using two items
adapted from the OCM (Gustafson et al., 2003) as suggested based on CFIR guidance
(Damschroder, 2016). Tension for change was applied as the degree to which participants felt a
change was needed in order to effectively reduce the spread of HIV. Compatibility measures
how well the intervention (PrEP implementation) fits within an organization (Damschroder,
2016). Compatibility was measured by two items adapted from the ORCA (Helfrich et al., 2009)
and OCM (Gustafson et al., 2003). Relative priority was measured by one item “Talking about
PrEP during HIV testing is less important than talking about other HIV prevention methods.”
This construct describes how important PrEP implementation is in relation to the other tasks in
which the staff who provide HIV testing take part. Available resources was measured by one
item describing the availability of physical materials related to PrEP that could be disseminated
to clients. The CFIR construct learning climate evaluates if an organizational culture allows for
mistakes during the learning process and empowers staff to believe they can make a difference
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in implementing the intervention (here, that they can make a difference in PrEP implementation)
(Damschroder, 2016). Two items, created based on the CFIR definition for learning climate,
were used to measure the organizational learning climate. These items were based on the
empowerment of staff in believing that they are an integral part of PrEP implementation.
Constructs of the process domain – engaging, executing, planning, and reflecting and
evaluating - were not included in this study, as staff performing HIV testing may not be best
suited to provide feedback on these processes; other programming staff may be more intricately
involved in these processes.
Qualitative Measures
Qualitative interviews were used to gather additional information about the most salient
barriers to, and facilitators of, PrEP implementation within HIV testing sites. These interviews
were used to provide a comprehensive and contextual look into the specific constructs most
important to how the CFIR domains Characteristics of Individuals, Inner Setting, and Outer
Setting domains affect PrEP implementation within HIV testing sites. Interviews were audio
recorded and transcribed. [A comprehensive instrument can be found in Appendix F.]
Sample Size
A total of 150 participants from 48 unique organizations were used in analysis. For the
qualitative sample, saturation was met after 22 interviews and determined when no new themes
emerged from the data.
Data Analysis
Quantitative data were exported from Qualtrics (Qualtrics, 2017) into SPSS v.24 (SPSS,
2011). Data were cleaned and examined for suspicious or repeat responses (i.e. outliers and
missingness were assessed; responses with matching IP addresses were reviewed).
Descriptive statistics and bivariate analyses were conducted.
Multiple participants from the same organization completed the survey and, as such,
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may be more similar to each other than they would otherwise be by chance alone. To account
for clustering (i.e. the groups of participants working within the same organization), generalized
linear mixed models (Heck et al., 2013) with multinomial distribution, logit link, and robust
variance estimator were used to estimate PrEP implementation as a function of key CFIR
variables from the domains Characteristics of Individuals, Inner Setting, and Outer Setting.
To address the first research question (What Characteristics of the Individual are
associated with PrEP implementation during HIV testing, as guided by the domain of CFIR (i.e.
Characteristics of individuals)?), PrEP implementation was estimated as a function of variables
from the CFIR domain Characteristics of Individuals. Predictor variables included PrEP
knowledge, PrEP beliefs, PrEP-related self-efficacy, gender, age, race, HIV status, and prior
personal experience with PrEP. Key organization characteristics (i.e. if a participant identified as
working for an organization that specializes in serving LGBT populations and organizational
PrEP policies) were controlled.
To address the second research question (What inner and outer setting factors are
associated with PrEP implementation during HIV testing, as guided by the domains of CFIR?)
PrEP implementation was estimated as a function of CFIR variables from the domains Inner
Setting and Outer Settings. Outer Setting predictors included: patient needs and resources,
cosmopolitanism, and external policy and incentives. Inner Setting predictors included:
structural characteristics (size of the organization, if the organization has offices in more than
one county or state, and if the organization specializes in serving Lesbian, Gay, Bisexual, and/or
Transgender populations), culture, tension for change, compatibility, relative priority, learning
climate, and available resources.
Qualitative interview transcripts were verified by the primary author to ensure correct
transcription. Qualitative data were imported into MaxQDA (Kuckartz, 2007) and analyzed
thematically (Guest et al., 2011). An initial codebook was created using the CFIR technical
assistance website (Damschroder, 2016) and emerging codes. Two researchers trained in
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qualitative data analysis coded the same transcript independently before discussing revisions
and edits for the codebook. An additional transcript was coded by both researchers to refine the
codebook. Following agreement on the codebook, four transcripts were coded to calculate
interrater reliability (IRR). At the first attempt the overall Kappa was K=0.75. The same two
coders reviewed these transcripts, discussed interpretation and clarification of codes, and again
attempted IRR with four new transcripts. IRR was reached, with an overall K=0.86. The primary
author coded the remaining transcripts (n= 12).
Data Integration and Interpretation
Data integration was included in the study design, methods, and interpretation. During
data collection and analysis, the quantitative data were used to recruit qualitative participants
via connecting (Creswell, 2013; Creswell et al., 2011). Moreover, the qualitative and quantitative
data were used iteratively to build upon each other for data interpretation via building (Fetters et
al., 2013), and the quantitative and qualitative data sets were merged (Creswell et al., 2011;
Fetters et al., 2013). A joint display of data was used with all analyses performed in MaxQDA –
where the qualitative data was displayed and analyzed in relation to the participants’
quantitative responses (Fetters et al., 2013).
Results
Participant and Organization Characteristics
A total of 150 participants from 48 organizations (M=3.1 participants per organization [117]; SD= 3.5); took part in the survey. Participants ranged in age from 20 to 73 years, with an
average age of 41.4 (+/-14.1) years. The majority of participants identified as male (53.7%),
heterosexual (48.3%), and White (51.3%). All full list of participant characteristics can be found
in Table 3.1.
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Participants also described the
agencies in which they worked.
About 29% (28.7%) of
participants described their
organization as small (under 20
staff members), 30% as
moderately sized (21-50 staff
members), and 41% as large
(more than 50 staff members).
Half of participants indicated
that their organization has
offices in multiple counties or
states (50.3%). Many (73.3%)
stated that their organization
specialized in serving lesbian,
gay, bisexual, and/or
transgender (LGBT) clients.
Participants served clients from
a range of geographic areas:
4.7% exclusively rural, 37.3%
exclusively urban, and 58% a

Table 3.1
Participant Characteristics (N=150)
Age (range)
Gendera
Male
Female
Transgender female to male
Another gender
Sexual Orientation b
Heterosexual (Straight)
Homosexual (Gay/Lesbian)
Bisexual
Another Sexual Orientation
Racec
White
Black/African American
Asian
American Indian/Alaskan Native
Native Hawaiian/Pacific Islander
Ethnicity
Hispanic
Employment Status
Full time
Part time
Volunteer
Prescriber (employed in position that
involves prescribing medicine)d
Ever taken PrEPe
Currently on PrEPf
HIV statuse
Living with HIV (HIV positive)
Not living with HIV (HIV negative)
a No

n (%)
41.4±14.1 (20-73)
80 (53.7)
65 (43.6)
2 (1.3)
1 (0.7)
72 (48.3)
61 (40.9)
7 (4.7)
5 (3.4)
77 (51.3)
35 (23.3)
6 (4.0)
4 (2.7)
1 (0.7)
50 (33.3)
118 (78.7)
13 (8.7)
19 (12.7)
4 (2.7)
20 (13.4)
14 (9.6)
29 (19.5)
120 (80.3)

participant identified as transgender male to female. One participant
selected “prefer not to answer”. One participant skipped the question.
N=149
b Two participants indicated “not sure” and two indicated “prefer not to
answer”. One participant skipped the question. N=149
c Participants could select all races/ethnicities that applied. Some
participants did not select a race, and only selected Hispanic ethnicity
d One participant skipped the question N=149
e One participant selected “prefer not to answer” N=149
f One participant selected “prefer not to answer”. Three participants
skipped the question N=146

mix of both rural and urban.
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Table 3.2. Bivariate analyses of factors within the CFIR domain Characteristics of Individuals and PrEP Implementation
Eligibility Dependent
Universal
(Ref: Limited)
(Ref: Limited)
wald

Sig

Knowledge

.754

.385

Age

5.029

.025*

Attitudes

.502

.479

Self-Efficacy

1.487

.223

6.088

.014*

Exp(B) [CI]
1.123
(.864-1.460)
.965
(.936-.996)
1.305
(.625- 2.724)
1.439
(.802-2.582)

wald

Sig

6.422

.011*

2.493

.114

5.726

.017*

8.951

.003*

3.547

.060

Exp(B) [CI]
1.431
(1.085-1.889)
.977
(.950-1.006)
2.471
(1.178-5.185)
2.694
(1.407-5.155)

Eligibility Dependent
(Ref: Universal)

wald

Sig

Exp(B) [CI]

3.202

.074

.785

.376

3.324

.068

3.785

.052

.651

.420

1.373
(.636-2.962)

.477

1.324
(.611-2.866)

.762

1.127
(.519-2.445)

.248

1.824
(.658-5.056)

.167

.480
(.169- 1.361)

.074
(.602-1.023)
.988
(.961-1.015)
.528
(.266-1.049)
.534
(.284-1.005)

Race
Racial minority
White
Sexual Orientation
Sexual minority
Heterosexual

3.077
(1.260-7.513)

Ref
8.612

2.242
(.968 - 5.193)

Ref
.003*

3.939
(1.577-9.842)

Ref

Ref

6.075

.014*

2.976
(1.250-7.085)

Ref

.506
Ref

Gender
Men
Women
Ever Taken PrEP

.993

1.556
(.652-3.709)

Ref

Yes

4.483

No
HIV Status

Ref

Living with HIV

.319

1.237

Not living with HIV
Ref
*Statistically significance p<.05

.590

.442

1.380
(.606-3.142)

Ref

.034*

9.730
(1.18479.950)

Ref

2.392

.122

5.333
(.639-44.486)

Ref
.266

.518
(.162-1.651)

.091

1.336
Ref

.023

.879

Ref

1.080
(.404-2.889)

1.907
Ref
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Table 3.3. Mixed model of factors within the CFIR domain Characteristics of Individuals associated with PrEP Implementation
Eligibility Dependent
Limited
Limited
(Ref: Universal)
(Ref: Universal)
(Ref: Eligibility Dependent)
Std.
Std.
Std.
B
t
Sig
Exp(B) [CI]
B
t
Sig
Exp(B) [CI]
B
t
Sig
Exp(B) [CI]
error
error
error
Intercept

3.89

2.11

1.83

.07

47.69
(.73-3131.30)

6.98

2.81

2.49

.01

1079.51
(4.17279480.08)

20.26
3.01

2.43

1.24

.22

(.162498.66)

Self-Efficacy

Attitudes

Knowledge

Age
Gender (Men;
Ref=Women)

-.39

-.48

-.17

-.002

.05

.47

.42

.16

.01

.54

-.83

-1.14

-1.07

-.17

.09

.41

.26

.29

.87

.93

.68
(.27-1.71)

-.69

.62
(.27-1.43)

-.71

.85
(.62-1.15)

-.31

.99
(.98-1.02)

.03

1.052
(.36-3.075)

-.53

.39

.62

.17

.02

.64

-1.76

-1.16

-1.81

1.95

-.83

.08

.25

.07

.05

.41

.50
(.23-1.09)

-.29

.40

.49
(.14-1.66)

-.20

.55

-.37

.71

.73
(.52-1.03)

-.16

.17

-.95

.35

1.03
(1.00-1.06)

.03

.02

1.96

.05

.59
(.17-2.08)

-.55

.57

-.95

.34

-.74

Ever Taken
1.410
.93
PrEP (Yes;
.34
.52
.66
.51
-.07
1.21
-.06
.95
-.55
1.21
-.46
(.502-3.96)
(.08-10.26)
Ref=No)
HIV Status
.366
1.88
(PLH;
-1.01
.75
-1.35 .18
.63
.73
.87
.39
1.49
.77
1.94
(.08 – 1.61)
(.44-7.97)
Ref=not PLH)
Race (Racial
1.46
.14
minority;
.38
.48
.78
.44
.55
-3.64
.00
.58
-4.12
(.56-3.81)
1.99
(.05-.40)
Ref=White)
2.37
Sexual
Orientation
2.84
.38
(Sexual
1.04
.66
1.57
.12
-.97
.62
-1.57
.12
.66
-3.06
(.76 – 10.57)
(.11-1.29)
minority; Ref=
2.01
heterosexual)
Probability distribution: Multinomial; Link Function: Generalized Logit
Model controlled for organizational policy for PrEP referral & identification as an organization specializing in serving LGBT populations.
CFIR – Consolidated Framework for Implementation Research
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.46

.65

.06

.00

.00

.745
(.34-1.64)
.82
(.28-2.4)
.86
(.62-1.19)
1.03
(1.00-1.07)
.58
(.19-1.81)
.58
(.05-6.28)
4.44
(.97-20.31)
.09
(.03-.29)
.13
(.04-.49)

Characteristics of HIV Testing Staff Affecting PrEP Implementation
In bivariate analyses (Table 3.2), significant differences existed between the Eligibility
Dependent participants and the Limited participants in age, race, sexual orientation, and ever
taken PrEP status. Significant differences were found between Universal and Limited
participants in knowledge, attitudes, self-efficacy, and sexual orientation. No statistically
significant differences were found between the Eligibility Dependent participants and the
Universal participants in bivariate analyses.
The intraclass correlation coefficients produced by the unconditional model reflected
limited intraclass correlation (Heck et al., 2013), with neither ICC being statistically significant.
This means that most of the variation between participants is due to individual characteristics,
rather than due to their organizational affiliation. When comparing the Universal group (Ref) and
the Limited group, organizational affiliation was responsible for approximately 25% of the
variation in responses – with individual characteristics being responsible for the remaining 75%.
This value was found to be lower between the Universal group (Ref) and the Eligibility
Dependent group – with only approximately 3% of the variation being attributed to
organizational affiliation.
In multivariate analyses, only race and sexual orientation remained significant predictors
of PrEP implementation group (Table 3.3). Participants who identified as a racial minority were
less likely to be in the Limited group (compared to both the Universal or Eligibility Dependent
groups) compared to their White counterparts; however, race did not differentiate the odds of
group affiliation when comparing the Eligibility Dependent vs. Universal groups. Sexual
orientation only played a role in differentiating between the Limited group and the Eligibility
Dependent groups –participants who identified as a sexual minority were less likely to be in the
Limited group compared to the Eligibility Dependent group; however, sexual orientation did not
appear to differentiate between the Limited vs. Universal groups, nor the Eligibility Dependent
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vs. Universal groups. Self-efficacy, attitudes, knowledge, age, gender, ever having taken PrEP,
and HIV status did not impact the odds of being in a specific PrEP implementation group.
The Characteristics of Individuals construct most salient in the data was participant
knowledge and beliefs about PrEP and implementing PrEP within HIV testing sites (i.e. the
knowledge and beliefs HIV testing staff have regarding PrEP). Regardless of PrEP
implementation groups, participants mentioned their personal knowledge and beliefs regarding
the side effects of PrEP. Participant concerns related to side effects were mentioned regardless
of race and sexual orientation. However, when examining the statements made by people
identifying as a sexual minority compared to heterosexual, people identifying as a sexual
minority often provided greater detail of PrEP-related side effects, such as one participant who
stated:
But it [PrEP] also has side effects. It's a strong medication, antiretroviral for HIV. These
people, they don't have HIV. They're negative. They're taking it as a prevention. They
have side effects in the liver, in the kidneys. Also, they said on the pamphlet that in
younger people, [PrEP can] diminish the density of the bones (Participant 103).
This detailed explanation can be contrasted to a participant identifying as heterosexual who
simply stated “I think it’s great. I know the side effects are bad (Participant 101).”
While quantitively PrEP knowledge was high across participants in all groups of PrEP
implementation, there were a few statements in the qualitative findings that reflected some staff
performing HIV testing had inadequate, or incorrect, knowledge of PrEP, such as:
Yeah, and oftentimes, it [PrEP] being a shot, and it staying in your system, we've
received concern from clients that ... because they'll be stuck with those side effects for
whatever, a month. So that just concerns them, as opposed to where they could just
stop taking it. (Participant 102)
Participants identifying as a sexual minority also brought up additional prevention concepts,
including undetectable=untransmittable (U=U). U=U is a campaign that promotes the science
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behind the statement that once a person living with HIV has an undetectable viral load, he or
she can no longer sexually transmit the virus (Rodger et al., 2018; Rodger et al., 2016). For
example, one participant stated:
I would say the main one, people, sometimes they just have issues believing the
science behind it [U=U], because at the beginning, it was so easy to say ’Yeah,
undetectable equals untransmittible,’ but at the time, people didn't feel like there was
enough research done in that. We're still getting research everyday saying that yes, this
is the thing, if you're undetectable for six months, and if you were to bareback, you'd
have no risk of … spreading the disease (Participant 112).
Only one participant identifying as heterosexual mentioned U=U. Cost (e.g. “Obviously it's
[PrEP] 700, 800, even $1000 a month, just for the medication… Then of course any doctors
bills, any lab work et cetera that would be included with that (Participant 119)”) and concerns
about clients not using condoms (e.g. “I see too many young men running around, saying, ‘Oh,
I'm taking PrEP now, I don't have to wear a condom’…what about HPV, syphilis, gonorrhea?
(Participant 111)”) were also commonly mentioned among participants. Less prevalent themes
included concerns regarding the limited research available regarding PrEP and concerns
regarding client adherence. These themes appeared in participants (i.e. staff performing HIV
testing) across race, gender, sexual orientation and other demographic characteristics
Organizational and Extra-Organizational Characteristics Affecting PrEP Implementation
[Inner Setting and Outer Setting]
Bivariate analyses (Table 3.4) revealed that, compared to participants in the Limited
group, participants in the Universal group were more likely to report the presence of PrEPrelated physical resources available at their organization (such as brochures related to PrEP),
greater tension for change, greater compatibility, a supportive learning environment, and a
culture more supportive of PrEP. Universal participants were also more likely to have knowledge
of external policies regarding PrEP than their counterparts in the Limited group. Universal
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participants were also more likely than Limited participants to specialize in serving LGBT
populations. Compared to Limited participants, Eligibility Dependent participants were more
likely to indicate tension for change, compatibility, learning climate, and a more PrEP positive
culture. Compared to participants in the Eligibility Dependent group, participants in the Universal
group were more likely to have physical resources available at their organization to assist in
PrEP implementation.
In multivariate analyses (Table 3.5), fewer Inner Setting and Outer Setting constructs
predicted group membership. Compared to the Limited group, participants in the Universal
group were more likely to have high scores in relative priority (aOR 1.65 [1.09-2.50]), indicating
that participants had the perception that PrEP implementation was a high priority within their
organization, even when compared to the many tasks that organizations providing HIV testing
perform. No constructs were statistically significant when comparing participants in the Eligibility
Dependent group to participants in the Limited group. Compared to participants in the Eligibility
Dependent group, participants in the Universal group were more likely to indicate the availability
of physical resources to assist in PrEP implementation (aOR 1.973 [1.197-3.253]).
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Table 3.4. Bivariate Analyses of inner and outer setting characteristics and PrEP implementation
Universal
Eligibility Dependent
(Ref: Limited)
(Ref: Limited)
t

Sig

Patient Needs

1.395

.165

Cosmopolitanism

1.424

.157

Resources

2.530

.012

Tension for Change

2.444

.016

Compatibility

3.380

.001

External Policies

2.010

.046

Learning Climate

3.116

.002

Relative Priority

2.907

.004

Culture

1.942

.054

.239

.812

Small

.372

.710

Medium

1.668

.098

2.016

.046

Offices in multiple counties
or states (Yes; Ref=No)
Organization Size
(Ref: Large)

Specializes in serving
LGBT populations

Exp(B) [CI]
1.642
(.813- 3.317)
1.411
(.875- 2.274)
2.127
(1.179- 3.834)
1.987
(1.140-3.465)
4.840
(1.925-12.171)
1.762
(1.009-3.076)
4.892
(1.787-13.393)
1.726
(1.191-2.503)
1.957
(.988-3.874)
1.148
(.366-3.601)

1.262
(.367-4.342)
3.253
(.803-13.171)
2.889
(1.021-8.180)

t

Sig

1.644

.102

.727

.468

-.123

.902

2.102

.037

2.930

.004

3.076

.254

2.912

.004

1.187

.237

2.325

.021

.627

.532

-.461

.645

1.436

.153

1.570

.119

Bivariate analyses conducted with mixed model and intercept (total of 2 random components)
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Exp(B) [CI]
1.502
(.921- 2.449)
1.135
(.805- 1.599)
.982
(.727-1.324)
1.718
(1.033-2.858)
2.907
(1.415- 5.973)
1.270
(.841-1.919)
2.863
(1.402-5.848)
1.227
(.873-1.726)
1.954
(1.106-3.455)
1.333
(.539-3.298)

.792
(.291-2.154)
2.692
(.689-10.523)
1.950
(.841-4.521)

Universal
(Ref: Eligibility Dependent)
t

Sig

.394

.694

1.134

.259

2.872

.005

.755

.452

1.217

.226

1.511

.133

.938

.350

1.935

.055

.013

.990

-.237

.813

.975

.331

.353

.724

.881

.380

Exp(B) [CI]
1.143
(.585-2.232)
1.256
(.844-1.868)
2.140
(1.267-3.613)
1.170
(.776-1.763)
1.716
(.714-4.127)
1.411
(.899-2.214)
1.718
(.549-5.372)
1.393
(.993-1.955)
1.004
(.518-1.947)
.893
(.349-2.290)

1.647
(.599-4.534)
1.191
(.447-3.172)
1.544
(.583-4.091)

Table 3.5. Mixed model of factors within the CFIR domains Inner Setting and Outer Setting associated with PrEP Implementation
Universal
Eligibility Dependent
Universal
(Ref: Limited)
(Ref: Limited)
(Ref: Eligibility Dependent)
B

Intercept

12.30
4
-.249

Std.
error
3.1706

.5006

t

Sig

3.88
1

.000

-.498

.620

Patient Needs

Exp(B)
[CI]
4.533E6
(8.489E9-.002)

B
8.15
1

Std.
error
2.1880

t

Sig

3.72
5

.000

-.186

.853

Exp(B)
[CI]
.000
(3.784E6-.022)

B

Std.
error

t

Sig

Exp(B)
[CI]

-

3.127

-

.175

.014

4.270

3

1.365

(2.853E5-6.852)

.779
(.2892.101)

-.079

.633
(.3451.162)

-.310

1.308
(.7472.289)

-.371

1.349
(.7702.363)

.227

1.464
(.4624.642)

.935

1.448
(.7262.887)

-.019

2.561
(.7598.637)

.372

1.646

.163

.4265

.924
(.3972.150)

-.146

.2870

-.508

.612

.864
(.4901.526)

-.458

.3068

Cosmopolitanism

1.49
1

.139

.950

.344

.3086

1.00
6

.317

1.71
9

.088

.642

.522

.733
(.3981.351)

-.103

.1652

-.622

.535

.902
(.6511.252)

.268

.2826

Resources

.2160

.690
(.4501.058)

.680

.2525

2.692

.008

1.973
(1.1973.254)

.300

.2829

Tension for
Change

1.05
9

.292

.3531

1.254
(.6232.525)

.105

.2385

.439

.662

1.110
(.6921.781)

.381

.5825

.655

.514

Compatibility

.4771

1.95
9

.053

2.546
(.9906.552)

-.557

.5106

-

.278

1.090

.573
(.2081.576)

.370

.3485

1.06
2

.291

External Policies

.2833

-.067

.947

.981
(.5601.720)

.416

.2278

1.826

.070

1.516
(.9652.380)

.940

.6137

1.53
2

.128

Learning Climate

.5023

.740

.461

1.450
(.5363.922)

.522

.7638

.683

.496

1.685
(.3717.650)

Relative Priority

.498

.2102

2.37
1

.019

.2338
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.698

.486

1.177

.313

.1883

1.663

.099

1.368

Table 3.5. Mixed model of factors within the CFIR domains Inner Setting and Outer Setting associated with PrEP Implementation
Universal
Eligibility Dependent
Universal
(Ref: Limited)
(Ref: Limited)
(Ref: Eligibility Dependent)
B

Std.
error

t

Sig

Exp(B)
[CI]
(1.0852.496)

B

Std.
error

t

Sig

Exp(B)
[CI]
(.7411.871)

B

Std.
error

t

Sig

Exp(B)
[CI]
(.9421.986)

.632

.4297

1.47
0

.144

Culture

1.881
(.8034.406)

.817

1.144
(.2525.203)

.180

.4239

1.92
8

.056

2.264
(.9785.243)

-.220

.3340

-.660

.511

.802
(.4141.555)

Offices in
multiple counties
or states (Yes;
Ref=No) Q20

.135

.7646

.176

.861

.6439

.280

.780

1.197
(.3344.287)

.043

.5515

.077

.938

1.044
(.3503.111)

Organization
Size
(Ref: Large, 3)
Q21
.445

.6736

.661

.510

Small 1

1.561
(.4115.927)

-.117

3.790
(.80817.770)

1.10
1

2.325
(.6168.775)

.752

.6567

-.179

.859

.889
(.2423.266)

.588

.5565

1.056

.293

1.800
(.5985.421)

1.332

.7801

1.70
8

.090

Medium 2

.8067

1.36
5

.175

3.007
(.60814.862)

.094

.5554

.169

.866

1.098
(.3663.300)

Specializes in
serving
LGBT
populations

.844

.6706

1.25
8

.211

.6371

1.18
0

.240

2.121
(.6017.492)

1.017
.017

.6359

.026

.979

(.2893.584)

Probability distribution: Multinomial; Link Function: Generalized Logit
CFIR – Consolidated Framework for Implementation Research

64

During the qualitative interviews, participants described the process by which PrEP
implementation took place within HIV testing sites. Such PrEP implementation could range from
handing clients materials and allowing them to make contact with someone if interested in PrEP,
physically connected clients with another organization providing PrEP (often referred to by
participants as a “warm handoff”), or referring a client to an internal medical provider. A
description of these referral processes and be found in Table 3.6. These referral processes also
changed over time, as described by one participant:
It's sort of all falling into place and people are readily able to talk to clients and feel safe
about talking to clients about PrEP, because we know that at least the ball is rolling…
Our job essentially now is we can educate about PrEP, whereas before I felt like
educating people about PrEP was like talking about the tooth fairy (Participant 119).
Table 3.6. Types of PrEP Implementation within HIV Testing sites
Sharing
“Yeah, so I'll list a couple, I'll write down the other doctors that aren't listed
materials
on there as well, and I'll discuss it with them if they're insured, call the
office, and make sure that they take their insurance, a lot of people will
touch base on location as well, how close it is to their home, so I'll tell them
check with the office on whether or not you're covered, and then if they
don't have insurance, there's a couple of the clinics that we know on there
that will take uninsured patients, and so we'll circle those from so they can
reach out to them, and now refer them for the health department as well.”
– Participant 121
Directly
“As far as the way that ... and it may be different for different organizations,
connecting
but my personal understanding of linkage is less like write a referral, give
clients with a
them the number. It's an offer. ’Yeah, hey listen, like while you're in the
provider “Warm room, I can call over and we can see if together we can set up your firsthandoff”
time appointment.’ If they don't have transportation services, then I can
provide them a bus pass to get over there and a bus pass to get home as
well, so that it's, yeah, less just give them the number, but instead like
facilitate that first meeting. I have never attended a first meeting, but that is
something that we can do as advocates, as testers, or at least
[Organization Name] allows us to link a client by taking them over there if
they're nervous.”
– Participant 119
Internal referral

“Most of them come to us [community organization that provides PrEP
internally] anyway at the end of the day. It's easier for us to do that directly;
it skips a step, and we make sure people get into care as soon as
possible.”
– Participant 110
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Although it was not explicitly included in the interview guide, leadership emerged as an
important factor in the initiation of some PrEP programs (i.e. leadership engagement under the
CFIR domain Inner Setting). If a participant described a strong organizational commitment to
PrEP implementation, he or she was asked to reflect on why their organization was able to
implement PrEP sucessfully. This is reflected in the quotes below.
It was the leadership. When I was at [Former Organization Name], I know we were
talking about doing a PrEP program, but there was only 1 or 2 people who really knew a
lot about PrEP. You're going back like 5 or 6 years. We had a nurse on staff, I cannot
remember her name and I worked with her for a long time, but she was the one who was
getting the idea up off the ground, but then there were other barriers about getting what
doctor, what provider, and then some of the doctors that we worked with did not want to
take on that. Here at [Current Organization Name] they made a requirement, like, ‘Look,
if you're going to be a part of this organization, if you're going to be a doctor who
supports our programs, this is part of your job.’ So there was more buy in from those
particular people. The leadership really stepped up, so I think that really made a
difference (Participant 106).
Others discussed leadership being involved in administrative decisions, such as creating
memorandums of understanding (MOUs). MOUs provided a clear path for participants to form
relationships with other organizations to which they could refer clients.
So the MOUs [memorandum(s) of understanding] in the clinical department are spearheaded by the Clinical Director, so either me or the person that was here before me.
Some of these MOUs have been intact for, I mean we renew them every year, but some
of them they've been there for five years, six years. So it just depends. But the Clinical
Director is the one that creates the MOUs [for PrEP referral] with these partnering
agencies (Participant 116).
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Some participants described PrEP as a natural extension of services from HIV care to HIV
prevention. The availability of resources was seen as a facilitator to PrEP Implementation in
both multivariate analysis (above) and in qualitative analyses. Available resources consisted of
time, written referral policies, physical handouts and brochures related to PrEP, and other
physical materials used in HIV prevention (e.g. condoms). The availability of physical materials,
especially those containing information about PrEP that could be provided to the client, assisted
participants in discussing PrEP. For example, one participant who described how available
resources assisted them in linking clients to PrEP:
Our testing kits, we have PrEP brochures and referral cards and all that, so they [HIV
testing staff] would have all that information. A lot of times we do testing at off site
locations. We actually have a box that has all sort of brochures and referral
information…More and more PrEP is part of that linkage to care for HIV negative
individuals. (Participant 104).
The importance of these materials was salient, as another participant stated: “Yeah, we have all
the material there. Like a little business card specifically for the PrEP clinic with the number that
is directly to someone who works there. Instead of having to call the menu. (Participant 105).”
Lastly, participants focused much of their discussion on utilization of the state-required form that
must be completed with each HIV test performed, the DH1628, referred to by participants as
“the 1628”. This form was a resource that created a natural transition to talking about PrEP. For
example:
In the 1628, which is the state form that you fill out when you're doing an HIV test, there
is a section on PrEP and nPEP, so we talk, I make sure that I talk to clients both about
PrEP, and PEP - post exposure prophylaxes, and how to get it, if they ever need it. Most
people have heard about PrEP, they haven't heard about PEP (Participant 104).
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Another participant noted a similar response:
The form that we use [DH1628] asks them if they've ever taken PrEP or PEP, so that
really is ... people most of the time are like, what's that? So it's really a way for us to talk
to them about it... A lot of people ask us, what is that? I don't know. So it starts a whole
conversation for us to be able to continue and talk to them about it and give them the
information about it and some of them ask more details and stuff (Participant 107).
In qualitative analyses, participants discussed how the Outer Setting influenced their
PrEP implementation behaviors. The Outer Setting includes factors external to the organization
that directly affect implementation within the agency. The most salient themes within the Outer
Setting were related to the needs and resources of the clients who HIV testing staff served (i.e.
needs and resources of the clients served by the organization; a construct within the CFIR
domain Outer Setting). Among the client barriers to PrEP were: client concerns regarding the
potential side effects of PrEP; lack of available and knowledgeable providers to prescribe PrEP;
inadequate or varied levels of client knowledge regarding PrEP; client concerns regarding the
costs associated with PrEP and PrEP use; and community-level HIV and PrEP related stigma
experienced by clients. Although the perspective of the clients was not directly captured in this
study, the perceived needs and resources of these clients do impact the behaviors of the staff
who perform HIV testing. Participants across all implementation groups referenced the needs
and resources of the clients they served; however, participants in the Universal group discussed
these barriers to the greatest extent.
Participants reported that although client knowledge of PrEP varied (some participants
were aware and knowledgeable of PrEP, others were not), generally clients identifying as LGBT
knew more about PrEP than their heterosexual counterparts. Participants in all implementation
groups indicated that their clients expressed concerns regarding the possible side effects of
taking PrEP. Client concerns about the cost of PrEP were cross-cutting and independent of
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implementation group; however, participants in the Universal and PrEP Eligibility groups were
more likely to reference the existence of the copay assistance program run by Gilead, the
producers of Truvada (the brand name of the medication used as daily PrEP).
Medical staff in the surrounding community acted as both a barrier and facilitator to PrEP
implementation within community-based organizations. Some clients told participants (i.e. staff
performing HIV testing) that they were unable to access PrEP via their general healthcare
providers or that their providers were unaware of, or uncomfortable prescribing, PrEP. However,
some participants identified key medical staff within their community to whom they could refer
their clients for PrEP referrals. Participants also reflected on the HIV and PrEP-related stigma
external to the agency in which they worked, but prevalent to the broader community they
served. HIV and PrEP-related stigma was also reported across implementation groups. Other
community factors, such as cosmopolitanism, also impacted PrEP implementation within HIV
testing sites.
Cosmopolitanism (i.e. how well an organization is networked with other organizations)
(Damschroder, 2016) was expressed in several ways. Some participants noted the formal role
of partnerships, such as one participant who described how memorandums of understanding
(MOUs) were present within her organization and aided in PrEP implementation.
We go to these huge meetings where we all talk about barriers to health and what lacks
in the community and stuff like that, and if a doctor's like ‘Hey, these are the services I
have, you can always send your clients over. We're doing this for free. Or we do this and
we're low income cost.’ That's how the MOU [memorandum of understanding] is kind of
drawn to place. So, it's honestly knowing people (Participant 116).
Quantitatively, cosmopolitanism was not statistically associated with PrEP implementation.
Similar findings were found in qualitative interviews – where participants discussed such
networking regardless of implementation group. Some participants described that relationships
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were established at planning meetings occurring in various places within the state of Florida and
often occurred because both organizations had a relationship with the state-run health
department. One participant, when asked to describe if he felt other organizations in his
community were familiar with PrEP, highlighted the role the health department has in networking
between community-based organizations:
At least from my CBO [community-based organization], which I can speak to with some
level of confidence, and then also from going to consortium meetings when other CBOs
are in the room, if they're absorbing what the health department is sending out, the
information that the health department is sending out, at the same rate that my CBO is,
then all the CBOs should have at least minimum knowledge to link clients to PrEP
services (Participant 119).
While cosmopolitanism is important for organizations implementing any program that may
require outside referrals, it may be most important for organizations without onsite medical
providers. One participant who was located at a community-based organization that did not
have medical providers on staff stated:
Yeah, so we don't have a health provider on site, but we do have a list of providers that
we know for sure that provide PrEP in the area. Now the health departments are also
rolling it out, so they're also going to be doing it, and there's a couple organizations that
are the HIV resource centers that are now implementing their own RN's that can
prescribe PrEP. So we go through the list, and tell them a couple more, and I'm currently
working on a project to determine what other primary care providers provide PrEP
because most of the people on the list are either ID [infectious disease] or HIV doctors,
or something of that nature. There's not very many primary care doctors on the list
(Participant 121).
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Participants also used external networking (i.e. cosmopolitanism) to understand how other
organizations worked – specifically, which organizations may be good to form partnerships with
and which organizations would not be appropriate for partnerships. Such partnerships were
seen as particularly important because participants were hesitant to refer their clients to an
unknown entity. One participant, stated the following:
I mean we work with a good amount of agencies and the agencies that we do work with,
we kind of know their work ethic 'cause we all literally go to the same meetings, our
missions are the same. 'Cause I don't want to send someone to an unknown area and
then them just get shut down because I don't know how everyone else is, like if I send
them to someplace that I've never heard of or never met, 'cause usually we have a
contact at every agency that we call for these reasons. They usually pick up and know
too, kind of like a mini counseling session with the client over the phone and kind of be
like, ‘Hey, okay you can come in at this time.’ And they set up the initial appointment
(Participant 116).
Here, the participant discussed the importance of not only cosmopolitanism, but developing trust
within networking relationships. By trusting the services that another organization provided, the
participant was able to refer client without fear of the client having a negative experience.
Discussion
Guided by the CFIR (Damschroder et al., 2009), this study investigated the role of
Characteristics of Individuals (i.e. characteristics of the staff performing HIV testing), Inner
Setting (i.e. organizational characteristics) and Outer Setting (i.e. characteristics of the
community that the organization serves) in PrEP implementation via a mixed methods
concurrent triangulation design (Creswell, 2013). Quantitative data were modeled using a
generalized linear mixed models to estimate PrEP implementation as a function of key CFIR
variables. Qualitative data was collected via in-depth semi-structured interviews.
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In the first research question we sought to understand how characteristics of the HIV
testing staff affected their PrEP implementation behaviors. Bivariate analyses revealed
significant associations between PrEP implementation group and select demographic variables,
knowledge, attitudes, and self-efficacy; however, after performing a multinomial generalized
linear mixed model, only sexual orientation and race remained statistically significant. These
findings are contrary to the expectation that all variables under the CIFR domain Characteristics
of Individuals (e.g. knowledge, self-efficacy, beliefs) would be associated with PrEP
implementation. Such findings can help in preparing training materials or programs for HIV
testing staff.
In the second research question we sought to understand how organizational (i.e. CFIR
domain Inner Setting) and extra-organizational (i.e. CFIR domain Outer Setting) characteristics
impacted the PrEP implementation behaviors of HIV testing staff. In a multilevel multinomial
model, only relative priority and availability of physical resources remained significantly
associated with PrEP implementation. Triangulation with the qualitative findings highlighted the
importance of physical resources and provided insight into the role of cosmopolitanism and
patient needs and resources in PrEP implementation. These findings are important because in
order to effectively implement PrEP, knowledge is needed on how best to equip communitybased HIV testing sites, and the role that the surrounding community has in such
implementation (Smith et al., 2016). Such knowledge could help community-based
organizations when planning what is needed to start a PrEP program and how their community
may receive such programs.
In this study, knowledge, self-efficacy, attitudes, and demographic characteristics were
captured under the domain Characteristics of Individuals. Race and sexual orientation were
important variables in predicting association with specific PrEP implementation classes in
quantitative analyses; however, in qualitative analyses, the race and sexual orientation of the
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person providing the testing were not directly discussed as an important factor in PrEP
implementation. It may be possible that those who identify as members of a racial minority
and/or sexual minority group are more prone to talking about PrEP than their peers because
HIV disproportionately affects these populations (CDC, 2015; FDOH, 2016a). These factors are
demographic characteristics that cannot be changed. As such, they may be important to note,
but may need to be considered in the larger context of Characteristics of Individuals.
Based on quantitative findings participants had relatively high rates of PrEP knowledge.
PrEP knowledge among HIV testing staff has been understudied; however, research of PrEP
knowledge among providers has indicated high rates of PrEP knowledge among HIV care
providers compared to their counterparts specializing in general medicine (Krakower & Mayer,
2016; Krakower et al., 2015; Mimiaga, White, Krakower, Biello, & Mayer, 2014). These findings
may provide some insight into why PrEP knowledge is high among staff specifically working in
HIV testing (i.e. the HIV field, much like HIV care providers). Perhaps knowledge may not play a
significant role in PrEP implementation during the HIV testing process because those working in
HIV testing are naturally more familiar with knowledge related to HIV prevention, regardless of
their views on PrEP. Previous research has indicated mixed findings regarding the association
between PrEP knowledge and PrEP prescribing practices; some researchers have found that
PrEP knowledge is associated with a greater likelihood of prescribing PrEP (Blumenthal et al.,
2015), and others have noted that PrEP knowledge alone was unlikely to result in an increase in
prescribing practices (Krakower & Mayer, 2016). This same line of reasoning may be true
among staff providing HIV testing, as knowledge may not be enough to increase rates of actual
referrals. Moreover, qualitative knowledge findings may reflect the need for future research into
a more nuanced scale to measure PrEP-related knowledge among non-clinical staff.
PrEP beliefs have also been found to play a role in PrEP prescription among providers
and were hypothesized to play a role in PrEP implementation occurring during the HIV testing
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process. Among HIV care providers the most important factor triggering screening for PrEP was
the patient being in a serodiscordant relationship (Tellalian, Maznavi, Bredeek, & Hardy, 2013),
especially those who were MSM in serodiscordant partnerships (Adams & Balderson, 2016;
Smith et al., 2015); these eligibility driven specifications were also mentioned among
participants of this study, particularly in the Eligibility Dependent group, who targeted their PrEP
discussions based upon presumed client eligibility. The concerns related to PrEP mentioned by
our participants were also similar to the concerns mentioned among providers, including
increased sexual risk behavior or a lack of adherence among patients (Blumenthal et al., 2015;
Calabrese et al., 2016; Krakower & Mayer, 2012; Tellalian et al., 2013; White et al., 2012).
The CFIR construct patients’ needs and resources (within the domain, Outer Setting),
although not a statistically significant predictor of group membership (i.e. patient needs and
resources does not predict if a participant is in the Universal, Eligibility Dependent, or Limited
class), was prominent throughout the qualitative interviews. Most staff providing HIV testing are
aware of the general facilitators and barriers their clients’ experience, likely resulting in this
construct not differentiating participants into a particular implementation group. Many of the
client barriers to, and facilitators of, PrEP initiation (i.e. starting a PrEP regiment) mentioned by
participants have also been stated as barriers and facilitators in recent provider and client
focused research (Koechlin et al., 2017; Pinto et al., 2018; Refugio et al., 2018). Among these
barriers are cost (Koechlin et al., 2017; Refugio et al., 2018), stigma (Pinto et al., 2018; Refugio
et al., 2018), and side effects (Koechlin et al., 2017). Moreover, the complex role that providers
have in community-wide uptake of PrEP has been discussed elsewhere; however, with a focus
on provider knowledge, attitudes and willingness to prescribe PrEP (Turner, Roepke, Wardell, &
Teitelman, 2018). More research is needed on how patient perceptions of providers’ willingness
to prescribe PrEP may impact PrEP implementation and initiation.
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Notably, all groups mentioned client concerns regarding the cost of PrEP; however, only
participants in the Universal and Eligibility Dependent groups referenced the co-pay assistance
program provided by Gilead, the manufacturer of Truvada. This may reflect a lack of awareness
of the co-pay assistance program in the Limited group. If participants in the Limited group are
unaware of co-pay assistance resources, they may be less likely to discuss PrEP with low
income clients whom they know could not afford PrEP without financial assistance.
Participants discussed the role of medical providers in PrEP implementation, as medical
providers are needed in order for a client to be medically screened for, and to initiate, PrEP.
There appeared to be a dichotomy in how participants viewed medical providers. Some
participants discussed the barrier of low knowledge of PrEP among general medical providers, a
theme prominent in the literature (Krakower & Mayer, 2016; Smith, Mendoza, Stryker, & Rose,
2016). When provider PrEP knowledge was low in a community, clients often became
discouraged to seek out PrEP. However, in some instances medical providers advocated for
PrEP and provided a trusted source to whom clients could turn. Participants also reiterated a
common theme in the literature –that at least some clients may be hesitant to talk to their
primary care doctor about PrEP; this hesitation was heightened if the client was a man who has
sex with men and not out to their provider about their sexual activity (Arrington-Sanders et al.,
2016; Mehta et al., 2011). These findings are important because they reinforce the need of
PrEP programs outside of traditional medical settings. They may also suggest a need for
provider education – a reoccurring suggestion in the literature (Turner et al., 2018).
Community level stigma also impacted the approach that staff performing HIV testing
took when discussing PrEP. Some participants discussed that sex and/or HIV was seen as
taboo in their community, so they had to tread lightly when bringing up HIV prevention methods
– including PrEP (Nunn et al., 2018; Pinto et al., 2018; Sang, Matthews, Meanley, Eaton, &
Stall, 2018). While consideration of such stigma is certainly important, the level of stigma may
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vary depending upon the community in which the agency exists. As in many community-based
programs, it may be particularly important for staff performing HIV testing to be aware of the
culture, norms, and stigma of the community they serve (Nunn et al., 2018; Pinto et al., 2018).
Cosmopolitanism, a construct under the CFIR domain Outer Setting which describes the
degree to which organizations are networked with each other, was also prominently discussed
in the qualitative findings, although not significant in the quantitative findings. Cosmopolitanism
may be important across implementation groups and thus may not be a predictor of group
membership. When studying PrEP implementation, cosmopolitanism may be particularly
important because at least some level of cosmopolitanism is needed in order for staff who
perform HIV testing to refer clients to external PrEP resources. Without a sense of which
external organizations are providing PrEP, or financial assistance programs, participants may
not know to whom to refer clients. Several participants also noted the importance of trusting
external organizations prior to any referrals being made. Trust is meaningful in all community
partnerships, but may be particularly important in this setting, as participants want the best for
their clients’ health. It may be important to draw a distinction regarding the strength of these
external ties – such as if formal partnerships (e.g. memorandums of understanding, etc.) are in
place, or if the participant is only merely aware of the resources provided by other organizations
outside of the one in which they work. This distinction in future quantitative and qualitative
research may be helpful to understand the types of networks necessary to realize the full
potential of PrEP implementation.
Available resources, a CFIR construct found under the domain Inner Setting, was
significant in quantitative findings and salient in qualitative interviews. Quantitatively, a greater
availability of PrEP resources was found among participants in the Universal group compared to
participants in the Limited group. Physical materials describing PrEP may be an important factor
for PrEP implementation, after all, if resources are not available they cannot be shared with
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clients. In qualitative findings, the importance of a form required by the health department – the
DH1628, was particularly salient. Participants commonly spoke about the ease of talking about
PrEP because of the format of the DH1628. Participants stated that they were required to fill
out the DH1628 for each client they test, and this form has a required question asking clients if
they have ever taken antiretroviral medication, providing an easy transition to discuss PrEP. In
2016, prior to the time of this study, specific questions regarding the use of antiretroviral
medications for PrEP and/or PEP were added to the DH1628 (FDOH, 2018a), a decision that
seems to facilitate an easy transition to talking about PrEP.
These findings also provide insight into how a PrEP referral typically looks within HIV
testing. While the availability of materials is certainly important in PrEP implementation (as
discussed above), participants also differentiated between simply handing a client materials
about organizations providing PrEP vs. helping a client to make the initial appointment. HIV
testing guidelines in Florida require that community-based staff providing HIV testing should be
able to assist clients with linkage to other related services such as PrEP – going beyond a
referral or distribution of materials (FDOH, 2018a). Based on these findings, this requirement
may not be met at all community-based HIV testing sites. Follow through of referrals was not
studied here, but these varying methods of PrEP referral may play an important role in PrEP
initiation and continued use. Additionally, several participants referenced that the ideal PrEP
program would be a one-stop-shop, or one in which participants can receive both social and
medical services within the same organization. This preference for a one-stop-shop has also
been noted elsewhere (Ongwandee et al., 2018). Participants felt that existence of a “one-stopshop” would facilitate internal referrals – or referrals to medical staff who work within the same
organization.
As with any study, limitations exist. CFIR technical assistance suggests that not all
constructs and domains of the CFIR need to be included in every study (Damschroder et al.,
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2009), nonetheless, constructs or domains that were not the focus of the study may also be
important to PrEP implementation within HIV testing sites. Measurement of CFIR constructs
was determined based on CFIR guidance (Damschroder, 2016); however, many of these scales
have not been previously validated for this use. Despite the scales not being previously
validated, all scales had adequate internal consistency. Additionally, some scales were adapted
for the population being studied (i.e. staff performing HIV testing). For example, an adapted
version of a scale originally intended to measure behavioral skills (Walsh & Petroll, 2016) was
used to estimate self-efficacy. It is possible that different scales could be more appropriate for
the given population. Lastly, this study only collected data from staff who perform HIV testing;
other types of staff members may have different experiences. Future research should
investigate other decision makers, such as administrative staff, as well as the clients receiving
an HIV test.
Despite these limitations, this study also has many strengths. The study investigated the
Characteristics of HIV testing staff, Inner Setting, and Outer Setting components related to PrEP
implementation within HIV testing sites – a relatively understudied context. The study design
was a mixed methods triangulation design and included concurrent analysis of the quantitative
and qualitative data, allowing for integration and contextualization of the findings. Overall, these
findings provide a greater understanding of how PrEP is implemented within HIV testing sites
and provides evidence for the potential use of such organizations in PrEP implementation.
Future research can build upon these findings to provide a more comprehensive understanding
of PrEP implementation within HIV testing sites. Additionally, given the possible limited role that
knowledge, self-efficacy, and PrEP attitudes may have in differentiating PrEP implementation
groups, organizational characteristics may be an important consideration when designing a
PrEP program.
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SECTION 4: ADDITIONAL ANALYSES AND EMERGENT FINDINGS
This section includes emerging findings from the data, not directly relevant to the research
questions presented here, but relevant to the larger context of PrEP implementation within HIV
testing sites.
Prevention Methods Discussed During HIV Testing
In the quantitative assessment, participants were asked a series of questions regarding
which prevention and testing methods they typically included when counseling for HIV
prevention during the testing process. The majority of participants (n=78; 52%) reported using
rapid testing (clients received their results on the same day they take the test), 6% (n=9) used
non-rapid tests (clients come back at a later date to receive their results, often referred to as the
2 week test), and 42% (n=63) provided HIV testing using a combination of both rapid and nonrapid testing. Participants were also asked what type of test they performed most often and
given the options of an 1) antibody test; 2) combination or fourth-generation test, or 3) I’m not
sure/don’t know. A total of 70.7% (n=106) of participants indicated that they most often
performed an antibody test, while nearly a quarter (n=37; 24.7%) performed combination/fourth
generation tests most often. Seven participants (4.7%) indicated that they did not know or could
not be sure what type of test they performed most frequently.
Participants also discussed the degree to which they included a number of prevention
methods during the HIV counseling process (Table 4.1). Participants most commonly discussed
regular testing for HIV and condom use with their clients. PrEP, TasP, and partner testing were
often discussed during counseling, but not as consistently as regular testing for HIV and

79

condom use. Monogamy and post-exposure prophylaxis were included least frequently in the
counseling process.
Table 4.1. How often do you discuss the following during HIV testing and counseling?
Never
Rarely
Sometimes
Regular testing for HIV
0 (0%)
0 (0%)
5 (3.3%)
Condom use
0 (0%)
0 (0%)
10 (6.8%)
Monogamya
11 (7.4%) 22 (14.9%) 39 (26.4%)
Partner testing
1 (.7%)
5 (3.4%)
24 (16.1%)
PEP
3 (2.0%) 16 (10.7%) 33 (22.0%)
PrEP
1 (.7%)
6 (4.0%)
20 (13.3%)
TasP
1 (.7%)
6 (4.0%)
27 (18.0%)
a.

Often
16 (10.7%)
27 (18.2%)
35 (23.6%)
51 (34.2%)
41 (27.3%)
44 (29.3%)
36 (24.0%)

Always
129 (86%)
111 (75%)
41 (27.7%)
68 (45.6%)
57 (38.0%)
79 (52.7%)
80 (53.3%)

Two participants skipped this question

In qualitative findings several themes emerged from the data unrelated to discussing PrEP
during the HIV testing process. Although the qualitative interview questions focused on PrEP
implementation, participants often discussed the undetectable = untransmittable movement,
PEP, Hep-C, and condom use.
Undetectable Equals Untransmittable (U=U)
Over a quarter of interview participants (6/22) discussed U=U (Rodger et al., 2018;
Rodger et al., 2016). Notably, in quantitative analyses, all off these participants were assigned
to either the Universal or Eligibility Dependent groups. Some participants spoke about a low, but
slowly increasing awareness of U=U in their communities:
So I'm definitely all about PrEP, but also a lot lately, I've been seeing an increase in
treatment as prevention, and people utilizing … undetectable equals transmittable.
There's still people that have their issues about it, but it's becoming a little bit more
accepted than what it was… people, sometimes they just have issues believing the
science behind it, because at the beginning, it was so easy to say "Yeah, undetectable
equals untransmittible," but at the time, people didn't feel like there was enough research
done in that. We're still getting research everyday saying that yes, this is the thing, if
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you're undetectable for six months, and if you were to bareback, you'd have no risk of
contracting HIV or spreading the disease (Participant 112).
Another participant described:
I think it's [U=U] mostly talked about by people in the community or in our circle of
people [who] are knowledgeable on HIV, people who currently have HIV, people who
work in the field, I think, know more about it and are more open about it. It's kind of like
the pay it forward thing. The people who are in the community are the main starters of it,
but then they tell other people, and then those people might tell other people and it goes
on like that. I think little by little, it'll start growing, kind of like PrEP did. But as of right
now, it's not widely known. It's minimally known. (Participant 115).
Several participants compared the knowledge of U=U to knowledge of PrEP within the
community.
Kind of the same way whenever PrEP first came out. They were worried about people
who were just going to take PrEP and be unsafe in other measures. They were thinking
the same way about undetectable, untransmittable ... meaning that people were just
going to go out and be completely unsafe. Like this was a method where you didn't have
to wear condoms anymore and who cares if you're HIV positive? You know, that sort of
thing. So there was this whole thing about it until the CDC actually said a little something
about it. And we're starting to work that in now, as far as whenever people come in …
who are in a relationship with an HIV positive person or considering a relationship with
an HIV positive person or recently slept with someone who is HIV positive, just trying to
get that message out as well. (Participant 105).
As seen in the quotes above, even participants who felt knowledge was increasing regarding
U=U noted the lack of general wide-spread awareness of the campaign. More often, participants
focused on the lack of awareness of the U=U campaign within their communities without
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acknowledging a slow increase in knowledge. Some people simply stated low community
knowledge of U=U. For example, one participant simply stated:
It's the same thing about the term undetectable. Some people, they don't know anything
about that. They're completely ignorant about it. (Participant 103).
Another participant, who was living with HIV, provided more context to the lack of knowledge of
U=U in their community:
There's needs, at least in my area, we need more education. If someone asks me if I'm
positive, I say yes, but I'm undetectable, and they automatically think they can catch it
from me…I feel like everyone knows what HIV is. They say it's manageable and we
compare it to diabetes now, but I think there needs to be more education about what
undetectable means, and how easy is it transmitted, and how fragile the virus actually is
(Participant 110).
This participant later affirmed that the lack of knowledge of U=U also perpetuates HIV related
stigma.
[During the HIV testing/counseling process] I try to get as much [information] as I can in
a small amount of time, just enforce it to retain. You can't get HIV by hugging, kissing.
When I first told people, my family used to bleach everything that I touched. That was a
horrible feeling, so I try to explain to them, it can't get transmitted like that. The virus is
very fragile actually. If you're undetectable, for 3-6 months then you can't pass it on,
they're like "Oh, I didn't know that." (Participant 110).
Another participant discussed the confusion between U=U and a “cure” for HIV:
… then I know the CDC says once an individual has been undetected [undetectable] for
about six months they're non-transferable [untransmittable], meaning they can't give the
HIV to another person. I think I was interested about that so I looked it up. I'm like "Oh,
that is something" because when I used to do testing with youth and young adults they'll
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tell me "Oh, well if I get it I can be cured of it" and it's reminding people that once you
have HIV, once you take this medication, yes, you can get better. Yes, you can be nontransmittable but you will still have the virus and it's educating people but also a lot of
people will tell you there's a cure and it's sort of that misconception (Participant 101).
Some participants stated that the training they had received prior to being certified to
tests/counsel for HIV did not include U=U, or stated a need for training to include the prevention
method; and, while they personally knew about the related research, they felt HIV prevention
training should be updated to include these findings, such as one participant who stated:
Well one thing that they [staff providing training on HIV prevention] did say was that if
someone's undetectable …they said yes, always the person can still transmit the
disease. You know, the CDC had come out two months prior to that saying that in a
study of some 400 couples, some were positive and some were negative, were having
unprotected sex, and no one contracted HIV. So they're still teaching that if you're
undetectable can still transmit you know, the virus. So I think that needs to be updated.
(Participant 110).
Another participant explained that the lack of training may be a contributor to the lack of
discussing U=U during the HIV testing and counseling process.
I think they were worried about not having enough training on it, maybe. And that we
were just telling clients without giving them the ... "You have to understand that if you are
in care and you adhere to your medication and you're being good, still take precautions,
but being undetectable means that you're untransmittable because XYZ." (Participant
105)
PEP
Although post-exposure prophylaxis was one of the least included methods of HIV
prevention during the counseling process, the prevention method was mentioned in over half of
83

the qualitative interviews (13/22). Mentioning PEP most often co-occurred when participants
discussed client knowledge and available resources. Some participants simply stated that client
PEP knowledge is low, such as “…so, a lot of people don't know what the pill preventions are,
like the prophylaxis that they have for HIV like PEP and PrEP (Participant 116) or “Also,
something that is very interesting, that in five years of use [at this time it was approximately 5-6
years since FDA approval of PrEP], almost no one heterosexual know about the use of PrEP or
PEP, it’s all in the gay community (Participant 103).” Other participants contrasted the
awareness of PrEP and PEP, such as “for the most part, most [clients] are more aware of PrEP
than they are of nPEP. I always let them know about that [PEP] as well (Participant 117)” or
“most people have heard about PrEP, they haven't heard about PEP (Participant 104).” This
finding was highlighted by another participant who described that, despite the number of years
PEP has been available in comparison to PrEP, many clients were still unaware of this
prevention option:
The same thing with PEP. I tell them that, because that's an option that you have, and
most of the people, they don't even know that they have it. If they have any risky
situation, in the first 72 hours, to get access to take the Truvada for 28 days, which is the
PEP. That's something that's a tool that you should know that you have… That's
something that has been in use for, I don't know, 10, 15 years. I remember when it used
only for people working in the medical field, and now it's available for everybody. I
explain all that, and at least they know, if they have sex last night with someone that,
today, they come and tell them that they have HIV, they have available PEP, and avoid
the infection. (Participant 103)
Some participants felt that this lack of PEP awareness was not only prevalent among clients,
but also providers, such as one participant who described PEP knowledge in emergency room
departments:
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You walk into an emergency room and say, "I was exposed to HIV. I want PEP." They
look at you like what? Because the education hasn't been done. The easiest way to get
PEP, is to go through a PrEP provider. ..I don't think PEP is utilized enough, I don't think
people know enough about it, but it's definitely part of the counseling we do whenever
we test (Participant 104).
For some participants, PEP came up naturally during the counseling process. In 2016,
the Florida Department of Health began collecting information about PrEP and nPEP on the
DH1628, a mandatory form required to be completed with publicly funded HIV tests in Florida
(FDOH, 2018a). Several participants discussed how the DH1628 acted as a resource to initiate
a discussion about PEP “because one of the questions on the 1628 is about if you've ever taken
PrEP or nPEP, which is non-occupational post-exposure prophylaxis (Participant 112).”
Usefulness of the DH1628 was reiterated throughout conversations with many participants:
Well, in the setup of a test, it's super easy, because it's on the same subject. I brought it
out. I just question, "Do you know about PrEP? Do you know about PEP?" Oh, no, I
don't know what it is. So then I start explaining the whole thing. It's super easy in a
testing location. (Participant 103)
Another participant stated:
I don't find it very hard to introduce the subject. In the 1628, which is the state form that
you fill out when you're doing an HIV test, there is a section on PrEP and nPEP, so we
talk, I make sure that I talk to clients both about PrEP, and PEP - post exposure
prophylaxes, and how to get it, if they ever need it. (Participant 104)
HEP-C
The concordance of testing for HIV and hepatitis C emerged in the qualitative interviews.
Participants naturally spoke about hepatitis C testing as a resource available at their
organizations. This can be seen through the following quotes: “So, we did a lot of HIV testing,
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hepatitis C testing, we also provided syphilis, gonorrhea, and chlamydia testing as well to the
local community (Participant 116)” or “We serve anybody who walks through the door from
whatever county they may come from. Free HIV testing is what we offer, and also Hep C
(Participant 117).” Some programs or funding required testing for both HIV and hepatitis C, such
as “and it's just a screen [screening] program for HIV and HCV actually, so Hepatitis C as well
(Participant 118).” The need for this dual testing within certain populations served was also
discussed, most often when referencing concurrent risk due to sexual risk behaviors and
injection drug use:
For this particular population [injection drug users], everything is geared towards
preventing people from contracting HIV and Hep C, and/or transmitting it to their
partners. (Participant 106)
Another participant stated:
Because we have a few clients once in a while from another organization that we have
close by that's called [Name of Organization], which is a rehab for people that they use
drug and alcohol. That population, actually, is super high on HIV transmitted through
needles, and more than HIV, hepatitis. Hepatitis B or C. (Participant 103)
There appeared to be an ease in testing for both HIV and hepatitis concurrently:
Normally when people come into our office to get a test, if they're voluntarily coming in,
they want whatever information you give them; and because we have a set amount of
time, usually we're doing the rapid test and we're also pushing for people to also go
ahead and take that Hep C rapid test, which is a little bit longer than the 15 minutes is
going to be for the HIV test. It may be as long as 20-25 minutes, so in that amount of
time, the paperwork isn't going to take 25 minutes so it's enough time to bring up
different information. (Participant 106)
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Reflecting on Alternative Forms of PrEP
In the quantitative survey participants were asked to respond to how they believed their
PrEP implementation behaviors would change if alternative forms of PrEP or alternative policies
existed. Responses to these questions can be found in Table 4.2.
Table 4.2. Likelihood of talking about PrEP

There is ongoing research about the use of
PrEP injections (instead of a daily pill). Which
is true of you? If injections were availablea
There is ongoing research about the use of
intermittent PrEP (instead of a daily pill, a pill
that would be used before and after a
potentially risky sexual encounter). Which is
true of you? If intermittent PrEP was
approveda
If talking about PrEP with clients during HIV
testing/counseling was required for funding
purposes, how would your likelihood of telling
clients about PrEP change?b
If talking about PrEP with clients during HIV
testing/counseling was mandated by the
state, how would your likelihood of telling
clients about PrEP change? b
a.
b.

My likelihood of
telling clients
about PrEP
would be about
the same
n (%)

I would be
less likely
to tell
clients
about PrEP
n (%)

I would be
more likely
to tell
clients
about PrEP
n (%)

126 (84.6)

2 (1.3)

21 (14.1)

111 (74.5)

4 (2.7)

34 (22.8)

103 (69.6)

0 (0)

45 (30.4)

100 (67.6)

0 (0)

48 (32.4)

One participant did not provide a response
Two participants did not provide a response

Alternative forms of PrEP, although not explicitly covered in the interview guide, emerged during
the qualitative interviews: This included injectable PrEP which is in clinical trials, but not yet
approved for general use (Landovitz, Kofron, & McCauley, 2016).
I learned that there's injectables. There's a little implant that they put under the skin that
has to be removed and then they could put another one in, but it's removed every two
months or something like that. The injectables that are ...they originally thought it was
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gonna be three months, but they found that it's probably gonna be two months because
it doesn't stay as long (Participant 115).
Participants also discussed “on-demand” PrEP:
There's also, I think a lot of curiosity and a lot of people asking about PrEP on demand is
what they're calling it back in Europe, but it's essentially the idea of getting certified for
PrEP, but not really taking it until you're going to expose yourself to risk, right. A lot of
the studies have been done in Europe that show as long as you've been taking your
medication for seven days or more you're protected. People might get their meds, but
not really start taking them…If they're on an insurance company that might cause trouble
with their insurance, we have to be careful not to get dropped off the program and stuff
like that, but I think people are trying to figure out how to make it work for themselves
(Participant 104).
While sometimes discussions of alternative forms of PrEP reflected knowledge of emerging
technology, other statements concerned participants:
The most common misconception is that they think it works immediately and they only
have to take it right before they go out or something like that (Participant 117)
It's even been found that there are people that get on PrEP and they almost treat it as a
Morning After pill (Participant 109).
Another participant described an alternative dosing regiment:
It varies. It really does vary because we have had instances where somebody was like,
"Oh, no, I only take two on Friday, one on Saturday, one on Sunday, and two on Monday
for my weekend so that I can have sex like that." It's like, that's not how it works.
(Participant 115)
These findings are important because clients believe they are receiving the protection of PrEP,
even when taking a dosing regimen not approved by the FDA. In reality, some methods of
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alternative dosing could be clients at greater risk, since their perception of risk would be
different than the actual risk they may be experiencing.
Client Barriers and Facilitators to PrEP Access and Use
Within the CFIR domain Outer Setting participants were asked to reflect on the
facilitators and barriers that their clients had to PrEP access and use. Client needs were a
particularly salient topic for HIV testing staff. Key sub-themes reflecting client needs and
resources are listed in Appendix B. While these barriers and facilitators to PrEP initiation among
clients were prevalent across all PrEP implementation groups (Universal, Eligibility Dependent,
and Limited), they were discussed in greatest detail among participants in the Universal group.
While it may seem contrary that those promoting PrEP are most aware of the barriers to PrEP
implementation, it is likely because the Universal participants talk about PrEP with their clients
most frequently; as such, Universal participants are most aware of the facilitators and barriers to
PrEP initiation experienced by their clients.
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SECTION 5: CONCLUSIONS AND PUBLIC HEALTH IMPLICATIONS
Overview of Findings
Together, the results of these two manuscripts and the emerging analyses provide
insight into the role HIV testing staff have in PrEP implementation. A description of related
hypotheses, analyses, and results can be found in Table 5.1.
Manuscript one sought to understand the latent PrEP implementation subgroups within
an existing population of HIV testing staff. Latent Class Analysis suggests three subgroups of
HIV testing staff taking part in PrEP implementation: 1) Universal participants who are
advocates for PrEP and speak about PrEP with most clients, regardless of eligibility status; 2)
Eligibility Dependent participants who talk with clients about PrEP when they believe the client
may be eligible; and 3) Limited participant who may speak to clients about PrEP, but do so
inconsistently.
Manuscript two answered two research questions. The first research question sought to
understand the relationship between the CFIR domain Characteristics of Individuals and PrEP
implementation within HIV testing sites. Understanding the role of Characteristics of Individuals
(i.e. staff performing HIV testing) is important because these staff are the people in closest
contact with the clients during the HIV testing process, thus able to directly connect with clients
and share information or referrals regarding PrEP. If PrEP-related knowledge, self-efficacy,
and/or attitudes were found to be significantly associated with PrEP implementation outcomes,
then PrEP implementation trainings could target these areas. The quantitative results from
manuscript one suggests no statistically significant findings between PrEP implementation
groups and most variables under the CFIR domain Characteristics of Individuals. Two
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participant characteristics, sexual orientation and race, were statistically significantly related to
PrEP implementation during the HIV testing process. Those in the Limited group were
significantly less likely to identify as a sexual minority (e.g. homosexual, bisexual) than as
heterosexual. Additionally, compared to participants in the Universal and Limited groups,
participants in the Limited group were less likely to identify as a racial minority. Qualitative
findings revealed that a more nuanced understanding of PrEP knowledge, beliefs, and selfefficacy may be needed to fully understand how these constructs may affect PrEP
implementation by HIV testing staff. Participants also noted their personal beliefs regarding
PrEP – including concerns about side effects, cost, and behavior change. These beliefs may
impact the way in which HIV testing staff talk about PrEP with their clients.
The second research question furthered the investigation of PrEP implementation in HIV
testing sites utilizing the CFIR. Quantitative results from manuscript two suggest that greater
access to PrEP-related resources, such as brochures to hand clients (i.e. available resources
under the CFIR domain Inner Setting) and relative priority to implement PrEP over the many
other things that need to be completed during the HIV testing process (a variable under the
CFIR domain Outer Setting) may be positively associated with PrEP implementation.
Specifically, participants in the Universal group were more likely than participants in the
Eligibility Dependent group to indicate availability of physical resources regarding PrEP to share
with clients (e.g. PrEP-related brochures, referral cards, etc.). Compared to the Limited group,
participants in the Universal group were more likely to indicate that implementing PrEP was a
priority within their organization. Qualitative findings revealed that staff providing HIV testing felt
they were aware of patient needs and resources (an Outer Setting construct within the CFIR).
This self-reported awareness of patient needs and resources occurred regardless of their
implementation group. Such needs and resources reflected facilitators and barriers to PrEP
implementation – namely, stigma, the role of medical providers, varied levels of client
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knowledge, and client concerns regarding the cost and side effects of PrEP. Although
participants in all implementation groups discussed these Outer Setting patient needs and
resources, solutions to potential barriers were primarily discussed among participants in the
Universal and Eligibility Dependent groups. Perhaps participants within these implementation
groups are more dedicated to PrEP implementation, thus more committed to finding a solution
for barriers to PrEP initiation for their clients. Cosmopolitanism also emerged in the qualitative
findings, reflecting a potential need for specific quantitative measures regarding the role of
cosmopolitanism in the referral process in future research. The strength of the ties occurring
between organizations may also be an important consideration to explain PrEP implementation
within HIV testing sites. For example, knowledge of the services another organization provides
may produce different outcomes than having a memorandum of understanding with another
organization. These ties between organizations could be quantified in a meaningful way to
better understand how cosmopolitanism affects PrEP implementation within HIV testing sites.
Theoretical Implications
Collectively, these findings provide an understanding of the role that staff who perform
HIV testing have in PrEP implementation, spanning multiple levels of the Socio-ecological
Model. Constructs found under the CFIR domains Characteristics of Individuals (i.e.
intrapersonal characteristics), Inner Setting (i.e. organizational characteristics) and Outer
Setting (i.e. characteristics external to the organization) can help to explain PrEP
implementation during HIV testing. Together these findings provide an initial understanding of
PrEP implementation within HIV testing sites.
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Table 5.1. Research Questions, Hypotheses, Related Analyses, and Related Findings
Research Question
Hypotheses
Research question 1:
Within the population of HIV testing staff, subpopulations
What, if any, PrEP
exist based on PrEP Implementation behaviors.
implementation subgroups
exist among staff
providing HIV testing in
Florida?

Research question 2:
What characteristics of the
individual are associated
with PrEP implementation
during HIV testing, as
guided by the domain of
CFIR (i.e. characteristics
of the individual)?

Research question 3:
What inner and outer
setting factors are
associated with PrEP
implementation during HIV
testing, as guided by the
domains of CFIR?

High levels of PrEP knowledge, PrEP-related self-efficacy,
prior/current PrEP use, and positive personal PrEP
motivations and beliefs will be associated with greater
frequency of referrals and/or PrEP discussion (i.e. PrEP
implementation), when controlling for key organizational
factors. Low levels of PrEP knowledge, PrEP-related selfefficacy, and negative personal PrEP motivations and
beliefs will be associated with lower frequency of referrals
and/or PrEP discussion (i.e. PrEP implementation) when
controlling for key organizational factors.

A belief that clients need the option for PrEP (patient
needs and resources), cosmopolitanism; pro-PrEP internal
policy and incentives, structural characteristics, culture,
tension for change, compatibility, relative priority; a positive
learning climate; and PrEP-related available resources will
be positively associated with high levels of PrEP
implementation; while a belief that clients do not have a
need for the option of PrEP (patient needs and resources);
limited cosmopolitanism; anti-PrEP external policy and
incentives, structural characteristics, culture, tension for
change, compatibility, relative priority; a negative learning
climate; and a lack of PrEP-related available resources will
be negatively associated with greater frequency of referrals
and/or PrEP discussion (i.e. PrEP implementation).
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Related Analyses
Descriptive Statistics
Latent Class Analysis
Thematic Analysis

Descriptive Statistics
Generalized linear
mixed model
[multinomial distribution;
logit link]
Thematic Analysis

Descriptive Statistics
Generalized linear
mixed model
[multinomial distribution;
logit link]
Thematic Analysis

Related Results
Latent Class Analysis suggests three
subgroups of HIV testing staff taking part
in PrEP implementation: 1) Universal
participants who are advocates for PrEP
and speak about PrEP with most clients,
regardless of eligibility status; 2)
Eligibility Dependent participants who
talk with clients about PrEP when they
believe the client may be eligible; and 3)
Limited participant who may speak to
clients about PrEP, but do so
inconsistently.
Generalized linear mixed model results
suggest that neither knowledge, selfefficacy, nor PrEP attitudes were
associated with assignment to a
particular PrEP implementation group;
however the participant characteristics
sexual orientation and race may be
important predictors of PrEP
implementation group affiliation.
Qualitative findings suggest the
important of participant knowledge and
beliefs in understanding PrEP
implementation
Inner setting constructs relative priority
(see generalized linear mixed model
results) and available resources (see
quantitative and qualitative findings) may
be important predictors of successful
PrEP implementation
Outer setting constructs patient needs
and resources (qualitative findings) and
cosmopolitanism (qualitative findings)
may be important predictors of
successful PrEP implementation

Alternative theoretical applications may have provided additional explanation of the data.
For example, manuscript two examined Characteristics of Individuals, a CFIR domain inclusive
of intrapersonal characteristics. Perhaps, then, a dual application of CFIR and an intrapersonal
theory could provide additional insight into the intrapersonal facilitators and barriers to PrEP
implementation. As discussed earlier, Walsh and Petroll (2016) investigated the role of primary
care providers in PrEP implementation via an exploration of the intrapersonal factors that could
predict provider discussion and prescription of PrEP. These researchers applied the
Information-Motivation-Behavioral Skills model in their investigation. Additional intrapersonal
theories that could be applied include the Theory of Planned Behavior and Health Belief Model,
as constructs related to these theories have been applied elsewhere in the PrEP
implementation literature (Krakower, Oldenburg, et al., 2015).
Study Strengths and Weaknesses
There are many strengths in this study. To date, there has been a paucity of research
investigating PrEP implementation within HIV testing sites. This study sought to fill this gap in
the literature by providing an investigation into the role HIV testing staff have in PrEP
implementation. Additionally, this study adds to the limited theory-based research on PrEP
implementation in non-medical sites. This study also utilizes a mixed methods design –
providing both qualitative and quantitative data related to PrEP implementation. This mixed
methods approach allowed for triangulation of the study findings and reliability of the findings.
Additionally, this study took place in a state with diverse geographic variability and high rates of
both HIV incidence and prevalence, Florida (FDOH, 2016a). Finally, the data in this study are
from staff who provide HIV testing at community-based organizations. As such, the participants
are nested within organizations. This study utilizes general linear mixed modeling to take the
nested nature of the data into account – a step often ignored in the literature.
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Weaknesses also exist in this study. This study occurred in Florida, a single state within
the United States. Although Florida is a high HIV prevalence state, these findings may not be
applicable to other geographic locations, especially those that were early adopters of PrEP.
Participants were assured that their responses would not be shared with their employers;
however, some participants may have feared organizational repercussions and not been truly
honest in all responses – especially if their actions were against the organizational policy of the
agency in which they worked. Additionally, even those participants who were not concerned that
their employer may see their responses may have been affected by social desirability bias.
Although treating the clustered data appropriately was a strength of the study, this approach
could be strengthened by including organizational (level 2) variables, such as the agencyreported number of clients served or internal policies of which the staff who provide HIV testing
may be unaware. Inclusion of organizational variables would allow for a deeper investigation
into organizational differences – possibly increasing our understanding of PrEP implementation
within HIV testing sites. In this dissertation data was only collected from staff who provide HIV
testing. Organization, agency, or supervisor data (all possible considerations for level 2
variables in a two-level multilevel model) were not collected in this dissertation for several
reasons. There is limited data available on the role that staff who provide HIV testing have in the
implementation process. Thus, data collection at one level (i.e. from the staff who provide HIV
testing) was an important first step. Future research should explore a diverse range of data
sources that could impact PrEP implementation during HIV testing, including, other agency staff,
supervisors, and/or clients.
Implications for Policy, Practice, and Future Research
Practice
This study was driven by the need to understand PrEP implementation occurring within
HIV testing sites. By its very nature, PrEP implementation within HIV testing sites is practice
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based. The theoretical framework used throughout this study (CFIR) also provides guidance on
how the study findings relate to practice-based implementation. Investigating the Characteristics
of Individuals can help us to better understand the intrapersonal characteristics needed to
implement PrEP. In this study, only participant characteristics (sexual orientation and race)
statistically significantly impacted group membership (i.e. if a participant belonged in the
Universal, Eligibility Dependent, or Limited group). However, qualitative findings revealed the
importance of a more intricate understanding of PrEP knowledge and beliefs. Some participants
had PrEP knowledge scores, despite stating an incomplete or inaccurate understanding of PrEP
implementation. In practice, hands-on training may be beneficial to further investigate gaps in
PrEP implementation knowledge by staff performing HIV testing. Additionally, people identifying
as a sexual and/or racial minority were less likely than their counterparts not identifying as
sexual or racial minorities to be in the Limited group; people in these demographic groups are
also more likely than their peers to be adversely impacted by HIV (CDC, 2015; FDOH, 2016a).
Perhaps this is because there is a more urgent need to address HIV within these communities,
thus influencing their commitment to PrEP implementation.
In this study, Outer Setting constructs were not statistically associated with PrEP
implementation; however, qualitative findings indicted that both patient needs and resources
and cosmopolitanism may be important to understanding the role of HIV testing staff in PrEP
implementation. In practice, staff providing HIV testing can use these findings to better prepare
the ways in which they engage with clients. For example, understanding client concerns
regarding PrEP-related side effects can help staff providing HIV testing to research and better
understand these concerns so that they have an appropriate, accurate, and culturally relevant
response for their clients. The salience of cosmopolitanism may suggest the need for staff who
provide HIV testing to attend networking or community-wide meetings. These findings also
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highlight the importance of formalizing organizational partnerships with written policies or
MOUs.
Several constructs within the CFIR domain Inner Setting were found to be associated
with PrEP implementation: relative priority and available resources. Inner Setting characteristics
help to explain which organizational characteristics may be enhanced or changed to promote
PrEP implementation within HIV testing sites. For example, if an organization is trying to
implement a PrEP program, providing physical resources to their clients may be a good place to
start. Some participants stated that these resources provided them with confidence, while others
simply noted their usefulness for clients.
Policy
These findings may also have implications for the interplay between federal and
organizational level policy on PrEP implementation. Some participants within the same
organization reported inconsistent knowledge of an organizational policy regarding if, or when,
they should talk about PrEP with clients. Organizations can use these findings to more
consistently promote internal policies within organizations to ensure all participants have the
same level of awareness. While some organizations may implement PrEP related activities due
to organizational values and a belief that PrEP is an important component of an HIV prevention
framework, others may need external motivation. Government agencies and community-based
organizations may be more likely to include PrEP in programming if it is linked to funding. The
CDC has linked some programmatic funding to PrEP related activities – making PrEP-related
counseling a required deliverable to for some, but not yet all, HIV prevention grants (CDC,
2016a). Other grant announcements encourage PrEP implementation activities, but do not
require them as a condition of funding (CDC, 2016b, 2016c). However, availability of, and the
terms associated with, such funding may vary based on the economic or political climates.
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Past research has shown providers may be more likely to adopt guidelines that are
endorsed by professional organizations. For example, in a study of dental health, professional
organizations were seen as influential in promoting and disseminating guidelines (Vamos et al.,
2015). This has already proven true to some degree for PrEP related guidelines. One study that
took place prior to the release of the CDC PrEP guidelines found that, among Massachusetts
providers, 96% indicated that formal CDC guidelines would increase their likelihood to prescribe
PrEP (White, Mimiaga, Krakower, & Mayer, 2012). It is not unrealistic to believe that
endorsements by other professional entities would also encourage consideration of PrEP.
Moreover, dissemination of PrEP guidelines (Lachowsky et al., 2016; The White House Office of
National AIDS Policy, 2015; U.S. Public Health Service, 2014; World Health Organization,
2012b, 2014, 2015) may also assist with giving medical staff and others the needed information
to implement PrEP within organizations.
Another area of policy implication is at the state level. The Florida Department of Health
(FDOH) is currently involved in a statewide push for PrEP implementation via state-run health
departments. The findings of this dissertation can help the state in implementing PrEP
programming within their own health departments and in partnering community organizations.
For example, although external policies and incentives were not particularly salient in these
findings, the use of the DH1628 was. The requirement to complete the DH1628 is due to the
mandatory reporting of HIV to the federal government. Thus, a continued policy enforcing the
use of this form would be supported by these findings.
Research
This study also has implications for future research. Based on the findings of this study,
a continued investigation into the role that HIV testing sites have in PrEP implementation is
needed. Future research could include organizational level data, or a three-level model inclusive
of clients receiving HIV testing, staff performing HIV testing and organizations/supervisors
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overseeing these staff. This multi-prong approach would provide more clarity on PrEP
implementation within this setting. The presence of significant or emerging CFIR constructs also
lends itself to engagement in future research. As discussed in theoretical considerations,
application of the intrapersonal data, from the CFIR domain Characteristics of Individuals, to an
intrapersonal level theory may be useful. Additionally, the role of weak and strong ties in relation
to cosmopolitanism could be further investigated through a social network analysis examining
how the strengths and density of such ties contribute to successful PrEP implementation.
Emerging qualitative findings suggest that staff who provide HIV testing may be a useful vehicle
to promote other important sexual health/HIV prevention techniques, including: Hepatitis C, the
undetectable = untransmittable movement, and PEP. Studies utilizing implementation science
could investigate the barriers and facilitators to implementation of these prevention mechanisms
in addition to PrEP.
Building on the study limitations, further work in the measurement of PrEP
implementation should also be explored. The items used for Latent Class Analysis could be
vetted by a broader audience and a variety of items could be applied. Additionally, although the
application of the CFIR constructs/variables was based on technical assistance provided on the
CFIR website, measurement work is needed to understand the best number and types of items
to measure each construct/variable (Damschroder, 2016).
Final Remarks
Despite PrEP being an important component of the HIV prevention toolkit, the prevention
method remains underutilized. PrEP implementation is needed via a variety of sites – including
those sites that could assist in non-medical implementation aspects of PrEP. HIV testing sites
are one such location. This study contributes to the growing body of literature examining the
implementation science behind PrEP programming. Findings indicate that key demographic
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characteristics, as well as highlighted variables with in the Inner and Outer Settings of the CFIR,
may be important to consider when implementing PrEP programs within HIV testing sites.
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APPENDIX A: LITERATURE REVIEW
Establishing a Need for PrEP
HIV Rates: Globally, Domestically, and Locally
Human Immunodeficiency Virus (HIV) is an incurable infection that can result in
Acquired Immune Deficiency Syndrome (AIDS). The virus is spread through exchange of blood,
fluids exchanged during sex, and sometimes breastmilk (CDC, 2015). Although preventable,
HIV remains a significant problem globally, in the United States (U.S), and in Florida. According
to the World Health Organization (WHO), over 36 million people worldwide were thought to be
living with HIV in 2015; including an estimated 1.9 million new diagnoses in that same year
(Joint United Nations Programme on HIV/AIDS, 2016). The number of new diagnoses, and the
treatment available to individuals who are diagnosed with a positive HIV serostatus, varies
widely by region, gender, and a multitude of other factors (Joint United Nations Programme on
HIV/AIDS, 2016).
The Centers for Disease Control and Prevention (CDC) estimated that approximately 1.2
million people in the U.S. were living with HIV in 2012 (CDC, 2015). Although the annual
number of newly diagnosed HIV cases has declined in the last decade, there were still nearly 45
thousand people newly diagnosed with HIV in 2014 (CDC, 2015). These new diagnoses have
disproportionately affected Black (44% of new diagnoses) and Hispanic (23% of new diagnoses)
Americans, women (19% of new diagnoses), and gay, bisexual, and other men who have sex
with men (MSM; 67% of new diagnoses) (CDC, 2015).
Florida is particularly important for HIV prevention. The state ranked second in the U.S.
for the number of new HIV infections in 2014, and third in the nation for the cumulative number
of people living with HIV (FDOH, 2016a). As with the nation, Black and Hispanic Floridians, as
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well MSM, have higher rates of HIV than other demographic groups in the state, with rates of
47%, 21%, and 77%, respectively (FDOH, 2016a).
The State of HIV Prevention
Social, behavioral, and structural HIV prevention has included efforts that address the
social determinants of health, community and structural changes, and behavioral interventions.
In a large-scale review, Rotheram-Borus and colleagues (2009) found that more than 140
interventions were available, and efficacious, in promoting HIV risk related behavior change;
however, the target populations for these interventions, as well as access to the interventions is
not universal. Biomedical prevention methods include those focusing on the non-behavioral
methods of HIV prevention, such as methods directly affecting the biological transmission of the
virus. Emtricitabine/tenofovir DF as pre-exposure prophylaxis (henceforth, PrEP) has been
introduced as an innovative way to curb the spread of HIV. This method of HIV prevention
includes daily use of antiretroviral medication (ARVs) by HIV-negative individuals who are at
high risk of acquiring HIV. The CDC (2016f) describes such high risk individuals as: “people who
are HIV-negative and in an ongoing sexual relationship with an HIV-positive partner.(para 4) ”
PrEP information delivery, referral, or prescriber visit (henceforth referred to as PrEP
implementation) is important to implementing these guidelines. PrEP is rooted in a history of
other biomedical methods for HIV prevention and care, among them: ARV use to reduce mother
to child HIV transmission, ongoing microbicide and vaccine trials, post-exposure prophylaxis
(PEP), male circumcision, and treatment as prevention (TasP) (McCormack, Gafos, Desai, &
Cohen, 2014; Rotheram-Borus et al., 2009). Some practitioners have also considered condom
use, treating sexually transmitted infections (STIs), and HIV testing as biomedical methods of
prevention (Rotheram-Borus et al., 2009).
Despite social dialogue suggesting there has been a shift away from socio-behavioral
prevention to biomedical HIV prevention, researchers tend to agree that combination prevention
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– including biological, structural, and socio-behavioral prevention methods – is the key to
furthering the success of HIV prevention (Kippax & Stephenson, 2012; Koblin et al., 2013;
McNairy & El-Sadr, 2014; Rotheram-Borus et al., 2009; Underhill, Operario, Skeer, et al., 2010).
This is because, even with the evolution of efficacious biomedical preventions, there exists a
social side of prevention – including promoting initiation and adherence to these methods,
partner-based communication, and the need for behavioral counseling or interventions
(Rotheram-Borus et al., 2009; Underhill, Operario, Skeer, et al., 2010). Additionally, McNairy
and El-Sadr (2014) recommend prevention to be an ongoing process, similar to the HIV care
continuum, where the HIV prevention continuum describes the iterative steps needed to reduce
the spread of HIV. Krakower and Mayer (2016) take this prevention continuum a step further to
propose a “cascade for PrEP” to document available providers, awareness and training of these
providers, prescription practices, and peer-based training. Similarly, Kelley et al. (2015) have
developed a PrEP cascade for clients, documenting the steps necessary to get the most
effective outcomes from PrEP (including actions such as PrEP initiation and adherence).
Efficacy and Effectiveness of PrEP for HIV Prevention
An Introduction to PrEP Trials
As previously stated, PrEP is the use of ARVs by individuals with a negative HIV
serostatus to reduce the likelihood of acquiring HIV (CDC, 2014). Pharmacological efficacy
studies have included tenofovir disoproxil fumarate (referred to as TDF) and a combination of
tenofovir-emtricitbine (referred to as TDF/FTC); some studies have also compared these two
formulations for the use of PrEP (Jiang et al., 2014; Spinner et al., 2016). This study refers to
combination TDF/FTC (also known by its brand name Truvada) as PrEP, and its use as a daily,
oral medication, as this is the formulation currently approved by the Food and Drug
Administration (FDA). Studies on intermittent PrEP use (PrEP used only immediately before and
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after HIV exposure) and other drug formulations used as PrEP are ongoing (Spinner et al.,
2016), and their implementation will not be directly studied in this study.
PrEP efficacy has varied across studies, with systematic reviews reporting efficacy to be
between 44 to 86%; when adjusted for adherence (and thus, concentration of the drug actually
in the blood), reported efficacy has been higher, varying between 74 to 92% (Spinner et al.,
2016). This has led many governmental agencies to market PrEP as up to 92% effective (CDC,
2016f). As will be noted in the following section, some agencies use the highest possible
efficacy when PrEP is taken every day as intended, as indicated in pharmacological studies to
be 99% (Anderson et al., 2012).
It is important to note that although studies are often segregated based upon sexual
orientation and gender categorization, the drug concentration present varies by the type of
tissue (vaginal, anal, etc.), and thus is most relevant to the type of sex in which an individual
engages (anal, vaginal, etc.), rather than solely based on the gender or sexual orientation of the
person taking PrEP (Buchbinder & Liu, 2015). However, studies addressing how the
pharmacological effect of the medication varies between males and females are also warranted.
Through the current dissemination of PrEP (as a daily, oral pill), studies have found that drug
concentrations are greatest in the rectal tissue, followed by blood and vaginal/cervical tissue
(Anderson et al., 2012). Because studies have found that the drug concentration in anal tissue
is higher than within vaginal tissue, it is plausible that PrEP may have a greater protective effect
for anal sex when compared to vaginal sex. It is also important to note that some studies have
found PrEP to be less efficacious than others. These studies, and the researchers’ rationale for
low efficacy, will also be reviewed in the following paragraphs, and have led to important
guidelines regarding the level of adherence needed to achieve the maximum effect of HIV risk
reduction (Murnane et al., 2013).
The efficacy of PrEP in seminal efficacy trials will be discussed in the sections following.
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Efficacy among Men Who Have Sex with Men and Transgender Women
One of the best known and most commonly cited PrEP efficacy trials, the iPrEx study,
occurred over four continents, enrolling 2499 MSM and transgender women in a randomized
control trial (Grant et al., 2010). This study reported that Truvada reduced the incident rate of
HIV by 44% in the study sample (Grant et al., 2010). Based on a secondary data analysis,
Anderson et. al. (2012) reported the rate of risk reduction varied based upon the number of
PrEP doses participants took each week; where, when PrEP was taken twice a week
participants were 76% less likely to contract HIV, 96% less likely when four doses were taken
per week, and 99% less likely when PrEP was taken all seven days of the week (Anderson et
al., 2012). Anderson and colleagues (2012) reported that the rate of efficacy in the iPrex trial
would likely have been greater if participant had better rates of adherence.
The iPrEx team hypothesized that PrEP may most benefit particular subpopulations of
MSM at the highest risk of HIV infection, and studied the factors most likely to result in HIV
infection among the participants in the control group (Buchbinder et al., 2014).These
researchers examined the number need to treat (NNT) across the control group, and within
specific sub-populations of the control group who may have been at increased risk of HIV
infection. When examining the full control sample, the NNT was 62 (meaning that 62 people
need to take PrEP daily for a year before someone receives the benefit of an adverted HIV
infection) (Buchbinder et al., 2014). The NNT was lower in subpopulations with increased risk of
HIV infection, such as those regularly engaging in receptive condomless anal sex (NNT of 36),
using cocaine (NNT of 12), or with a current STI diagnosis (NNT of 41) (Buchbinder et al.,
2014). Meaning that without PrEP, men and transgender women in these subpopulations would
have been at a particularly heightened risk of acquiring HIV. In fact, these researchers suggest
that:
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the simplest and perhaps most effective strategy for identifying MSM/TGW [men who
have sex with men and transgender women] who may benefit most from PrEP would be
to ask two questions of men and TGW: In the last three months, have you 1) had sex
with men, women, or both; and 2) had anal sex as a bottom without a condom (ncRAI).
By offering PrEP to MSM/TGW reporting ncRAI, regardless of partner serostatus, PrEP
would be offered to the subgroup of MSM/TGW most likely to benefit from PrEP
(Buchbinder et al., 2014, p.6).
The iPrEx study had very few transgender women and, although the risk behaviors
being examined in transgender women study participants were the same as those being studied
among the MSM participants (condomless anal sex, drug use, etc.), research has shown that
transgender women are at an increased risk of HIV acquisition, warranting further studies
(Deutsch et al., 2015; Grant et al., 2016). Combining MSM and transgender women in the study
has been noted as a limitation by the iPrEx researchers (Grant et al., 2016), but has also
allowed the benefits of PrEP to be studied in a population at a particularly high risk for HIV
infection. Sub analyses by the iPrEX team revealed that adherence was particularly low among
transgender women when compared to MSM (Deutsch et al., 2015). Additionally, staff in both
research and practice have questioned how the hormones used by some transgender women
may impact the efficacy of PrEP (Anderson, Reirden, & Castillo-Mancilla, 2016). However, initial
findings have suggested that these hormones will likely not affect the efficacy of PrEP, and that
more research is needed specifically among transgender women (Anderson et al., 2016).
Researchers examining PrEP implementation have further investigated the unique barriers and
facilitators to PrEP initiation and use among transgender women.
Efficacy among Heterosexuals and Opposite-sex Partners
A recent systematic review indicated that several randomized control trials have
investigated PrEP efficacy among heterosexual men and women (Jiang et al., 2014). These
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studies included sexually active women, heterosexual couples, and serodiscordant couples
(Jiang et al., 2014). The efficacy achieved across these studies ranged widely, including rates of
65% (study inclusive of only high-risk women), 62% (study inclusive of heterosexual discordant
couples), 73% (study inclusive of heterosexual discordant couples), 6% (study inclusive of
women), and 63% (study inclusive of heterosexual men and women).
The Partners PrEP study was a randomized, double-blind, placebo controlled clinical
trial of nearly 5000 serodiscordant heterosexual couples throughout Kenya and Uganda,
examining the use of FTC/TDF and TDF alone as PrEP (Baeten et al., 2012). This study
resulted in such significant efficacy results (reporting an overall 67% protection with TDF; 75%
efficacy with FTC/TDF) (Baeten et al., 2012; Donnell et al., 2014), that the placebo arm of the
study was discontinued (Donnell et al., 2014). These protective results were found in both the
male and female participants taking part in the study.
Subsequent studies of the clinical data from Partners PrEP study further investigated the
drug concentrations in the blood of participants. Donnell et al. (2014) examined the treatment
arm of the study, comparing the 29 cases in which seroconversion occurred with 196 randomly
chosen participants from those who did not seroconvert. Researchers found that the
concentration of PrEP in the blood of those who did not convert was consistently high; among
those who seroconverted the concentration of PrEP in the blood was only high among 5 of the
29 seroconverters. Thus, among the majority of participants who converted to a positive HIV
serostatus, adherence was likely low (Donnell et al., 2014). This study also found that the
protective effect of PrEP was higher among participants taking FTC/TDF, compared to TDF
alone (Donnell et al., 2014). Subanalyses investigating the protective rate of PrEP for individuals
at a particularly high risk of HIV infection (such as having a partner with a high viral load) and by
gender have also been reported (Murnane et al., 2013). In high risk women, efficacy ranged
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from 69 to 84% (Murnane et al., 2013). In an additional study of over 1,000 heterosexuals in
Botswana, PrEP efficacy was 62.2% (Thigpen et al., 2012).
Some studies have reported lower rates of efficacy for PrEP. The FEM PrEP study
among African women found PrEP to not be efficacious, either as TDF or FTC/TDF (Marrazzo
et al., 2015). This study cites low adherence as a possible reason for the findings; but points to
an important need to better understand adherence in PrEP implementation. Kingori (2015)
explains that these trials began as a way to further social justice and create better prevention
methods for women, particularly African women who were disproportionately affected by, and
infected with, HIV (Kingori, 2015). However, women in the intervention arm of this study were
just as likely to contract HIV as their counterparts in the control arm. Low adherence is thought
to be the culprit in this trial. The reports, however, are conflicting, as biological data indicates
low adherence and self-reported data indicated consistent PrEP and birth control use. In
addition to the lack of protection from HIV, nine pregnancies occurred in this study, leading
researchers to increase their suspicions of low adherence (Kingori, 2015).
Efficacy among Injection Drug Users
There is limited clinical data available assessing the efficacy of PrEP among injection
drug users. Only one clinical trial (a randomized, double-blind, placebo-controlled trial), the
Bangkok Tenofovir Study, has assessed the efficacy of PrEP among injection drug users
(Choopanya et al., 2013). This study was conducted in Thailand among 2413 men and women
who had injected drugs in the past year (Choopanya et al., 2013). Findings resulted in a nearly
50% reduction in HIV incidence; 17 participants (of 1204 in the study arm) and 33 participants
(of 1209 in the control arm) seroconverted during the study. When participants with low (or not
present) levels of PrEP were removed from efficacy analyses, the efficacy in the treatment arm
increased to 73.5%.

127

International and Domestic Guidelines for PrEP
PrEP is supported by a wide array of governmental agencies. These agencies are
similar in that they support, or provide suggested guidelines, for PrEP implementation. As in all
public health implementation, the guidelines are a great start, but only the beginning of creating
systematic organizational change (Bhattacharyya et al., 2009).
It is also important to note that PrEP is not the right choice for everyone. These
guidelines suggest indications for beginning PrEP, but this is just an option. People should be
offered the information and given the choice in making the decision best for them, typically
alongside a healthcare provider.
WHO/Global PrEP Recommendations
Early guidance from the WHO in 2012 found the clinical trials to be promising, and
encouraged demonstration projects for serodiscordant couples, MSM, and transgender women
(World Health Organization, 2012b). WHO officially recommended PrEP for MSM in 2014, and
expanded this recommendation to all high risk populations in 2015 (World Health Organization,
2015). The WHO recommendations are similar to those elsewhere (to be discussed in the
paragraphs following), in that PrEP is recommended only when combined with other prevention
methods, such as condom use and behavioral counseling. PrEP has also been included as an
important option within the WHO report Guidance on couples HIV testing and counselling
including antiretroviral therapy for treatment and prevention in serodiscordant couples:
recommendations for a public health approach (World Health Organization, 2012a).
U.S. National Guidelines and Recommendations
In 2011, the CDC published interim guidelines for PrEP use (Smith et al., 2011), followed
by comprehensive guidelines recommending the use of PrEP, alongside condom use and other
prevention methods, for such individuals at high risk for acquiring HIV
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Other County-Specific Guidelines
The availability and recommendation to use Truvada as PrEP varies widely between
countries. Currently, PrEP demonstration projects are also ongoing in Australia, Belgium,
Botswna, Brazil, Canada, Netherlands, Nigeria, Peru, South Africa, Thailand, France, India,
Italy, Kenya, Malawi, Uganda, United Kingdom, United States, Zambia, and Zimbabwe (PrEP
Watch, 2016b), but many of these countries do not have regulations or guidelines regarding
PrEP use. A review by Elion and Coleman (2016) noted that, as of 2015, PrEP had only been
approved by regulatory bodies in the United States; yet, this has not stopped researchers from
exploring the potential for PrEP implementation worldwide, or stopped people from beginning
the use of PrEP (either post clinical trials or independent of clinical trials). Since Elion and
Coleman’s review, PrEP has been registered in several countries, including: Australia, Canada,
France, Kenya, Peru, and South Africa (PrEP Watch, 2016a). However, outside of the U.S., only
Botswana, France, Kenya, Malawi, and South Africa have current national guidance for PrEP
implementation (PrEP Watch, 2016a). The cost and availability of PrEP also varies by country;
for example, in France and Norway PrEP is provided free of charge (PrEP Watch, 2016a).
However, PrEP was only recently approved by the European Medicines Agency for high risk
populations, and remains unregistered in many countries, limiting its prescription availability in
many European countries (Cairns, McCormack, & Molina, 2016; Spinner et al., 2016).
PrEP Implementation in the United States and Beyond
As review by Elion and Coleman (2016) eloquently described:
The first challenge in [PrEP] implementation in the US is to get individuals to recognize
the actual risks that their behaviors represent and to engage with providers to address
these issues. The second challenge is getting a population of providers to recognize the
exact same issues and offer PrEP in a compassionate, nonjudgmental fashion. The third
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challenge is identifying the set of providers and locations to scale-up the response in a
timely, cost-effective fashion. (p.1).
These challenges are being researched to determine the most effective way to implement PrEP
in the U.S., and certainly have implications for PrEP implementation globally. This section will
discuss the main issues in PrEP implementation, with a focus on domestic implementation in
the U.S. Special considerations for PrEP implementation globally, and within Florida, will also be
discussed.
Demonstration Trials
Although PrEP is now considered to be part of an HIV prevention regiment for at-risk
populations (Liu et al., 2014; Mayer et al., 2013), many individual, structural, and communitylevel barriers limiting the success of PrEP initiatives still exist. PrEP demonstration projects are
ongoing in the U.S. and abroad (AVAC: Global Advocacy for HIV Prevention, 2016). For
example, PrEP Watch, an advocacy organization, has logged at least 51 demonstration and
implementation projects worldwide (AVAC: Global Advocacy for HIV Prevention, 2016; PrEP
Watch, 2016b). According to the WHO (2014),
“The demonstration projects are aimed to serve two purposes: 1) enable countries to
learn enough about implementation issues related to PrEP so that the transition between
research, including demonstration project research, and the wider expansion and
institutionalization that is entailed in scaling up implementation is more feasible; and 2)
enable WHO to extract generalizable information for the eventual development of
guidelines for PrEP delivery more generally” (para. 2).
Such demonstration projects are ongoing and supported by governmental agencies such as the
CDC and the National Institute of Health (NIH) (CDC, 2016c).
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Provider/Stakeholder Awareness, Knowledge, and Opinions on PrEP
Engaging providers and other stakeholders is critical to PrEP implementation. Although
research is still needed, there is a growing literature surrounding stakeholder views of PrEP
implementation (Arnold et al., 2012; Brooks et al., 2011; Scholl, 2016; Tellalian, Maznavi,
Bredeek, & Hardy, 2013). Common themes have emerged in the literature regarding the views
of both medical providers and other stakeholders.
PrEP awareness, knowledge, and prescribing practices have varied across specific
types of clinical providers. Several studies have found that, compared to doctors specializing in
HIV or infectious diseases, general medical providers were less aware, less informed, and less
likely to prescribe PrEP to their clients (Krakower & Mayer, 2016; Krakower et al., 2015;
Mimiaga, White, Krakower, Biello, & Mayer, 2014). It has been suggested that, although HIV
care providers primarily serve people living with HIV, these providers may be important in
disseminating PrEP to people who are at a high risk of HIV infection with a negative serostatus;
largely because they are already familiar with the medication, side effects, and speaking openly
about HIV with clients. Several studies have reported high levels of PrEP knowledge and
awareness among HIV care providers (Blumenthal et al., 2015; Finocchario-Kessler et al., 2016;
Krakower, Oldenburg, et al., 2015; Tellalian et al., 2013). In 2011, Tellalian et al. (2013)
surveyed nearly 200 American HIV care providers regarding PrEP. Knowledge that PrEP was
an efficacious intervention was high in this population (90% familiar with efficacy results and
CDC recommendations); yet, rates of ever having prescribed PrEP were low (19%) (Tellalian et
al., 2013). Another study of HIV care providers found similar results; almost half of the providers
had been asked about PrEP from their clients, and nearly 20% had prescribed PrEP (Krakower
& Mayer, 2012). However, in a recent mixed methods study of 85 providers across seven U.S.
cities, HIV care providers were aware of PrEP; Approximately 20% had prescribed it and over
70% would consider prescribing it (Finocchario-Kessler et al., 2016). However, these studies
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are limited by convenience samples that may bias the results. Beyond HIV care providers, other
provider types have also been studied to assess PrEP awareness and knowledge. A study of
over 1000 infectious disease doctors found that while most doctors had heard of PrEP, the
majority (91%) had never prescribed it (Karris et al., 2014). Moderate rates of PrEP knowledge
were found in a studies of generalist in several U.S. based states (Krakower & Mayer, 2012;
Krakower, Oldenburg, et al., 2015; White, Mimiaga, Krakower, & Mayer, 2012). Lower rates of
PrEP knowledge have been reported in military-based healthcare providers (Hakre et al., 2016)
and family planning providers (38% of providers being able to define PrEP) (Seidman et al.,
2016). Additionally, at least one study has found that policy members and program level staff
expressed initial willingness to support PrEP implementation (Wheelock et al., 2012).
Acceptance and awareness of PrEP has appeared to increase in providers since the release of
the CDC PrEP Guidelines in 2014 (Krakower & Mayer, 2016; Smith, Mendoza, Stryker, & Rose,
2016). However, despite this general increase in knowledge and acceptance, there may be
differential understanding in the prescribing practices of PrEP, where prescribers are more
comfortable addressing a need for sexual risk reduction, than for injection drug users (another
target group for PrEP consideration) (Adams & Balderson, 2016; Krakower & Mayer, 2016). A
2015 study found that providers may differentially provide PrEP to clients within certain risk
populations, such as prescribing to those at highest possible risk for HIV – MSM in
serodiscordant partnerships (Adams & Balderson, 2016; Smith et al., 2015), or biases in
prescription by race (Calabrese et al., 2014). Moreover, there are mixed findings regarding if
PrEP awareness and knowledge alone results in prescribing practices; with some researchers
finding this PrEP knowledge was associated with a greater likelihood of prescribing PrEP
(Blumenthal et al., 2015), and others noting that PrEP knowledge was unlikely to result in an
increase in prescribing practices (Krakower & Mayer, 2016). Therefore, it is important to
examine other factors that may affect prescribing practices.
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Providers have noted several benefits of and facilitators to PrEP implementation. As
described above, high knowledge of PrEP has been found in some studies to be associated
with a greater likelihood to be willing to prescribe PrEP (Blumenthal et al., 2015; Tripathi,
Ogbuanu, Monger, Gibson, & Duffus, 2012). A Massachusetts based study found that providers
believed several factors would increase their likelihood of prescribing PrEP: patient request of
PrEP, recommendations by professional or government groups, and additional efficacy trials
yielding promising results (White et al., 2012). Since the time of this study, the latter two items
on this list have become a reality. Another facilitator prompting willingness to prescribe PrEP
among providers included a belief that PrEP could empower women (Tripathi et al., 2012).
Among HIV care providers the most important factor triggering screening for PrEP was the
patient being a serodiscordant relationship; however, these findings may be unique to HIV care
providers who regularly serve people living with HIV (Tellalian et al., 2013).
However, providers have also expressed concern regarding PrEP implementation in a
standard clinical environment, and uncertainty regarding the most appropriate locations to
dispense PrEP (Arnold et al., 2012; Karris et al., 2014). HIV care providers have expressed
some concern with PrEP, including: fear of medication resistance, increased sexual risk
behaviors, and lack of adherence among patients (Blumenthal et al., 2015; Calabrese et al.,
2016; Krakower & Mayer, 2012; Tellalian et al., 2013; White et al., 2012). Additional barriers
have included structural barriers, such as the need for training (Bacon et al., 2016; Calabrese et
al., 2016; Seidman et al., 2016), logistical concerns (Calabrese et al., 2016; Seidman et al.,
2016), and questions about billing and laboratory needs (Calabrese et al., 2016; Seidman et al.,
2016). The amount of clinical efficacy data to support PrEP prescription has also been
questioned by some providers (Hakre et al., 2016).
A broader concern regarding the lack of sexual health communication between clients
and providers may also limit the reach of PrEP interventions (Krakower & Mayer, 2012; Thrun,
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2013). However, suggestions for incorporating HIV risk screening into routine health exams
have been suggested in the literature (Krakower & Mayer, 2012; Thrun, 2013). Hesitation
regarding talking about sexual health may occur in both clients and providers. For example,
Mehta et al. (2011) found that, among MSM in New York City, the majority of men stated their
primary care provider was not aware that they had sex with men; these findings were replicated
in a study in several urban locations throughout the east coast, where over half of young MSM
reported that they had never told their provider that they had sex with men (Arrington-Sanders
et al., 2016). This is particularly important because some findings have suggested that being out
to a provider about sexual orientation is associated with awareness of PrEP (Raifman et al.,
2016). Clients not being out to their provider about their sexual orientation may further
complicate the implementation of PrEP because providers may not be aware of which HIVrelated risk factors for which to screen. One solution to both the lack of provider knowledge
about client risk behaviors, and overcoming the discomfort in talking about sex with clients, is
the use of tablet based risk assessment; a focus group of MSM suggested this method could
assist providers in conducting preliminary risk behavior screenings and may start the
conversation about sexual health between patients and providers (Jones et al., 2014).
Client/At-risk Population Views
Recent data suggests that over one million people in the U.S meet the clinical
indications for PrEP (Smith et al., 2015). This includes nearly 25% of sexually active MSM,
nearly 19% of injection drug users, and nearly 0.5% of heterosexual adults (Smith et al., 2015).
Studies have found that candidates for PrEP use are willing to consider using it. In one study of
nearly 2,000 people considered possible candidates for PrEP across seven countries,
willingness to use PrEP was found to be at least moderately high (Eisingerich et al., 2012).
Population specific barriers have also been identified, such as varied programmatic needs for
MSM and women (Arnold et al., 2012; Mayer et al., 2013; Underhill, Operario, Mimiaga, et al.,
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2010). Specific implementation considerations for priority populations are described in greater
detail below. Additional county-level barriers will be discussed in the section Special
Considerations for Global PrEP Implementation.
PrEP, MSM, and Transgender Women
The majority of social-behavioral PrEP research has focused on MSM and transgender
women, due to the disparate rates of HIV that occur in these populations. The term MSM is
widely used throughout public health research and practice. The term is thought to provide an
epidemiological approach to measure sexual behavior, without the complexity added by the
introduction of culture and identity (Young & Meyer, 2005). The differentiation between sexual
behavior and sexual orientation is thought to be important because a greater number of men are
categorized as MSM than identify as homosexual or bisexual alone (Gates, 2011). To further
complicate matters, many studies group MSM and transgender women into a single risk
category, despite transgender women being at increased risk of HIV infection and identifying as
women (Baral et al., 2013; Herbst et al., 2008). Typically, this is because the studies are using
risky anal sex or use gender assigned at birth as the inclusion criteria for the study. MSM have
also been identified as a priority population for being screened for HIV related risks and possible
PrEP prescription (CDC, 2014; FDOH, 2016c; U.S. Public Health Service, 2014; World Health
Organization, 2012b, 2014, 2015). This section will discuss several factors important to PrEP
implementation among MSM (including TGW); namely, awareness of PrEP, barriers and
facilitators to PrEP uptake, and other factors affecting PrEP implementation.
Early PrEP studies proposed hypothetical scenarios depicting a medication that could
reduce the likelihood of contracting HIV; during this time PrEP trials were underway and
promising results had emerged (Liu et al., 2008; Nodin, Carballo-Dieguez, Ventuneac, Balan, &
Remien, 2008). Additional studies asked participants about both PrEP and post-exposure
prophylaxis (PEP) concurrently (Liu et al., 2008; Mehta et al., 2011). However, more recently
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researchers have identified repeat PEP users to discuss the possibility of PrEP (Jain, Krakower,
& Mayer, 2015; Siemieniuk et al., 2015). In 2011, Mehta et. al. found limited awareness of PrEP
among MSM surveyed in New York City bathhouses; in a sample of over 550 participants, less
than 40% had knowledge of PrEP or PEP, the latter of which has been approved for many
years. This knowledge and acceptance of PrEP among MSM has increased over time, as noted
in a systematic review of 33 studies conducted between 2008 and 2012 (Young and McDaid,
2014). This same systematic review found that acceptability of PrEP ranged from 28 to 80%
among MSM (Young & McDaid, 2014). However, despite this acceptability, PrEP initiation
remains low (Scholl, 2016), warranting an investigation into facilitators and barriers to PrEP
initiation beyond knowledge.
Several facilitators of and barriers to PrEP implementation among MSM have been
noted in the literature. Reasons for interest in PrEP among MSM have included desires to
protect oneself against HIV, reduce the associated fears with contracting HIV, or to have
unprotected sex (Young & McDaid, 2014). Facilitators to going on PrEP have included the
availability of free or low-cost medication, as well as access to healthcare and HIV testing
(Golub et al., 2013). However, among men who were already engaged in PrEP care, several
studies have found that medication costs were not seen as a significant barrier to its initiation or
continued use (Chan et al., 2016). Men have also noted concerns with the availability of PrEP
(Brooks et al., 2011; Young & McDaid, 2014) and fears regarding potential side effects of the
medication (Brooks et al., 2011; Golub et al., 2013; Mantell et al., 2014; Scholl, 2016; Young &
McDaid, 2014). Some men and transgender women have also noted concerns regarding drug
resistance if they were to acquire HIV after using PrEP and questioned the efficacy of PrEP
(Golub et al., 2013). Because concerns may vary between men and transgender women in
monogamous relationships compared to those who are not in a monogamous relationship,
researchers have noted that specific interventions may be needed based on relationship status,
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and that it is important to remember that a “standard” system for implementing PrEP may differ
even within groups of MSM (Muessig & Cohen, 2014).
Moreover, specific strategies may be needed to implement PrEP in transgender women.
Recent data has suggested that there has been low uptake of PrEP by TGW (Kuhns et al.,
2016; Marshall & Mimiaga, 2015). Facilitators for PrEP initiation among these women have
included stigma free clinical environments and medical staff who are gender affirming (Grant et
al., 2016; Marshall & Mimiaga, 2015; Sevelius, Deutsch, & Grant, 2016). Barriers specific for
transgender women have included fear of discrimination and violence (Escudero, Kerr,
Operario, et al., 2015; Marshall & Mimiaga, 2015).
Demographic and behavioral factors have also been studied in relation to willingness to
try, or acceptability of, PrEP among MSM and transgender women. To date, the studies
comparing demographic factors to PrEP acceptability or willingness have yielded mixed results
(Young & McDaid, 2014). In an analysis based on 2011 data collected in New York City, interest
in taking PrEP varied significantly based upon race and ethnicity; where Latino men expressed
the most interest in PrEP (over 70% interested), followed by Black men (just under 70%
interested), and lastly White men (less than 40% interested) (Mantell et al., 2014). Golub et al.
(2013) also noted possible racial differences in the acceptance of PrEP; however, these
findings indicated that men who were Black and Latino rated the concerns and barriers to PrEP
use higher than their White counterparts. Although there is no comprehensive database of PrEP
users, available data suggests the men most likely to use PrEP are middle and older aged
adults who are White (Snowden et al., 2016). This variation in PrEP uptake by race and
ethnicity may further exasperate the disparities in HIV rates in minority populations (Galindo et
al., 2012; Snowden et al., 2016). Other studies have confirmed that PrEP knowledge may be
higher among men living with HIV than in the general population of MSM (Mantell et al., 2014).
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This may help implementation because, although men living with HIV cannot use PrEP, they
can suggest its use to appropriate partners.
PrEP and Women
Because women are at greater biological susceptibility to HIV than men, and are more
likely to experience partner resistance to condom use, there has been a push for female
centered HIV prevention methods (Chen, Meyer, & Springer, 2011; Kofman & Adashi, 2014;
Mastro, Sista, & Abdool-Karim, 2014). PrEP is one such method women can use to reduce the
spread of HIV (Kofman & Adashi, 2014; Mastro et al., 2014; Matthews et al., 2010). Despite this
need, lower rates of PrEP awareness among women, compared to MSM, have been cited
throughout the literature (Auerbach et al., 2015; Garfinkel et al., 2016). In a study of nearly 150
young adult women accessing a family planning clinic in 2014, 60% of women would be willing
to take a daily pill to reduce the likelihood of HIV infection, but few were aware of it (Garfinkel et
al., 2016). Data has suggested that despite limited knowledge of PrEP, women in the U.S. may
find PrEP an acceptable and worthwhile intervention after being informed about the risks and
benefits of the intervention (Auerbach et al., 2015; Flash et al., 2014; Rubtsova et al., 2013).
Many of the facilitators of and barriers to PrEP uptake for women are similar to those
experienced by MSM. For example, women have noted concerns with costs, side effects, and
related stigma from using PrEP (Auerbach et al., 2015; Flash et al., 2014; Geary & Bukusi,
2014). The efficacy of PrEP in women was also questioned among women (Auerbach et al.,
2015). Women have also expressed concern with side effects their partner may experience, a
barrier not noted in the literature regarding men (Flash et al., 2014).
Demographic characteristics have also been shown to affect PrEP uptake in women.
One study found Black women were more likely than their non-Black counterparts to report
willingness to take PrEP (Garfinkel et al., 2016). Despite hope that PrEP can be utilized among
women experiencing domestic violence, at least one study indicated women who had
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experienced domestic violence were less willing to take PrEP (Garfinkel et al., 2016). Potential
barriers to PrEP among women experiencing intimate partner violence have included the
partner questioning the need for the medical visit and/or their partner expressing resistance to
PrEP initiation (Braksmajer, Senn, & McMahon, 2016).
PrEP and Serodiscordant Couples
PrEP also has implications to provide another method of safe conception for
serodiscordant couples, sometimes referred to as PrEP-C (Heffron et al., 2016; Lampe et al.,
2011; Mack et al., 2014; Matthews et al., 2010; Matthews et al., 2014; Matthews et al., 2012;
Ngure et al., 2016; Whetham et al., 2014). This method has been used in the United Kingdom
(UK), resulting in no HIV infections and in seven of ten couples birthing a child (all also with a
negative HIV serostatus) (Whetham et al., 2014). Some results have also suggested that PrEP
adherence may be higher in serodiscordant couples attempting pregnancy than in general
populations of people using PrEP (Matthews et al., 2014); but this adherence may be
complicated by the typical ups and downs that occur in relationships (Ware et al., 2015; Ware et
al., 2012). Heterosexual serodiscordant couples have also expressed interest in learning more
about PrEP (Falcao et al., 2016). Similar to other groups meeting PrEP indications, concerns
over cost, efficacy of PrEP, and related side effects were salient among serodiscordant couples
(Falcao et al., 2016). Additional studies have found concerns regarding increased stigma
brought to the relationship due to PrEP use (Idoko et al., 2015; Mack et al., 2014).
Of course, PrEP may also be useful for serodiscordant couples not trying to get
pregnant. A study among women in serodiscordant relationships found that hormone birth
control can be safely used with PrEP, affecting neither the efficacy of the birth control or PrEP
(Heffron et al., 2014). Men were more likely than women to mention such non-conception based
reasons for PrEP use in serodiscordant relationships (Falcao et al., 2016).
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PrEP and Injection Drug Users
Compared to other risk groups, limited research has been conducted on PrEP and
injection drug users. This dearth of research was noted in a 2014 review of PrEP
implementation among injection drug users, citing limited empirical research on the topic
beyond the initial efficacy trials (Escudero et al., 2014). Not surprisingly, injection drug users are
perhaps the population least aware of PrEP. A Washington, D.C. based study found that out of
over 300 participants surveyed in 2012, only 13% had heard of the use of ARVs to prevent HIV
(Kuo et al., 2016). Other studies have also produce low rates, averaging about 30% willingness
to use PrEP (Escudero, Kerr, Wood, et al., 2015).
Among injection drug users, cost of PrEP was the most frequently cited concern related
to PrEP use (Kuo et al., 2016); however, gender specific norms and housing concerns also
emerged in the literature (Stockman, Ludwig-Barron, Hoffman, Ulibarri, & Dyer, 2012).
Adherence may also be an issue among injection drug users, especially among young men,
those who are transient, or those who experience time in jail or prison; preliminary results have
indicated that adherence may also differ based on the type of injection drug being used (Martin
et al., 2015). Stakeholders have also noted concerns regarding how PrEP may affect the uptake
of other harm reduction activities (Escudero et al., 2014; Kuo et al., 2016). Similarly, there has
also been some concern that PrEP will become a solely biomedical approach, limiting the
conversation about other HIV prevention strategies for injection drug users, such as
rehabilitation or needle exchange programs (Escudero et al., 2014; Kuo et al., 2016).
Demographic characteristics may also play a role in PrEP implementation among those
who inject drugs. Page et al. (2015) suggest that women who are injection drug users are told
about, or screened for, PrEP less often than their male counterparts; they go on to suggest that
specific interventions and strategies may be needed to target women who are injection drug
users. Des Jarlais et al. (2015) call for a need to address minority groups of people who are
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injection drug users, as this population is most at risk for HIV transmission via injection drug
use. If we do not address these demographic factors, disparities in HIV infection could increase.
Other Considerations
Other considerations important to PrEP implementation do exist. While these topics are
critical to the long-term implementation of PrEP, they are beyond the scope of this project
(examining the implementation of information delivery and prescription referral within HIV testing
sites in Florida), and will only be briefly mentioned here. Such considerations include fear of risk
compensation, uncertainty of PrEP adherence, and debates regarding the cost-effectiveness of
PrEP. Each of these will be briefly explained below.
In the context of PrEP, risk compensation has been described as a perception of
decreased HIV related risk due to using PrEP (Golub, Operario, & Gorbach, 2010). There have
been mixed findings in the literature regarding PrEP and risk compensation resulting in riskier
sexual behavior. Some studies have reported a possible increase in possible risk compensation
while using PrEP (de Wit et al., 2015), while others have found that PrEP use does not affect a
persons perceived level of risk (Grov, Whitfield, Rendina, Ventuneac, & Parsons, 2015; Marcus
et al., 2013; Sowicz, Teitelman, Coleman, & Brawner, 2014). There is a field of literature
studying sexual risk behaviors while a person is on PrEP, and how these behaviors may differ
from sexual behaviors prior to PrEP use. Sexual risk compensation is important in the study of
PrEP implementation, but not directly related to the factors affecting the facilitators and barriers
of PrEP implementation within the context of publicly funded HIV testing sites. Sexual risk
compensation is briefly mentioned again below, as it relates to ethical implications of PrEP.
Biomedical researchers have suggested that adherence should play a particularly
important role in the PrEP demonstration projects (Anderson et al., 2012). Social-behavioral
PrEP research has included studies on adherence (Daughtridge, Conyngham, Ramirez, &
Koenig, 2015; Hosek et al., 2013; Marcus et al., 2014; Tangmunkongvorakul et al., 2013;
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Underhill, Operario, Skeer, Mimiaga, & Mayer, 2010; Ware et al., 2012). For example, PrEP
adherence was found to be high in a group of young men who have sex with men, where, on
average, participants who had been on the medication for at least one month were 73%
adherent to their daily dose (Daughtridge et al., 2015). A qualitative study of serodiscordant
couples found that adherence may be motivated by trying to maintain the serostatus of the
negative partner, while also fulfilling the emotional and physical needs of both partners (Ware et
al., 2012). Research also suggests that adherence may be greater in those who actively seek
out and bring up the possibility of PrEP on their own accord, without prompting from medical
staff (Calabrese et al., 2016). Adherence may also be affected by time. Six-month retention in
care was low (approximately 50%) across a study of MSM in three urban locations (Chan et al.,
2016). Although researchers have noted the importance of adherence, they have also reminded
us that this is not a new phenomenon; in fact, adherence is not unique to biomedical programs,
but a requirement for any program to be effective (Rotheram-Borus et al., 2009).
The cost-effectiveness of PrEP implementation have also been studied. Costeffectiveness analyses have found PrEP to be a cost-effective addition to standard HIV
prevention activities in some populations (Alistar, Owens, & Brandeau, 2014); although these
findings have varied based upon the age of the client and long-term pricing of PrEP (Paltiel et
al., 2009). A systematic review of cost-effectiveness analyses found mixed results regarding
PrEP use in a U.S. based setting; where some studies found PrEP use to be cost effective,
especially when considering how PrEP may limit the horizontal transmission of HIV, while others
noted that it is only cost-effective when aimed at those most at particularly high risk of acquiring
HIV (Gomez et al., 2013). It has also been suggested that PrEP may be most cost effective in
global contexts or within populations where HIV is endemic (Verguet, Stalcup, & Walsh, 2013).
Special Considerations for implementing PrEP globally
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Although PrEP is recommended for high risk populations, it remains unregistered in
many countries, limiting its ability for prescription (Cairns et al., 2016). Despite this, researchers
have studied PrEP acceptability in numerous global settings, for example: Peru, UK, China,
Kenya, Uganda, and India (Young & McDaid, 2014).There are some people within these
countries who are able to receive PrEP through research trials, friends, or through off label
prescription scripts from their providers (Philpott, 2013). Other countries may not require
medication to undergo review at a national regulatory body, limiting prescribing restrictions.
There are also online pharmacies catering to those who are unable to get PrEP in their country
of residence or unable to obtain the medication otherwise (An et al., 2014) .
Target populations for PrEP implementation may vary between countries. For example,
the need for PrEP implementation with women may be higher in sub-Saharan Africa compared
to the United States, based upon social norms and risks and prominent transmission routes
(Celum et al., 2015; Chirenje, Marrazzo, & Parikh, 2010; Matthews et al., 2014). Different
cultural aspects may also come into play for a global PrEP perspective. For example, in
Western Kenya, fishermen and widows are considered targeted populations for PrEP
implementation due to the cultural norms surrounding the trade of sex for fish and widow
cleansing (Mack et al., 2014); while in India a target group for PrEP implementation has
included truck drivers (Schneider et al., 2010). Concerns regarding staffing to assist with PrEP
implementation are also particularly salient in the global community (Mack et al., 2014).
Not surprisingly, just as access to PrEP varies, awareness and willingness to take PrEP also
varies globally. Due to the wide variety of countries in which PrEP may be helpful, it is
impossible to provide comprehensive rates of awareness and knowledge. However, some
themes do exist. Some Western countries, such as Canada, have rates of PrEP knowledge and
acceptance similar to those of the U.S. (Karris et al., 2014) For example, limited awareness of
PrEP was found in Canada in 2011 (approximately 12% of the sample) (Leonardi, Lee, & Tan,
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2011), but these rates were much higher (greater than 50%) in a 2016 study (Kesler et al.,
2016). In a multinational study of PrEP acceptability, with respondents from Peru, Ukraine,
India, Kenya, Botswana, Uganda, and South Africa, acceptability of PrEP was generally high;
over 90% of the sample said they had at least some level of interest in using PrEP (Eisingerich
et al., 2012), although knowledge of PrEP prior to the survey was not assessed. Research
conducted by Zablotska et al. (2016) found that knowledge and use of PrEP were low in the
Asia-Pacific region, with the exception of a few countries. For example, willingness to use PrEP
in 2013 among Thai MSM was high, with 80% of one study’s sample reporting willingness
(Wheelock et al., 2013). Thailand may be better prepared, in terms of infrastructure and
resources, for PrEP implementation (Zablotska et al., 2016). In Latin America, PrEP knowledge
varied widely, but implementation was found to be very limited (Ravasi et al., 2016).
The concerns among global PrEP candidates are similar to the concerns documented
among PrEP candidates in the U.S. For example, cost (Eisingerich et al., 2012; Galea et al.,
2011; Ravasi et al., 2016; Wheelock et al., 2013), efficacy (Galea et al., 2011; Kesler et al.,
2016), stigma (Galea et al., 2011; Zablotska et al., 2016), and related side effects (Eisingerich et
al., 2012; Galea et al., 2011; Kesler et al., 2016; Wheelock et al., 2013) were noted concerns in
many global contexts. The facilitators and barriers to PrEP implementation in Canada are
particularly similar to those in the United States (Karris et al., 2014). Globally, some studies
have reported a moderate likelihood that clients would share their PrEP medication with family
or friends (Eisingerich et al., 2012; Kingori, 2015)or, in some cases, sell the medication
(Eisingerich et al., 2012; Wheelock et al., 2013). This is concerning because intermittent PrEP
use is currently not medically indicated, and adherence is an important part of the efficacy of
PrEP. Concerns over client ability to trust the prescribing staff have also been raised (Galea et
al., 2011; Schneider et al., 2010). Internationally, significant barriers may also exist surrounding
sexual orientation, legality, and stigma (Taegtmeyer et al., 2013; Zablotska et al., 2016). For
144

example, in Kenya, providers have noted that although PrEP may be a good intervention for
MSM, being publicly out as a man who has sex with men has serious legal ramifications that
would likely affect uptake (Taegtmeyer et al., 2013).
Special Considerations for implementing PrEP in Florida
Florida is a particularly important climate for PrEP implementation, as it consistently
ranks among the top three states for new HIV diagnoses (FDOH, 2016a), thus warranting a
need for prevention activities. The State of Florida Integrated HIV Prevention and Care Plan
2017–2021 (FDOH, 2016c) lists the following as one of four key components in the state plan:
“Incorporate antiretroviral pre-exposure prophylaxis (PrEP) and non-occupational post-exposure
prophylaxis (nPEP) as a risk reduction strategy” (p.11). Along with this component are specific
PrEP related activities that the state hopes to implement within the next 4-5 years, among them:
to develop resources for community based organizations, create a statewide inventory of PrEP
friendly providers, increase and train PrEP navigators, and utilize social marketing in the
dissemination of PrEP related information (FDOH, 2016c). There are some challenges to
achieving this goal, however, because of Florida’s diverse geography, demographic groups, and
political climates.
A handful of PrEP-related studies have been conducted specifically in Florida. DobleckiLewis and Jones (2016) conducted focus groups with providers and other administrative staff
working in south Florida Federally Qualified Health Centers. These staff supported PrEP
implementation, though it was not currently being prescribed at most of their sites (DobleckiLewis & Jones, 2016). Although these findings mirrored some of the same facilitators and
barriers described in the rest of the United states (in terms of cost, availability, and insurance);
some concerns were raised that have not been seen elsewhere in the literature, including
concerns related to immigration and related access to healthcare (Doblecki-Lewis & Jones,
2016). Shaeer, Sherman, Shafiq, and Hardigan (2014) surveyed pharmacists in Florida to
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assess knowledge, attitudes, and perceptions of PrEP. This study revealed low levels of
knowledge among pharmacists in Florida regarding PrEP and PrEP counseling (Shaeer et al.,
2014). Pharmacists expressed concerns regarding sexual risk compensation, cost, and an
increase in the spread of sexually transmitted infections (Shaeer et al., 2014), similar to those
previously reported among primary care providers.
Major Gaps in the Literature Regarding PrEP Implementation Domestically
The PrEP literature is relatively new and, in many ways, still emerging. Researchers
investigating PrEP have indicated several directions for future research in the field of HIV
prevention and PrEP. Researchers investigating the biological efficacy of PrEP have suggested
future research on intermittent PrEP, or alternative delivery methods - including gels, rings, and
injections (Jay & Gostin, 2012). It has also been suggested that future research should address
disparities in PrEP accessibility and uptake (Jay & Gostin, 2012; Sugarman & Mayer, 2013),
and an increase in locations where PrEP is implemented (Underhill, Operario, Mimiaga, et al.,
2010; Underhill, Operario, Skeer, et al., 2010). There is also a lack of theoretically driven
research for PrEP implementation, despite the fact that HIV frameworks and theories for guiding
HIV prevention activities are widely available in the literature (Fishbein, 2000). After the success
of the efficacy trials, there was a call for the need of implementation research – including the
best ways to move the clinical PrEP findings into practice (AVAC: Global Advocacy for HIV
Prevention, 2016; Caceres, Mayer, Baggaley, & O'Reilly, 2015; Caceres, O'Reilly, Mayer, &
Baggaley, 2015). The proposed research contributes to this literature by answering the call for
implementation research via unique provider settings – HIV testing sites.
Implementing PrEP in HIV Testing Programs
To best reach the populations in need, researchers have suggested that PrEP
information delivery, referral, and prescriber visits should occur in a diverse array of settings,
including emergency room departments, primary care doctors, and infectious disease specialist
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sites (Smith et al., 2015; Underhill et al., 2014; Underhill, Operario, Mimiaga, et al., 2010;
Underhill, Operario, Skeer, Mimiaga, & Mayer, 2010); however, not all of these settings have
been explored for PrEP implementation. A notable amount of research has been conducted
within sexually transmitted disease clinics, as well as an array of non-generalists sites. A study
of Lesbian-Gay-Bisexual-Transgender (LGBT) clinics in Boston suggests that PrEP referral and
prescription may be higher in LGBT focused settings than in generalist offices alone (Krakower,
Maloney, Grasso, Melbourne, & Mayer, 2016). Smith et. al. (2016) conducted a study of 175
community-based organizations, both clinical and non-clinical in nature, and examined the
knowledge and infrastructure for PrEP implementation at these sites. While the organizations
were knowledgeable about PrEP, non-clinical CBOs felt ill-equipped for PrEP related activities
(Smith et al., 2016). Despite feeling ill-equipped, these agencies were still interested in being
involved in PrEP implementation (Smith et. al., 2016).
There is a paucity of research regarding the specific role HIV testing sites in non-clinical
settings may have in PrEP implementation. Existing studies have only utilized HIV testing sites
for recruitment of people who may be eligible for PrEP (Gallagher et al., 2014; King, et al. 2014),
and have not focused on the role staff performing HIV tests have in PrEP implementation. HIV
testing sites are an ideal location for PrEP implementation because these sites often provide
services free of charge, and not dependent upon health insurance - unlike many other health
care services. Additionally, such locations already collect information on sexual risk behavior,
and may provide an easy outlet for PrEP implementation. Research with providers has indicated
that support staff were important to the successful implementation of PrEP (Calabrese et al.,
2016). Staff performing HIV testing could be one group of support staff to bridge the gap
between PrEP information delivery and clinical prescription. Furthermore, researchers
examining practice viewpoints of PrEP implementation also suggested the possibility of
providing PrEP linkages during HIV testing campaigns (Jay & Gostin, 2012; King et al., 2014).
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Integration of HIV Testing and Other Related Services
Advocates of PrEP have stated that it is necessary to develop integrated delivery
systems to increase the number of people accessing PrEP; akin to the suggestion to meet
people where they are (Delany-Moretlwe, Mullick, Eakle, & Rees, 2016). HIV testing has been
successfully integrated into other healthcare settings – perhaps most notably immunization
programs (Chamla et al., 2015; Wang et al., 2015), antenatal care settings (An et al., 2015;
Turan et al., 2015), family planning settings and sexual and reproductive healthcare services
(Ngo, Ha, Rule, & Dang, 2013; Schwartz et al., 2015; White et al., 2013), sexually transmitted
infection clinics (Balira et al., 2015; Moss, Martin, Klausner, & Brown, 2014; Sweeney et al.,
2014), and as part of substance abuse rehabilitation (Guerrero, Aarons, & Palinkas, 2014;
Hood, Robertson, & Baird-Thomas, 2015). In addition to specialty clinics, HIV testing has also
been conducted as part of primary care services (Myers et al., 2012). Despite concerns about
stigma related to HIV testing (Chamla et al., 2015; White et al., 2013), such programs have
been successful and considered acceptable (Chamla et al., 2015). In fact, in some settings,
such integration has been shown to increase the utilization of both services (HIV testing and the
services provided at the site of HIV testing integration) (Chamla et al., 2015; Ngo, Ha, Rule, &
Dang, 2013; Turan et al., 2015; Wang et al., 2015). Concerns about integrating HIV testing and
other services have included limited resources, such as supplies and staff time (An et al., 2015;
Hood et al., 2015; Sweeney et al., 2014). These concerns will likely hold true for integration of
PrEP referral and prescription into HIV testing sites; but, in the long run such integration may
prove to be successful, just as the programs discussed above have been.
Existing Systems for Training People to Implement PrEP Referral and Prescription
To my knowledge no public PrEP implementation training is available specifically for
staff performing HIV testing, although, anecdotally, some organizations may have internal
trainings. Additionally, referral systems would likely be based on the geographic area in which
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the organization is based. However, numerous trainings are available for clinical providers,
government staff, researchers, and others regarding PrEP. These resources can be accessed
and used by those implementing PrEP referral and prescription during HIV testing.
These resources include assistance with payment, indications for PrEP, and general information
about PrEP. They also have resources for both lay workers, providers, and clients available.
Training and informative resources can be found at many locations, including the government
and nonprofit entities [for example, the CDC (CDC, 2016d, 2016e), AIDS Education and
Training Centers (Herman, 2014), National Network of STD Clinical Prevention Training Centers
(National Network of STD Clinical Prevention Training Centers, 2015)], through the
manufacturer of Truvada, Gilead (Gilead, 2016) , and state-specific agencies [for example, the
Florida Department of Health (FDOH, 2016b), or the Minnesota AIDS Project (Minnesota AIDS
Project, 2016)]. The U.S. Public Health Service (2014) has a clinical supplement for the PrEP
guidelines, with resources that can be used to screen for HIV-related risk, handouts that can be
used to discuss PrEP with clients, and many other helpful resources. Although designed for
medical providers, these resources could be used and adapted by staff performing HIV testing
to provide accurate and complete information to clients.
PrEP navigators, and related training programs, have also been created to assist clients
with navigating the procedures and paperwork necessary for PrEP prescription and payment
(California Department of Public Health, 2016; Minnesota AIDS Project, 2016). In addition, it is
within the Florida state plan to expand PrEP navigators within our state (FDOH, 2016c). To
assist with PrEP referral or finding a provider who is PrEP-friendly, Emory has a PrEP locator
service (Emory University, 2016). In addition to the information described above, specific
resources are offered to medical providers. The University of San Francisco is federally funded
to provide clinical consultation about PrEP free of cost via the Internet or phone to anyone in the
U.S. (UCSF Clinician Consultation Center, 2016). One limitation is that this resource is meant to
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assist with clinical matters and does not assist with navigating the insurance, payment, or
existing co-pay assistance programs (UCSF Clinician Consultation Center, 2016). The
university also provides free consultation on PEP, HIV care, and prevention of mother to child
transmission (UCSF Clinician Consultation Center, 2016).
Contribution to PrEP Implementation Literature and HIV Prevention
This study is among the first to investigate the facilitators of and barriers to PrEP
implementation specifically occurring during HIV testing. Such findings could support PrEP
implementation at other less conventional sites for PrEP implementation, such as drug
rehabilitation sites or community-based organizations. This study is also among the first to
examine PrEP implementation using a theoretical framework. This study may contribute to
findings promoting the availability and uptake of PrEP in Florida and more broadly. It adds a
particularly important piece to the literature, because programs implemented based on findings
from a theoretical framework are thought to be more likely to produce positive change (Davidoff,
Dixon-Woods, Leviton, & Michie, 2015; Glanz & Bishop, 2010).
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APPENDIX B: QUALITATIVE THEMES DERIVED FROM CFIR CONSTRUCT PATIENT
NEEDS AND RESOURCES
Table B.1. Qualitative themes derived from CFIR construct Patient Needs and Resources:
Perceived client barriers and facilitators to PrEP initiation
Client concern regarding the potential side effects of PrEP
“Some people would come in and be concerned, they would have a very high sexual activity
throughout the year, but they would be like, ‘No, PrEP gives people symptoms, I don't wanna
have to not sleep at night or get nauseous all the time.’ Then we would go and explain,
symptoms happen with every drug, but once your body gets used to it, once your body
notices the drug then it won't do that anymore. So, some people wouldn't even try PrEP
because of those fears.”
– Participant 116, Universal implementation group
“People are worried about side effects of taking PrEP”
– Participant 107, Eligibility Dependent implementation group
“I’ve gotten a couple where I've been asked if there's any side effects of PrEP, and so I would
discuss some possible side effects, the reason why the labs are drawn, to measure kidney
and liver function is one of the possible side effects, and a couple of the common ones like
nausea, vomiting, or uneasiness in the first couple weeks. Kind of going through common
symptoms.”
– Participant 121, Eligibility Dependent implementation group

Medical doctors as a barrier to PrEP implementation
“The big thing that I have seen is physicians, especially primary care physicians who don't
even know what PrEP is. I don't think that in all of their continuing education that physicians
have to do, or even nurse practitioners or anything of that nature ... I think that having that
implemented toward care providers would go a long way. Because I have seen so many
people who come in and they'll say, "One, I don't want to bring it up with my doctor." Or
they're not out to their doctor if they happen to be LGBTQ. And then of course, like the older
private practice physicians, around here especially, it's just not anything they know about, so
they're not going to prescribe it. So that's been our biggest barrier as far as getting people on
PrEP, is we have a lot of people who do have primary care physicians, but they don't know
about it or they refuse to prescribe it because they don't know about it. Whether we send the
material or try to set up a meeting with them or not.”
– Participant 105, Universal implementation group
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“I feel like there needs to be more providers that are knowledgeable about PrEP that we don't
have. I've had so many clients come and tell me, ‘Hey, I went to my primary care doctor and
they told me that they couldn't prescribe me PrEP because they didn't know what it was.’ Or,
they would be like ‘You need to go see Infectious Disease because it's an Infectious
Disease.’”
-- Participant 116, Universal implementation group
“So roadblocks since PrEP came about was that trying to find a doctor who would write the
script and you would think they would want to write the script, but it was like well if you don't
have the insurance or you don't have the right insurance or we don't do that. Just roadblocks.”
– Participant 107, Eligibility Dependent implementation group
Medical doctors as a facilitator to PrEP implementation
“I believe the doctor presented PrEP information to us as an organization, and we just started
to utilize him, as far as, you know, referrals.”
– Participant 102, Universal implementation group
“One doctor told me when I was getting my certification he said, "If I knew 20 years ago that
there was a pill I could take every day and I wouldn't get HIV, I would take that pill without a
doubt." Hearing that from somebody who is in practice and who is working with clients who
have HIV, was something that really kind of changed my mind in regards to the whole PrEP
talk. I'm obligated as somebody who's doing HIV prevention and testing to talk to somebody
about this. It's just like if I have heart disease and I should exercise. Or I should take X, Y, and
Z.”
– Participant 113, Universal implementation group
“There are some people who, maybe they have a partner or something who recently found
out about their HIV status, or something like that, and they'll come to us and they'll be like,
"You know, I was trying to research it online," or "My partner's doctors mentioned something
where I could maybe get some type of treatment, and then continue to have sex with my
partner."
-- Participant 108, Limited implementation group
Varied client knowledge of PrEP
“You would get a lot of people that were like, "Yeah, I heard about it, but what does it do?" So,
then you kind of explain it to them and their minds would be blown because they're like,
"What, it's a drug that can help prevent HIV?" And I'm like, "Yeah. There are medication out
there that does help. It's not 100 percent, I don't want you to get the wrong idea and kind of a
sex spree. But it's a preventative method that you can, to give you that extra layer of
precaution I guess."
– Participant 116, Universal implementation group
“When they [gay men] come, they ask you questions, but they already know. They did
research. They have friends that they're on it. Yes, definitely.”
– Participant 103, Eligibility Dependent implementation group
“That's fine. I would say here in North Florida, we are in [specific region], but in North Florida,
it seems like fewer members of the community have awareness of PrEP or what PrEP is as
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compared to other locations within the state. For instance, South Florida, when you're talking
more about Miami or Ft. Lauderdale, knowledge about PrEP seems to be wider than it is up
here. The thoughts about PrEP, a lot of times it's "I don't know what PrEP is."
– Participant 100, Limited implementation group

Client concerns about cost or insurance
“And there's definitely a split of people who say, ‘I've never heard of that’ or of people who
say, ‘I know of it, but I don't know what it is.’ And then we have a large section of people who
are, ‘I know about it, but I can't afford it.’ And that seems to be sort of the split.”
-- Participant 105, Universal implementation group
“You know, they think it costs too much. So, I give them their results and then I get up and I
go.”
-- Participant 110, Universal implementation group
“But on the patient side, I would say education about both PrEP itself and access and
financial would be a big thing because that's kind of a big hindrance that I've seen would be
hesitation about cost.”
-- Participant 121, Eligibility Dependent implementation group
“It's pretty difficult. If someone is uninsured, then our best option is to set up a linkage to a
community clinic here. Then from the community clinic, same deal, I can help that person
navigate the first-time meeting with their essentially primary care provider now, at that
community clinic, to try and see if that primary care provider has resources for the uninsured
for PrEP services, but so far I've not had much success as far as finding PrEP for the
uninsured. It might become a matter of helping that person apply for any sort of insurance that
they can afford. That's another thing that the community clinics can help with.
– Participant 119, Limited implementation group

Copay assistance as a solution to cost concerns
“Then we break down, well there is a Gilead co-pay system. There is different resources
available to get PrEP to you at a very reasonable co-pay, if not for free. As soon as we're able
to break down that barrier, then clients are a lot more apt to use PrEP.”
– Participant 113, Universal implementation group
“[The next question clients ask] Which is, ‘How am I supposed to afford PrEP?’ And then we
have to go through the co-pay assistance program. Which I have the form there, but the
doctor or the nurse fills it out for them. And I just walk them through that. And most of the
time, the majority of the time, people get PrEP paid for like a year. The only thing you have to
come up with, you have two initial visits. You see the doctor and then you'll go back to get
your results and see the nurse and you'll pick up your prescription. And then you have to go
get it filled. And then you have to have your three other blood tests for the rest of the year. So
that's what you have to pay for.”
-- Participant 105, Universal implementation group
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“Yeah, I guess paying for PrEP is a big thing, because a lot of people don't know about the
copay program, or if they're not insured, how to get it that way. The patient finance-assistance
program, or not going through the health department, that kind of thing, those are an issue.”
– Participant 121, Eligibility Dependent implementation group
Financial help for PrEP outside of copay assistance
“We usually refer people to programs that we know do a real good job of getting people
access to the medications with the least amount of grief, or based upon where they live, if it's
like being more convenient for them to see one provider over another. We also have a
provider that has been paying people's insurance premiums in order to provide them with
PrEP and then have the insurance pay for PrEP. If we come up on uninsured people, we
sometimes will refer them to that provider, because we know that if people are insured, not
only are they going to get full affordable care act health insurance, but they'll also get PrEP.
They have health insurance, so that means that if they have any other conditions that they're
suffering from, they will have health insurance and they'll be able to be seen for those other
conditions.”
– Participant 104, Limited implementation group
“But we talk about the sliding fee that goes along with that at the health department and if
they really need PrEP then they can go do this. And then there's a couple of little
organizations here, and by organization I mean a few people who have banded together who,
if a person really needs PrEP, like we think they are super at risk, and they are like "I want
PrEP." Then we can set them up with them and they may be able to provide some financial
assistance.”
– Participant 105, Universal implementation group
“We're finding out, of course, as PrEP is becoming more prevalent, insurance companies are
covering it. It's my understanding now that the state Florida has mandated to all of their health
departments within each county and area that the health departments cover, that they are
required. If they cannot offer PrEP within their clinics inside the Health Department, they are
required to connect that individual to someone where they can receive PrEP based on their
limitations or personal issues that might prevent them from going to just a standard clinic to
sign and get PrEP.”
-- Participant 109, Limited implementation group
Community level HIV and PrEP-related stigma
“PrEP is easy to talk about. It's when you say the word HIV that people kind of shudder and
pull back and get quiet that I find. When I say PrEP, they know what it's for, and so I don't
have to say HIV or AIDS, and then the conversation is much more smooth.”
– Participant 110, Universal implementation group
“But we have a big split here. Like we have a very conservative population, a very religious
population, but we also have the biggest [holiday] gathering, which is coming up this
weekend, where we'll be at work. And that's on [City Name]. We have a very large split as far
as low income Black and African-American hetero males and females. And then we have
another group of MSMs [men who have sex with men] of all races and ethnicities. So it's kind
of like this trifecta of stigma and discrimination and knowledge that you have to kind of work
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around. Where all three groups have very, very different beliefs as it pertains to, especially
PrEP. But whenever you start talking about HIV in general.”
-- Participant 105, Universal implementation group
“Stigma is still a big thing. I don't know what it looks like to have a world free of stigma,
because God knows I've never lived in one of them. As bad as that sounds ... but definitely
like the stigma associated with it, because at the beginning of the whole Truvada as PrEP
movement, you can actually look it up, there was an individual and I think he was in southern
California, maybe LA -ish, but he started campaign called Truvada Whore.”
-- Participant 112, Eligibility Dependent implementation group
“But the areas tend to dictate the amount of stigma that's there and who may be providing the
stigma, so to speak. Whether, you know, again it's from a religious perspective or some other
perspective. The areas kind of determine that. But going back to the stigma, plays a huge part
and it's what I personally say, that's what causes death when you're dealing with HIV. It's not
HIV. Because if someone has HIV, you can live a healthy life and not die from it. But if to
choose to die from it based on stigma and how stigma affects you, then of course HIV would
then rain on that persons' life.”
-- Participant 109, Limited implementation group
Client perception of risks
“So I don't know a lot of women that are getting it because of, again I think that a lot of people
still have the mind set of, ‘It's a gay disease, so why should I worry about it?’. But I do mention
in my classes that African-American women have now been put on the list of recommended
recipients for PrEP, because the HIV infection is so high in the African-American community.
So I try to emphasize that. That anybody should have access to PrEP, not just because you're
gay or bisexual, but anyone in the ... and I give them the behaviors: multiple partners, sharing
IV drugs, prostitution, solicitation, you have another STD. Go talk to your doctor, sharing IV
needles. So if you fall in any of these categories, you are a strong candidate for PrEP, but
anyone should go and talk to their doctor about PrEP.”
- Participant 111, Universal implementation group
“A lot of times, I've found that the heterosexual women that I've dealt with really don't
understand or see themselves as being at any risk until it's too late. They don't think that they
need to be on PrEP. I'm careful with my words because I do know that a lot of these women
are certain that they're in a mutually monogamous relationship, that they're at no risk for HIV.”
– Participant 100, Limited implementation group
“I don't think folks that are a little less aware of these things, sometimes have a skewed
perception of risk. You know, ‘I don't have to worry about it because I'm in a monogamous
relationship’, and the numbers don't seem to bear that out.”
– Participant 104, Limited implementation group
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APPENDIX C: DESCRIPTION OF RATIONALE FOR INCLUSION/EXCLUSION OF CONSOLIDATED FRAMEWORK OF
IMPLEMENTATION RESEARCH (CFIR) CONSTRUCTS
Table C.1. Rationale for Inclusion and Exclusion of Consolidated Framework for Implementation Research (CFIR) Constructs
Short
Rational for
OCM and ORCA Past Items
Domain
Construct
Potential Item(s) for Inclusion
Description a
Inclusion/Exclusion
Used a, b
Intervention
Intervention
Perception of key Exclude. PrEP is a
OCM 8b Project has been
No items for the construct will be
Characteristics Source
stakeholders
pharmaceutical medical
influenced strongly by:
included
about whether
that must be developed
Successful applications from
the intervention is outside of a clinical or
non-health care organizations; 8c
externally or
social service organization.
Project has been influenced
internally
The way in which PrEP is
strongly by: Successful health
developed.
implemented during HIV
care applications outside our
testing would naturally vary
organization
based upon location.
Intervention
Evidence
Stakeholders’
Include.
Some skeptics OCM 9a The change we have in • Based on your assessment of
Characteristics Strength
& perceptions of the have
questioned
the mind: Is supported by concrete the evidence supporting PrEP,
Quality
quality
and efficacy of PrEP. This is also evidence from an organization please rate the strength of the
validity
of a common barrier to PrEP similar to ours
evidence in your opinion, on a
evidence
initiation. This may, or may ORCA 1a. Based on your scale of 1 to 5 where 1 is very
supporting
the not, be a barrier for staff to assessment of the evidence basis weak evidence and 5 is very strong
belief that the discuss PrEP during HIV for this statement, please rate the evidence. (adapted from ORCA
intervention will testing. It has previously strength of the evidence in your measure 1a).
have
desired been found in the literature opinion, on a scale of 1 to 5 where • How confident are you that there
outcomes.
to be a client-level and 1 is very weak evidence and 5 is is good research that shows PrEP
provider-level barrier to very strong evidence; 1b. Now, can reduce HIV transmission?
PrEP initiation.
please rate the strength of the • Now, please rate the strength of
evidence basis for this statement the evidence supporting PrEP
Support:
based on how you think based on how you think respected
Hakre et al., 2016
respected clinical experts in (your clinical
experts
in
your
Golub et al., 2013
organization) feel about the organization feel about the
Auerbach et al., 2015
strength of the evidence, on a 1 to strength of the evidence, on a 1 to
Falcao et al., 2016
5 scale similar to the one above; 5 scale similar to the one above.
2a. The (proposed practice (adapted from ORCA measure 1b)
changes
or
guideline
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Intervention
Characteristics

Relative
Advantage

Stakeholders’
perception of the
advantage
of
implementing the
intervention
versus
an
alternative
solution.

Include.
Some
disadvantages have been
discussed with regard to
PrEP implementation (e.g.
risk compensation, resource
deprivation). These may
affect PrEP implementation
during HIV testing.
Support:
Philpott, 2013
Sugarman & Mayer, 2013
de Wit et al., 2015
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implementation)
are
(is)
supported by randomized control
trials (RCTs) or other scientific
evidence from the VA.; 2b. The
(proposed practice changes or
guideline implementation) are (is)
supported by randomized control
trials (RCTs) or other scientific
evidence from other health care
systems; 2c. The (proposed
practice changes or guideline
implementation)
should
be
effective, based on current
scientific knowledge; 3a. The
(proposed practice changes or
guideline implementation) are
supported by clinical experience
with VA patients; 3b. The
(proposed practice changes or
guideline implementation) are
supported by clinical experience
with patients in other health care
systems; 4a. The (proposed
practice changes or guideline
implementation) have been wellaccepted by VA patients in a pilot
study; 4b. The (proposed practice
changes
or
guideline
implementation) are consistent
with clinical practices that have
been accepted by VA patients.
OCM 6d Staff, in general, are not
depressed by the prospect of
change; 9c The change we have
in mind: Appears to have many
more
advantages
than
disadvantages; 9d The change
we have in mind: Is likely to be
supported by staff because they
will believe that the advantages
outweigh disadvantages
ORCA 4d. The (proposed
practice changes or guideline
implementation) appear to have

• PrEP use is supported by
research or other scientific
evidence. (adapted from ORCA
measure 2a)
• Talking to my client about PrEP
during HIV testing will result in
fewer new cases of HIV in my
community.
• Talking to my client about PrEP
during HIV testing would result
in more people in my
community taking PrEP daily
for HIV prevention

• Talking about or referring people
to where they can get a
prescription for PrEP has more
advantages than disadvantages. –
strongly disagree to strongly agree
(adapted from OCM and ORCA)

Intervention
Characteristics

Adaptability

The degree to
which an
intervention can
be adapted,
tailored, refined,
or reinvented to
meet local needs.

Intervention
Characteristics

Trialability

Intervention
Characteristics

Complexity

The ability to test
the intervention
on a small scale
in the
organization, and
to be able to
reverse course
(undo
implementation) if
warranted.
Perceived
difficulty of
implementation,
reflected by
duration, scope,
radicalness,
disruptiveness,
centrality, and
intricacy and
number of steps
required to
implement.

Intervention
Characteristics

Design Quality &
Packaging

Perceived
excellence in how
the intervention is
bundled,
presented, and
assembled.

Grov, Whitfield, Rendina,
Ventuneac, & Parsons,
2015 Marcus et al., 2013
Sowicz,
Teitelman,
Coleman, & Brawner, 2014
Exclude. PrEP
implementation during HIV
testing can already be
changed to meet local
needs. PrEP as a
medication cannot be
adapted given its current
FDA approval
Exclude. While important,
this cannot be assessed by
staff performing HIV testing.

more
advantages
than
disadvantages for VA patients.

OCM 11a The likely change can
be adapted to fit current situation
11b The likely change can be
adapted and retain effectiveness;
11c The adaptation will be
ethically easy to make; 11d The
adaptation will be politically easy
to make
None

No items for the construct will be
included

Include. The literature has
suggested that training may
be needed to implement
PrEP. This may also be
true among staff performing
HIV testing

None

• Referring a client to a place they
could talk to a provider about
a PrEP prescription would be
complicated.
• Talking to clients about PrEP
during HIV testing would be
too complicated.

None

No items for the construct will be
included

Support:
CDC, 2016d, 2016e
AIDS Education and
Training Centers - Herman,
2014
National Network of STD
Clinical Prevention Training
Centers, 2015
Exclude. This construct
could vary between
implementing
organizations.
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No items for the construct will be
included

Intervention
Characteristics

Outer Setting

Cost

Patient Needs &
Resources

Costs of the
intervention and
costs associated
with
implementing the
intervention
including
investment,
supply, and
opportunity costs.

The extent to
which patient
needs, as well as
barriers and
facilitators to
meet those
needs, are
accurately known
and prioritized by
the organization.

Outer Setting

Cosmopolitanism

The degree to
which an
organization is
networked with
other external
organizations.

Outer Setting

Peer Pressure

Mimetic or
competitive
pressure to
implement an

Exclude. Cost, and the cost
effectiveness, of PrEP
implementation have been
investigated in the
literature. These concerns
may be relevant to PrEP
implementation at HIV
testing sites. However,
while important, this cannot
be accurately assessed by
staff performing HIV testing.
Support:
Elion & Coleman, 2016
Alistar, Owens, &
Brandeau, 2014
Gomez et al., 2013
Include. Lack of information
about PrEP (that could be
addressed during HIV
testing) is a concern noted
in the literature. HIV rates in
Florida are also high,
reflecting patient needs.
Support:
FLDOH, 2016a
Smith et al., 2015
Young and McDaid, 2014

Include. There may be
some pressures to learn
about PrEP from other
organizations.
Cosmopolitanism may also
increase an organization’s
ability to refer clients to a
provider who can prescribe
PrEP.
Exclude. Competitive
pressure may encourage
organizations to include
PrEP in HIV prevention
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None

• Including PrEP in the prevention
discussion during HIV testing
would involve a lot of outside
costs

ORCA 4c. The (proposed
practice changes or guideline
implementation) take into
consideration the needs and
preferences of VA patients.
5c. Senior leadership/clinical
management in (your
organization) seek ways to
improve patient education and
increase patient participation in
treatment. 18c. The following
are available to make the
selected plan work: patient
awareness/need.
None

• Senior leadership in your
organization seek ways to
improve patient education and
increase patient participation in
treatment.
• Senior leadership values asking
clients what they think about how
our services could be improved?
• The clients I serve would benefit
from access to PrEP
• The clients I serve would
appreciate the opportunity to learn
about new ways to protect
themselves from HIV
• I go to local, statewide or
national meetings that discuss
HIV prevention.
• If a client asked me about places
they could go to get a PrEP
prescription, I would know clinics
or organizations to suggest to
them.

None

• Other organizations in my
community talk about (or refer
people to organizations that
provide) PrEP during HIV testing.

Outer Setting

Inner Setting

External Policy &
Incentives

Structural
Characteristics

intervention;
typically because
most or other key
peer or
competing
organizations
have already
implemented or
are in a bid for a
competitive edge.
A broad construct
that includes
external
strategies to
spread
interventions,
including policy
and regulations
(governmental or
other central
entity), external
mandates,
recommendations
and guidelines,
pay-forperformance,
collaborative, and
public or
benchmark
reporting.

discussions. This can be
noted through funding
announcements that
include PrEP. However, this
may not be accurately
assessed by staff
performing HIV testing.

The social
architecture, age,
maturity, and size

Include. The structural
characteristics of
organizations may affect

Sources:
CDC, 2016a, 2016b, 2016c
Include. Research has
shown providers may be
more likely to adopt
guidelines that are
endorsed by professional
organizations.

• Implementing PrEP (via
education, interventions, or
prescriptions) would make my
organization more
competitive for funding
opportunities.

OCM 8a Project has been
influenced strongly by: Pressures
from outside the organization

Sources:
Vamos et al., 2015
White et al., 2012
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ORCA 7b. Senior
leadership/Clinical management
in (your organization) clearly

• How much have national PrEP
guidelines (such as those from the
CDC) impacted your view on
PrEP implementation during HIV
testing?
• How much have guidelines
within your organization impacted
your view on PrEP implementation
during HIV testing?
• How much have international
guidelines (such as those from the
WHO) impacted your view on
PrEP implementation during HIV
testing?
• The organization I work for has
formal guidelines (guidelines
that are written or provided in
training) in place about how,
when, and if I should talk
about PrEP when performing
HIV testing, counseling, or
testing.
(Yes, this is true of the
organization I work for; No, this is
not true of the organization I work
for)
• Do these guidelines state that
you should NOT talk about
PrEP or that you SHOULD
talk about PrEP during
testing/counseling?
• How would you describe the
size of the organization you work
for? Small, medium, or large?

of an
organization.

their ability to implement
new ideas.

Inner Setting

Networks &
Communications

The nature and
quality of webs of
social networks
and the nature
and quality of
formal and
informal
communications
within an
organization.

Exclude. While internal
communication networks
can help staff to learn more
about PrEP internally,
access to training and
educational opportunities is
accessed elsewhere.

Inner Setting

Culture

Norms, values,
and basic
assumptions of a

Include. Organizational
culture often affects
implementation. This may

161

define areas of responsibility and
authority for clinical managers
and staff.
OCM 3b Linkages and
Communication: Senior
Leadership: Mechanisms have
been developed to keep leaders
informed and involved 4b
Linkages and Communication:
Operating Unit Managers:
Mechanisms have been defined
to keep key managers informed
and involved
ORCA 5b. Senior
leadership/clinical management
in (your organization) solicit
opinions of clinical staff regarding
decisions about patient care. 7a.
Senior leadership/Clinical
management in (your
organization) provide effective
management for continuous
improvement of patient care. 7c.
Senior leadership/Clinical
management in (your
organization) promote team
building to solve clinical care
problems. 7d. Senior
leadership/Clinical management
in (your organization) promote
communication among clinical
services and units. 16a.
Communication will be
maintained through regular
project meetings with the project
champion and team members
16b. Communication will be
maintained through involvement
of quality management staff in
project planning and
implementation.
OCM 8d Project has been
influenced strongly by: Our
proven ability to adapt ideas from

• My organization has offices in
multiple counties or states?
• There are people in my
organization I can talk to if I have
a question about PrEP

• Senior leadership in my
organization reward

given
organization.

be the case in
implementing PrEP during
HIV testing.
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outside to fit our organization's
way of doing things
ORCA 5a. Senior
leadership/clinical management
in (your organization) reward
clinical innovation and creativity
to improve patient care; 6a. Staff
members in (your organization)
have a sense of personal
responsibility for improving
patient care and outcomes; 6b.
Staff members in (your
organization) cooperate to
maintain and improve
effectiveness of patient care; 6c.
Staff members in (your
organization) are willing to
innovate and/or experiment to
improve clinical procedures; 6d.
Staff members in (your
organization) are receptive to
change in clinical processes; 8a.
Senior Leadership/ clinical
management in (your
organization) provide staff with
information on VA performance
measures and guidelines. 8b.
Senior Leadership/clinical
management in (your
organization) establish clear
goals for patient care processes
and outcomes; 8c. Senior
Leadership/clinical management
in (your organization) provide
staff members with
feedback/data on effects of
clinical decisions; 8d. Senior
Leadership/clinical management
in (your organization) hold staff
members accountable for
achieving results; 11a. Senior
leadership/clinical management
will propose a project that is
appropriate and feasible; 11b.

•

•

•
•
•

•

innovation and creativity to
improve client care.
Staff members in my
organization have a sense of
personal responsibility for
improving the health
outcomes of the people we
serve.
Staff members in my
organization cooperate to
maintain and improve
effectiveness of patient care.
Staff members in my
organization are open to
change.
Senior Leadership in my
organization provide staff with
information about PrEP.
Senior Leadership in my
organization provide staff
members with feedback from
clients who receive HIV
testing.
PrEP doesn’t fit in with my
organization’s values.

Inner Setting

Implementation
Climate

Inner Setting

Tension for
Change

Inner Setting

Compatibility

The absorptive
capacity for
change, shared
receptivity of
involved
individuals to an
intervention, and
the extent to
which use of that
intervention will
be rewarded,
supported, and
expected within
their organization.
The degree to
which
stakeholders
perceive the
current situation
as intolerable or
needing change.

The degree of
tangible fit
between meaning
and values
attached to the
intervention by
involved
individuals, how
those align with

Exclude. Although the idea
of implementation climate is
important, this will be
assessed by PrEP related
policy (either formal or
informal). PrEP related
Implementation climate is
also not persistent in the
existing PrEP literature.

Include. Many Florida
communities have high
rates of HIV. This may
contribute to the tension for
change, and in turn affect
PrEP implementation.
Support:
FLDOH, 2016a
Smith et al., 2015
Young and McDaid, 2014
Include. PrEP has been
associated with values and
morals. This may play a
role in PrEP
implementation.
Sources:
Spieldenner, (2016)
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Senior leadership/clinical
management will provide clear
goals for improvement in patient
care; 11c. Senior
leadership/clinical management
will establish a project schedule
and deliverables; 11d. Senior
leadership/clinical management
will designate a clinical
champion(s) for the project.
None

No items for the construct will be
included

OCM 6a Informal opinion leaders
really dislike current process; 6b
Informal opinion leaders believe
change is essential; 6c Staff, in
general, are very upset with the
current process

• Staff at my organization believe
that new prevention methods are
needed to stop the spread of HIV
• I believe that new prevention
methods are needed to stop the
spread of HIV

OCM 5a Linkages and
Communication: Operating Unit
Staff: The project, if successful
will meet staff needs
ORCA 3c. The (proposed
practice changes or guideline
implementation) conform to the
opinions of clinical experts in this
setting.

• People in my organization think
PrEP could help to decrease the
spread of HIV
• I think PrEP could help to
decrease the spread of HIV

Inner Setting

Relative Priority

Inner Setting

Organizational
Incentives &
Reward

Inner Setting

Goals &
Feedback

individuals’ own
norms, values,
and perceived
risks and needs,
and how the
intervention fits
with existing
workflows and
systems.
Individuals’
shared
perception of the
importance of the
implementation
within the
organization.
Extrinsic
incentives such
as goal-sharing
awards,
performance
reviews,
promotions, and
raises in salary,
and less tangible
incentives such
as increased
stature or
respect.
The degree to
which goals are
clearly
communicated,
acted upon, and
fed back to staff,
and alignment of
that feedback
with goals.

Include. Organizations are
often overworked and the
relative priority of this task
may be relevant.

ORCA 13d. Senior leadership/
clinical management/staff opinion
leaders set a high priority on the
success of the intervention.

Exclude. There is no
current evidence in the
PrEP implementation
literature to support the
inclusion of this construct.

OCM 14a The following items
are likely to be set up to make
the new solution work: Staff
incentives
ORCA 18a. The following are
available to make the selected
plan work: staff incentives.

Exclude. This cannot be
accurately assessed by
staff providing HIV testing.

OCM 3a Linkages and
Communication: Senior
Leadership: The project, if
successful, will help the
organization meet corporate
goals; 4a Linkages and
Communication: Operating Unit
Managers: The project, if
successful will meet an important
operating unit goal; ORCA 13a.
Senior leadership/clinical
management/staff opinion
leaders agree on the goals for
this intervention.
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• Talking about PrEP during HIV
testing is less important than
talking about other HIV prevention
methods
• Talking about PrEP during HIV
testing is more important than
talking about other HIV prevention
methods.
No items for the construct will be
included

No items for the construct will be
included

Inner Setting

Learning Climate

Inner Setting

Readiness for
Implementation

Inner Setting

Leadership
Engagement

A climate in
which: a) leaders
express their own
fallibility and need
for team
members’
assistance and
input; b) team
members feel
that they are
essential, valued,
and
knowledgeable
partners in the
change process;
c) individuals feel
psychologically
safe to try new
methods; and d)
there is sufficient
time and space
for reflective
thinking and
evaluation.
Tangible and
immediate
indicators of
organizational
commitment to its
decision to
implement an
intervention.
Commitment,
involvement, and
accountability of
leaders and
managers with
the
implementation.

Include.

None

Exclude

• I can decide what I should talk
to clients about when I am
testing/counseling for HIV
• I have an important role in HIV
prevention
• I have an important role in
educating clients about PrEP

No items for the construct will be
included

Include. Because staff
providing HIV testing are
often employees, the views
of leadership may impact
their decisions to talk about
PrEP.
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OCM 1c Project launch: You
and the Senior Leadership team:
Indicated that not changing is
unacceptable and set a firm
deadline; 1d Project launch: You
and the Senior Leadership team:
Designated a champion/s to
make the project succeed; 3c
Linkages and Communication:
Senior Leadership: Leaders have
endorsed the project in visible
ways; 4c Linkages and

• My organization requires that I
talk to clients about PrEP
• My organization prohibits
counselors from talking about
PrEP
• Senior leadership openly
endorses PrEP
implementation during HIV
testing
• It would be acceptable to senior
leadership if I talked about
PrEP during HIV testing

Inner Setting

Available
Resources

The level of
resources
dedicated for
implementation
and on-going
operations,
including money,
training,
education,
physical space,
and time.

Include. Research has
suggested that availability
of resources affects PrEP
implementation.
Support:
Zablotska et al., 2016
An et al., 2015
Hood et al., 2015
Sweeney et al., 2014
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Communication: Operating Unit
Managers: Those operating unit
managers openly endorse the
project; 14b The following items
are likely to be set up to make
the new solution work:
Leadership roles
ORCA 13b. Senior
leadership/clinical
management/staff opinion
leaders will be informed and
involved in the intervention; 13c.
Senior leadership/clinical
management/staff opinion
leaders agree on adequate
resources to accomplish the
intervention
OCM 3d Linkages and
Communication: Senior
Leadership: Leaders have
committed to spend their time &
resources to remove obstacles
when they arise; 4d Linkages
and Communication: Operating
Unit Managers: The operating
unit managers have committed to
spend their time & resources to
remove obstacles when they
arise in the project; 10a Enough
money is available to support:
The customer needs assessment
10b Enough money is available
to support: Solution exploration
(to identify key features of
solutions); 10c Enough money is
available to support: Solution
development
10d Enough money is available
to support: Implementation and
Testing
14d The following items are likely
to be set up to make the new
solution work: Equipment and
materials

• My organization gives out free
condoms to clients who want them
• I have physical information
(such as pamphlets or flyers)
about HIV prevention that I give
clients during HIV
testing/counseling
• I have physical information
(such as pamphlets or flyers)
about PrEP that I give clients
during HIV testing/counseling
• My organization has physical
information (such as pamphlets or
flyers) about PrEP available for
clients to pick up if they are
interested
• My organization has physical
information (such as pamphlets or
flyers) about HIV prevention
available for clients to pick up if
they are interested
• There is enough time during the
HIV testing/counseling process to
discuss PrEP
• My organization provides
training to learn about updates in
HIV prevention

Inner Setting

Access to
Knowledge &
Information

Ease of access to
digestible
information and
knowledge about
the intervention
and how to
incorporate it into
work tasks.

Include. Without access to
knowledge and information
about PrEP, PrEP
implementation would be
difficult.

Characteristics
of Individuals

Knowledge &
Beliefs about the
Intervention

Include. Personal attitudes,
etc. toward PrEP may affect
if a staff member discusses
PrEP with clients.

Characteristics
of Individuals

Self-efficacy

Characteristics
of Individuals

Individual Stage
of Change

Individuals’
attitudes toward
and value placed
on the
intervention as
well as familiarity
with facts, truths,
and principles
related to the
intervention.
Individual belief in
their own
capabilities to
execute courses
of action to
achieve
implementation
goals.
Characterization
of the phase an
individual is in, as

ORCA 14c. The implementation
team members have release
time or can accomplish
intervention tasks within their
regular work load;14d. The
implementation team members
have staff support and other
resources required for the
project; 18b. The following are
available to make the selected
plan work: equipment and
materials.
13b The changes in staff jobs are
likely to be: Clearly spelled out in
writing
13c The changes in staff jobs are
likely to be: Supported by good
training and training materials
14c The following items are likely
to be set up to make the new
solution work: Organization
structure and documented
procedures
None

See Available Resources above

Items on knowledge, attitudes,
and behavior scales in
quantitative assessment

Include. A person must be
confident in discussing
PrEP or referring people to
an outside organization to
learn more about PrEP.

OCM 13d The changes in staff
jobs are likely to be: Changes
that staff believe are confident
they can do well

Items on knowledge, attitudes,
and behavior scales in
quantitative assessment

Exclude. Exclude. Not yet
included in the literature.

None

No items for the construct will be
included
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Characteristics
of Individuals

Individual
Identification with
Organization

Characteristics
of Individuals

Other Personal
Attributes

Process

Planning

he or she
progresses
toward skilled,
enthusiastic, and
sustained use of
the intervention.
A broad construct
related to how
individuals
perceive the
organization, and
their relationship
and degree of
commitment with
that organization.
A broad construct
to include other
personal traits
such as tolerance
of ambiguity,
intellectual ability,
motivation,
values,
competence,
capacity, and
learning style.
The degree to
which a scheme
or method of
behavior and
tasks for
implementing an
intervention are
developed in
advance, and the
quality of those
schemes or
methods.

May be used for future
work.

Exclude. Not yet included in
the literature. May be used
for future work.

None

Include. Personal attributes,
such as prior PrEP use and
personal values may affect
PrEP implementation.

Exclude. Constructs related
to the Process domain
cannot be accurately
measured via staff
performing HIV testing.
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No items for the construct will be
included

Items on knowledge, attitudes,
and behavior scales and
demographics

OCM 1a Project launch: You and
the Senior Leadership team:
Carefully selected the project; 1b
Project launch: You and the
Senior Leadership team:
Provided a very clear aim for the
project 7d Problem Exploration:
Reviewed data proving the
problem's severity 12a The plan
for implementing the change will
likely: Be detailed; 12b The plan
for implementing the change will
likely: Be simple; having no
unnecessary or overly complex
steps 12c The plan for
implementing the change will
likely: Have clear and realistic
time schedule 12d The plan for

No items for the construct will be
included

Process

Engaging

Attracting and
involving
appropriate
individuals in the
implementation

Exclude. Constructs related
to the Process domain
cannot be accurately
measured via staff
performing HIV testing.
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implementing the change will
likely: Be understood by those
affected 13a The changes in
staff jobs are likely to be: Few in
number
ORCA 15a. The implementation
plan for this intervention
identifies specific roles and
responsibilities.15b. The
implementation plan for this
intervention clearly describes
tasks and timelines. 15c. The
implementation plan for this
intervention includes appropriate
provider/ patient education.15d.
The implementation plan for this
intervention acknowledges staff
input and opinions. 18f. The
following are available to make
the selected plan work:
evaluation protocol. 19a. Plans
for evaluation and improvement
of this intervention include
periodic outcome measurement
.19b. Plans for evaluation and
improvement of this intervention
include staff participation/
satisfaction survey.19c. Plans for
evaluation and improvement of
this intervention include patient
satisfaction survey.19d. Plans for
evaluation and improvement of
this intervention include
dissemination plan for
performance measures.
19e. Plans for evaluation and
improvement of this intervention
include review of results by
clinical leadership.
OCM 7c Problem Exploration:
Personally experienced the
problem

• Someone has assessed my
ability to talk about PrEP during
HIV testing

Process

Opinion Leaders

Process

Formally
Appointed
Internal
Implementation
Leaders

Process

Champions

and use of the
intervention
through a
combined
strategy of social
marketing,
education, role
modeling,
training, and
other similar
activities.
Individuals in an
organization who
have formal or
informal influence
on the attitudes
and beliefs of
their colleagues
with respect to
implementing the
intervention.

Individuals from
within the
organization who
have been
formally
appointed with
responsibility for
implementing an
intervention as
coordinator,
project manager,
team leader, or
other similar role.
Individuals who
dedicate
themselves to
supporting,
marketing, and
‘driving through’

• There is education about PrEP
available to me (inside or outside
of my organization)
• I have observed someone talk
about PrEP during HIV testing

Exclude. Constructs related
to the Process domain
cannot be accurately
measured via staff
performing HIV testing.

Exclude. Constructs related
to the Process domain
cannot be accurately
measured via staff
performing HIV testing.

Exclude. Constructs related
to the Process domain
cannot be accurately
measured via staff
performing HIV testing.
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OCM 5b Linkages and
Communication: Operating Unit
Staff: Mechanisms have been
developed to inform and involve
staff opinion leaders; 5c
Linkages and Communication:
Operating Unit Staff: Staff
opinion leaders openly endorse
the project
5d Linkages and
Communication: Operating Unit
Staff: Informal leaders have
committed to spend time &
resources to support the project
ORCA 14a. The implementation
team members share
responsibility for the success of
this project; 14b. The
implementation team members
have clearly defined roles and
responsibilities.
18e. The following are available
to make the selected plan work:
intervention team.

No items for the construct will be
included

OCM 2a Project champion: Is
very committed to making this
project successful
2b Project champion: Has
substantial power to make things
happen 2c Project champion:

No items for the construct will be
included

• There is someone I can go to
when I have questions about HIV
testing in my organization
• There is someone I can go to
when I have questions about
PrEP

an
implementation,
overcoming
indifference or
resistance that
the intervention
may provoke in
an organization.

Process

External Change
Agents

Process

Executing

Process

Reflecting &
Evaluating

Individuals who
are affiliated with
an outside entity
who formally
influence or
facilitate
intervention
decisions in a
desirable
direction.
Carrying out or
accomplishing
the
implementation
according to plan.
Quantitative and
qualitative
feedback about
the progress and
quality of
implementation
accompanied
with regular
personal and
team debriefing

Exclude. Constructs related
to the Process domain
cannot be accurately
measured via staff
performing HIV testing.

Exclude. Constructs related
to the Process domain
cannot be accurately
measured via staff
performing HIV testing.
Exclude. Constructs related
to the Process domain
cannot be accurately
measured via staff
performing HIV testing.
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Has substantial prestige in the
organization
2d Project champion: Shows
respect for the involved staff
ORCA 12a. The project clinical
champion accepts responsibility
for the success of this
project.12b. The project clinical
champion has the authority to
carry out the implementation.12c.
The project clinical champion is
considered a clinical opinion
leader.12d. The project clinical
champion works well with the
intervention team and
providers.18d. The following are
available to make the selected
plan work: provider buy-in.
7b Problem Exploration: Involved
many staff to understand the
problem
7a Problem Exploration: Involved
many customers to understand
the problem that will be attacked

No items for the construct will be
included

15d Small pilot tests of the
improvement are set up to: Use
results to make continued
improvements

No items for the construct will be
included

OCM 15a Small pilot tests of the
improvement are set up to:
Collect honest reactions from
customers; 15b Small pilot tests
of the improvement are set up to:
Collect honest reactions from
staff; 15c Small pilot tests of the
improvement are set up to:
Publicly display performance
measures over time

No items for the construct will be
included

about progress
and experience.

ORCA 16c. Communication will
be maintained through regular
feedback to clinical management
on progress of project activities
and resource needs; 16d.
Communication will be
maintained through regular
feedback to clinicians on effects
of practice changes on patient
care/outcomes; 17a. Progress of
the project will be measured by
collecting feedback from patients
regarding proposed/implemented
changes; 17b. Progress of the
project will be measured by
collecting feedback from staff
regarding proposed/implemented
changes.
17c. Progress of the project will
be measured by developing and
distributing regular performance
measures to clinical staff; 17d.
Progress of the project will be
measured by providing a forum
for presentation/discussion of
results and implications for
continued improvements.
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APPENDIX D: QUANTITATIVE INSTRUMENT
Eligibility
Items
1. Which of the following statements is true of you? Please select
all that apply.
a. Part of my job (or all of my job) is to provide HIV
testing/counseling with clients
b. I volunteer with an organization and provide HIV testing
and/or counseling to clients
c. I work at an organization that provides HIV testing, but I
do not test for HIV or take part in the testing/counseling
process
d. My work is not related to HIV prevention
2. When was the last time you tested/counseled someone for HIV?
a. Within the past 3 months
b. Not within the last 3 months, but within the past 6
months
c. Between 6 months to a year ago
d. More than a year ago
3. How old are you?

Question Source
N/A

N/A

N/A

Organization/Work Characteristics
First, I have a few questions about where you are working. I am only asking the next two
questions to make sure the same person does not answer the survey twice.
Items
What is the name of the organization you work for? All of your
information will be kept private and your answers will not be shared
with anyone at your work place.
What are your initials?
1. Who do you primarily serve?
a. Rural clients
b. Urban clients
c. A mix of both rural and urban clients
2. What type of organization do you work for?
a. Community based organization
b. AIDS service organization
c. Clinic
d. Government agency
e. Other (describe) _______________
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Question Source
N/A
N/A
N/A

N/A

3. Do you work full time, part time, or volunteer for the organization
you listed?
a. Full time
b. Part time
c. Volunteer

N/A

4. On average, how many hours do you provide HIV testing?
___________ (Fill in and drop down: day/week/month
5. Do you work for an organization that specializes in serving
people who identify as lesbian, gay, bisexual, transgender, or
queer?
6. Do you work for an organization that specializes in serving
youth?

N/A
N/A

N/A

HIV Testing and Prevention Discussions
1. How often do you discuss the following during HIV testing? [Source: N/A]
Never Rarely Sometimes Often
HIV transmission methods and relative
risk
Regular testing for HIV
Condom use
Monogamy
Abstinence (or waiting to have sex)
Partner testing
PEP
PrEP
Treatment as Prevention

Always

Organizational PrEP Implementation Outcomes [Source: N/A]
1. The organization I work for has formal guidelines (guidelines that are written or provided in
training) about how, when, or if I should talk about PrEP when performing HIV testing or
counseling.
a. Yes, this is true of the organization I work for;
b. No, this is not true of the organization I work for
Leadership Engagement (strongly disagree to strongly agree)
• My organization requires that I talk to clients about PrEP
• My organization prohibits counselors from talking about PrEP
Also listed under Available Resources & Access to Knowledge & Information (strongly disagree to
strongly agree)
2. At my organization there is physical information (such as pamphlets or flyers) about PrEP
available for clients to pick up if they are interested
Same scale, not under leadership engagement
3. At my organization there is a formal referral system set up if someone is interested in starting
PrEP
4. My organization has medical professionals (doctors, nurse practitioners, etc.) on site who
could prescribe PrEP if a client was eligible and interested
174

Individual PrEP Implementation Outcomes [Source: N/A]
(Yes; No)
1. I talk to clients about PrEP when I think they might be eligible
2. I talk to clients about PrEP every time I test for HIV
Also items under Available Resources & Access to Knowledge & Information (only asked
once)
3. I give physical information (such as pamphlets or flyers) about PrEP to clients during HIV
testing/counseling
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PrEP Implementation CFIR Questions
Note: Adapted from ORCA and OCM measures and CFIR definitions (Damschroder, 2016)
Intervention Characteristics
Construct
Evidence
Strength &
Quality

Relative
Advantage

Complexity

Item(s)
• There is good research that shows PrEP can reduce HIV transmission.
• Talking to my client about PrEP during HIV testing would result in fewer
new cases of HIV in my community.
• Talking to my client about PrEP during HIV testing would result in more
people in my community taking PrEP daily for HIV prevention
• More research is needed to determine if PrEP can reduce the risk of HIV
transmission. (reverse coded)
• Talking about PrEP during HIV testing/counseling has more advantages
than disadvantages.
• Referring people to where they can get a prescription for PrEP during
the HIV testing/counseling has more advantages than disadvantages.
• Referring a client to a place where they could talk to a provider about
PrEP would be too complicated. (reverse coded)
• Talking to clients about PrEP during HIV testing would be too
complicated. (reverse coded)

Scoring
• On a scale from strongly disagree
to strongly agree
• Higher the score, greater belief in
evidence strength and quality

• On a scale from strongly disagree
to strongly agree
• Higher the score, greater belief in
relative advantage
• On a scale from strongly
disagree to strongly agree
• Higher the score, greater belief
in complexity

Outer Setting
Construct
Patient Needs &
Resources

Cosmopolitanism

Item(s)
• Leadership at my organization seeks ways to improve client
education about HIV.
• Leadership at my organization values asking clients what they think
about how our services could be improved.
• The clients I serve would benefit from access to PrEP
• The clients I serve would appreciate the opportunity to learn about
new ways to protect themselves from HIV
• I go to local, statewide or national meetings that discuss HIV
prevention.
176

Scoring
• On a scale from strongly
disagree to strongly agree
• Higher the score, greater belief
in patient needs and resources

• On a scale from strongly
disagree to strongly agree

• I go to local, statewide or national meetings that discuss PrEP.
• If a client asked me about places they could go to get a PrEP
prescription, I would know clinics or organizations to suggest.
External Policy & • National PrEP guidelines (such as those from the CDC) have
Incentives
impacted my view on PrEP implementation during HIV testing
• Internal organization guidelines have impacted my view on PrEP
implementation during HIV testing
• International guidelines (such as those from the WHO) have
impacted my view on PrEP implementation during HIV testing

• Higher the score, greater
cosmopolitanism
• On a scale from strongly
disagree to strongly agree
• Higher the score, greater proPrEP External Policy &
Incentives

Inner Setting
Construct
Structural
•
Characteristics
•
Culture
•
•

Tension for
Change

Compatibility

Relative
Priority

Item(s)
How would you describe the size of the organization you work for?
Small, medium, or large?
Does your organization have offices in multiple counties or states?
Leadership in my organization rewards innovation and creativity.
Staff members in my organization have a sense of personal
responsibility for improving the health outcomes of the people we
serve.
• Staff members in my organization are open to change.
• PrEP doesn’t fit in with my organization’s values.
• Staff at my organization believe that new prevention methods are
needed to stop the spread of HIV
• I believe that new prevention methods are needed to stop the spread
of HIV
• People in my organization think PrEP could help to decrease the
spread of HIV
• I think PrEP could help to decrease the spread of HIV
• Talking about PrEP during HIV testing is less important than talking
about other HIV prevention methods. R
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•

Scoring
Individual items

• On a scale from strongly disagree
to strongly agree
• Higher the score, greater pro-PrEP
culture
• On a scale from strongly disagree
to strongly agree
• Higher the score, greater tension
for change
• On a scale from strongly disagree
to strongly agree
• Higher the score, greater
compatibility
• On a scale from strongly disagree
to strongly agree
Higher the score, greater degree of
relative priority

Learning
Climate

•

Available
Resources

•
•
•
•

&

•

Access to
Knowledge & •
Information
•

I can decide what I should talk to clients about when I am
testing/counseling for HIV.
I have an important role in HIV prevention
I have an important role in educating clients about PrEP
My organization gives out free condoms to clients who want them
I give clients physical information (such as pamphlets or flyers) about
HIV prevention during HIV testing/counseling
There is physical information (such as pamphlets or flyers) about HIV
prevention at my organization available for clients to pick up if they are
interested
There is enough time during the HIV testing/counseling process to
discuss PrEP
My organization has a referral system set up if someone tests positive
for HIV

• On a scale from strongly disagree
to strongly agree
Higher the score, greater pro-PrEP
learning climate
• On a scale from strongly disagree
to strongly agree
• Higher the score, greater PrEPrelated available resources &
access to knowledge and
information

Characteristics of Individuals
Skip patterns will be inserted for staff based on if they do, or do not, prescribe.
Construct
Knowledge &
Beliefs about
the Intervention

Item(s)
Participant PrEP knowledge [Walsh & Petroll, 2016]
1. According to current guidance, is HIV antibody testing suggested
prior to initiating PrEP in a patient who is not experiencing any
symptoms?
a. Yes
b. No
c. I don’t know
Original question listed below. Will consider removing the question.
2. How many antiretroviral medications are in the regimen that is
FDA-approved for PrEP?
a. 1
b. 2
c. 3
d. 4
e. Not sure/Don’t know
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Scoring
• Scored as correct or incorrect

Original item listed below. Will consider taking the other options out,
and only keep in the combined option, Truvada.
4. Which antiretroviral medication(s) are FDA-approved for PrEP?
(choose all that apply)
a. Zidovudine, also known as AZT or Retrovir
b. Lamivudine, also known as 3TC or Epivir
c. Abacavir, also known as Ziagen
d. Tenofovir, also known as Viread
e. Emtricitabine, also known as FTC or Emtriva
f. Lopinavir, also known as Kaletra
g. Efavirenz, also known as Sustiva
h. Emtricitabine + tenofovir, also known as Truvada
i. Emtricitabine + tenofovir + efavirenz, also known as Atripla
j. Not sure/don't know
5. What is the FDA-approved dosing frequency for the antiretrovirals
used for PrEP?
a. Once weekly
b. Immediately prior to sexual activity
c. Once daily
d. Immediately following sexual activity
e. Twice daily
f. Three times per day
g. Not sure/don’t know
6. Which of the following is a relative contraindication to prescribing
PrEP?
a. Reduced creatinine clearance (<50 mL/min)
b. Squamous cell carcinoma of the skin
c. Previous myocardial infarction
d. Hypertension
e. Obesity
f. None of the above
g. Not sure/don't know
7. How often should individuals be tested for HIV while taking
PrEP?
a. Weekly
b. Every 2-3 months
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c. Every 6 months
d. Annually
e. Monthly
f. Not sure/don’t know
g. Other: _______________________
8. In the U.S., what is the approximate retail cost of the
antiretrovirals used for PrEP (without insurance coverage)?
a. $50/month
b. $2,400/month
c. $200/month
d. $1,200/month
e. Not sure/don’t know
Participant PrEP knowledge [Blumenthal et al., 2015]
1. How often should patients on PrEP be followed for medication
side effects and lab toxicities after initial assessment?
(PrEPMonitor)
a. Every month
b. Every 3 months
c. Every 6 months
d. Yearly
e. Not necessary to monitor after the first year
PrEP attitudes (Walsh & Petroll, 2016; 1=completely disagree,
5=completely agree)
1. PrEP can be a cost-effective HIV prevention intervention if
used with an appropriate population of patients.
2. PrEP is too costly to warrant its use. (R)
3. Individuals who are at risk for HIV should be encouraged to
use condoms rather than to take PrEP. (R)
4. Individuals who take PrEP are likely to increase their sexual
risk behaviors and negate the benefits of PrEP. (R)
5. Individuals who take PrEP are likely to have increased rates of
sexually transmitted infections. (R)
6. Money should not be spent on HIV prevention for men who
have sex with men. (R)
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7. There is insufficient evidence at this time for me to consider
PrEP an appropriate preventive treatment option. (R)
8. Widespread use of PrEP will likely significantly increase rates
of antiretroviral resistance. (R)
9. Individuals who are prescribed PrEP are not likely to adhere to
their medication. (R)
Self-efficacy

Other Personal
Attributes

Self-efficacy (Described by Walsh & Petroll, 2016 as Behavioral
skills): Comfort prescribing PrEP (1=completely uncomfortable,
5=completely comfortable)
1. Determining whether a patient’s sexual risk behaviors warrant
the use of PrEP.
2. Determining whether a patient’s IV drug use behaviors
warrant the use of PrEP.
3. Discussing the efficacy of PrEP with a patient.
4. Discussing whether PrEP is a good option for a patient.
5. Discussing the potential side effects of the antiretroviral
medications used for PrEP (emtricitabine and tenofovir,
together called Truvada) with a patient.
6. Prescribing PrEP to a patient for whom PrEP was appropriate
and no contraindications were apparent.
7. Determining whether a patient has a contraindication to using
PrEP.
8. Following patients on PrEP to monitor for side effects.
9. Following patients on PrEP to test them for HIV.
Please answer the questions below. If you do not feel comfortable
answering a question you can skip the question and move on to the
next one.
1. What is the highest level of education you have achieved?
a. Some high school
b. High school/GED
c. Associates degree
d. Some college
e. Bachelor’s degree
f. Master’s degree
g. Professional degree (J.D., M.D. etc.)
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•
•

•

On a scale from completely
uncomfortable to completely
comfortable
Higher the score, greater selfefficacy

h. Doctoral degree (Ph.D.)
2. How would you describe yourself?
a. Male
b. Female
c. Transgender male to female
d. Transgender female to male
e. Another gender
3. Have you ever had sex with a man?
a. Yes
b. No
4. Have you ever had sex with a woman?
a. Yes
b. No
5. How would you describe your sexual orientation?
a. Heterosexual (straight)
b. Homosexual (gay/lesbian)
c. Bisexual
d. Another sexual orientation
6. Have you ever taken PrEP?
a. Yes
b. No
7. Are you currently on PrEP?
a. Yes
b. No
8. Have you ever taken PEP?
a. Yes
b. No
9. What is your HIV status?
a. I am living with HIV
b. I am not living with HIV
c. I am not sure of my HIV status
10. (If yes to living with HIV). Are you currently in treatment?
a. Yes
b. No
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Introduction to Contact Information
Items
1. Would you like to be entered into a raffle to receive one of three $50
gift cards?
2. For the second part of my study, I plan to follow up with about 20
people to do an interview via phone or video-conferencing. I will
offer a $20 gift card to everyone who completes the interview. This
will help me to complete my dissertation research and it will
contribute to the literature on HIV prevention. Would you be willing
to let me contact you?
a. Yes
b. No

Question Source
Adapted from Dr.
Marhefka Survey
Adapted from Dr.
Marhefka Survey

Gift Card Raffle
If you would like to be entered into the gift card raffle, please provide your contact information
below. If you are selected for the gift card I will contact you using the information you provide.
Items
First name: ___________
Email: ___________
Phone number: ___________
Preferred gift card: (List of options provided)

Question Source
Adapted from Dr.
Marhefka Survey

Future Contact
Items
1. If yes, please provide the following:
First name: ___________
Email: ___________
Phone number: ___________

Question Source
N/A
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APPENDIX E: FINAL SCALE DECISIONS
Table E.1. Rationale for Scale Use and/or Development
Scale
Scale Cronbach’s Alpha
Knowledge
Scale Statistics
Std.
Mean Variance Deviation
4.1733 2.359
1.53591

N of Items
6

Reliability Statistics
Cronbach's
Alpha
N of Items
.658
6

Attitudes
Scale Statistics
Std.
Mean
Variance Deviation
37.9510 33.261 5.76726

N of Items
10

Reliability Statistics
Cronbach's Alpha
Based on
Cronbach's Standardized
Alpha
Items
N of Items
.772
.779
10

Items in survey
1. According to current guidance, is HIV
antibody testing suggested prior to
initiating PrEP in a patient who is not
experiencing any symptoms?
2. Which antiretroviral medication(s) are
FDA-approved for PrEP? (choose all that
apply)
3. How often is the FDA-approved dosing for
PrEP?
4. Which of the following might make a
doctor question prescribing PrEP?
5. How often should individuals be tested for
HIV while taking PrEP?
6. How often should patients be followed for
medication side effects after starting
PrEP?
1. PrEP can be a cost-effective HIV
prevention intervention if used with an
appropriate population of patients.
Q31_1
2. PrEP is too costly to warrant its use. (R)
Q31_2
3. Individuals who are at risk for HIV should
be encouraged to use condoms rather
than to take PrEP. (R) Q31_3
4. Individuals who take PrEP are likely to
increase their sexual risk behaviors and
negate the benefits of PrEP. (R) Q31_4
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•
•

•
•

Items in analysis
All items kept in
analysis
Missingness counted
as incorrect

All items kept in
analysis
Average value used
for missingness

Statistics
ScorePrEPAttitudesMean
N
Valid
150
Missing
0
Mean
3.7951
Median
3.8291

Self-efficacy
Case Processing Summary
N
%
Cases
Valid
150
100.0
Excludeda
0
.0
Total
150
100.0
a. Listwise deletion based on all variables in
the procedure.

Scale Statistics
Mean
26.6847

Std.
N of
Variance Deviation Items
16.444
4.05514 6

Reliability Statistics
Cronbach's Cronbach's Alpha Based N of
Alpha
on Standardized Items
Items
.865
.876
6

5. Money should not be spent on HIV
prevention for men who have sex with
men. (R) Q31_5
6. There is insufficient evidence at this time
for me to consider PrEP an appropriate
preventive treatment option. (R) Q31_6
7. Widespread use of PrEP will likely
significantly increase rates of antiretroviral
resistance. (R) Q31_7
8. Individuals who are prescribed PrEP are
not likely to adhere to their medication.
(R) Q31_8
9. Individuals who take PrEP are likely to
have increased rates of sexually
transmitted infections. R Q31_9
10. There are resources available to help
people to pay for PrEP if they cannot
afford it on their own. Q31_10
1. Determining whether a patient’s sexual
risk behaviors warrant the use of PrEP.
Q32_1
2. Determining whether a patient’s IV drug
use behaviors warrant the use of PrEP.
Q32_2
3. Discussing the efficacy of PrEP with a
patient. Q32_3
4. Discussing whether PrEP is a good option
for a patient. Q32_4
5. Discussing the potential side effects of
the antiretroviral medications used for
PrEP (emtricitabine and tenofovir,
together called Truvada) with a patient.
Q32_5
6. Following patients on PrEP to test them
for HIV. Q32_9

185

•
•

All items kept in
analysis
Average value used
for missingness

Culture

With all items:
Reliability Statistics
Cronbach's Alpha
Based on
Cronbach's Alpha
Standardized Items N of Items
.628
.647
4

With item Q19_4_Recode removed
Reliability Statistics
Cronbach's Alpha
Based on
Cronbach's Alpha
Standardized Items N of Items
.747
.761
3

• Leadership in my organization rewards
innovation and creativity. Q19_1
• Staff members in my organization have a
sense of personal responsibility for improving
the health outcomes of the people we serve.
Q19_2
• Staff members in my organization are open
to change. Q19_3
• PrEP doesn’t fit in with my organization’s
values. R Q19_4

Reliability Statistics
Cronbach's Alpha
Based on
Cronbach's Alpha
Standardized Items N of Items
.649
.656
2

• People in my organization think PrEP
could help to decrease the spread of HIV
Q19_7
• I think PrEP could help to decrease the
spread of HIV Q39_8

Relative Priority

N/A single item

•

Learning Climate

Cronbachs alpha without removing item:

Compatibility

Reliability Statistics
Cronbach's Alpha
Cronbach's Based on
N of
Alpha
Standardized Items Items
.564
.638
3

Talking about PrEP during HIV testing is
less important than talking about other
HIV prevention methods. R Q39_9
• I can decide what I should talk to clients
about when I am testing/counseling for HIV.
Q39_10
• I have an important role in HIV prevention
Q39_11
• I have an important role in educating
clients about PrEP Q39_12

With item removed:
Reliability Statistics
Cronbach's Alpha
Cronbach's Based on
N of
Alpha
Standardized Items Items
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•

PrEP doesn’t fit in
with my
organization’s values.
R Q19_4
REMOVED – by
removing it changed
the Cronbach’s alpha
from .647 to .761.
This was the only
item negatively coded
so this may have
affected the scaling.
This was also the
only item that
specifically
mentioned PrEP.

•
•

Single item
No missingness

• I can decide what I
should talk to clients
about when I am
testing/counseling for
HIV. Q39_10
REMOVED – by
removing this item
Cronbachs alpha
changed from .564 to
.743
• No missingness

.743

.773

2

Patient Needs
Reliability Statistics
Cronbach's Alpha
Based on
Cronbach's Standardized
Alpha
Items
N of Items
.776
.777
4

Cosmopolitanism
Reliability Statistics
Cronbach's Alpha
Based on
Cronbach's Alpha
Standardized Items N of Items
.829
.826
3

External policy
and incentives

Reliability Statistics
Cronbach's Alpha
Based on
Cronbach's Standardized
Alpha
Items
N of Items
.769
.773
3

• Leadership at my organization seeks ways • 1 item missing for
to improve client education about HIV.
44_13, replaced with
Q44_1
mean
• Leadership at my organization values
asking clients what they think about how our
services could be improved. Q44_2
• The clients I serve would benefit from
access to PrEP Q44_3
• The clients I serve would appreciate the
opportunity to learn about new ways to
protect themselves from HIV Q44_13
• I go to local, statewide or national
• Q49_5 missing 1,
meetings that discuss HIV prevention. Q49_5
Q49_6 missing 2;
Q49_7 missing 1
• I go to local, statewide or national
meetings that discuss PrEP. Q49_6
• If a client asked me about places they
could go to get a PrEP prescription, I would
know clinics or organizations to suggest.
Q49_7
• National PrEP guidelines (such as those
• Q44_12 missing 3
from the CDC) have impacted my view on
participants, used mean
PrEP implementation during HIV testing
to replace
Q44_10
• Internal organization guidelines have
impacted my view on PrEP implementation
during HIV testing Q44_11
• International guidelines (such as those
from the WHO) have impacted my view on
PrEP implementation during HIV testing
Q44_12
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Scale
Complexity

Scale Cronbach’s Alpha
Reliability Statistics
Cronbach's Alpha
Based on
Cronbach's Alpha
Standardized Items N of Items
.708
.735
2

Evidence
Reliability Statistics
Cronbach's Alpha
Based on
Cronbach's Standardized
Alpha
Items
N of Items
.796
.797
3

Relative
advantage

Reliability Statistics
Cronbach's Alpha
Based on
Cronbach's Alpha
Standardized Items N of Items
.870
.870
2

Items in survey
• Referring a client to a place where they
could talk to a provider about PrEP would be
too complicated. (reverse coded)
Q17_7 New: Q17_7_Recode
• Talking to clients about PrEP during HIV
testing would be too complicated. (reverse
coded) Q17_8 New: Q17_8_Recode
• There is good research that shows PrEP
can reduce HIV transmission. Q17_1
• Talking to my client about PrEP during HIV
testing would result in fewer new cases of
HIV in my community. Q17_2
• Talking to my client about PrEP during HIV
testing would result in more people in my
community taking PrEP daily for HIV
prevention Q17_3
More research is needed to determine if PrEP
can reduce the risk of HIV transmission.
(reverse coded) Q17_4 New variable
Q17_4_Recode
• Talking about PrEP during HIV
testing/counseling has more advantages
than disadvantages. Q17_5
• Referring people to where they can get a
prescription for PrEP during the HIV
testing/counseling has more advantages
than disadvantages. Q17_6
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•

Items in analysis
No missingness

•

4 missing, replaced
with mean

•

No missingness

APPENDIX F: QUALITATIVE INSTRUMENT
A completed interview guide with all possible constructs is listed below.
Core questions to be included with all participants:
•
•
•
•
•
•
•
•
•
•
•
•
•

Tell me about the area your organization is in – is it a high prevalence area, low prevalence?
Describe the type of clients you normally see – high income, low income, men, women,
LGBT populations? What type of people do you generally serve?
What types of HIV prevention methods do people in your community prefer?
Tell me about what your community thinks of PrEP? What about other organizations
outside of the one you work for?
Are you aware of any policies surrounding PrEP – in the government, etc.?
Has administration, or anyone in your org, ever said what they think about PrEP?
Does your organization have any trainings, etc. about HIV testing? What about PrEP?
Have any clients ever talked to you about using PrEP?
What do you personally think about PrEP? Is it a worthwhile prevention option, or not so
great?
Is PrEP better or worse than other prevention methods?
What do you, personally, know about PrEP? What makes it easy for you to talk about PrEP
during HIV testing?
What makes it hard? How confident are you in your knowledge to navigate the system – and
help a client to navigate the system to end up talking to someone about a PrEP referral?
What makes it difficult or easy for your clients to get access to PrEP?

Additional questions to include, as needed and appropriate:
OUTPUT FROM CFIR TECHNICAL ASSISTANCE WEBSITE (Damschroder, 2016)
Welcome to the Interview Guide Tool
•
•
•

•

Choose Interview Questions: Choose this option to select domains, constructs,
questions for your customized interview guide.
Get Guide: Choose this option after you've selected all the questions you want.
Then follow the instructions for copying your guide to a word processor.
Start Over: Your question choices are cumulative. You can choose some
questions, get a guide, then choose more questions. The ensuing guide will
contain ALL the questions you've chosen during the session - unless you click
"Start Over".
Main Site: Choose this option to return to the main CFIR site.
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Intervention Characteristics
Evidence Strength & Quality What kind of information or evidence are you aware of that
shows whether or not the intervention will work in your setting?
o

What evidence have you heard about from your own research? Practice
guidelines? Published literature? Co-workers? Other settings?
o How does this knowledge affect your perception of the intervention?
2. In a healthcare setting, influential stakeholders may include influential and wellrespected clinicians, where as in an education setting, this may include influential and
well-respected teachers or educators.
What do influential stakeholders think of the intervention?
o What do administrative or other leaders think of the intervention?

Relative Advantage Is there another intervention that people would rather implement?
you describe that intervention? Why would people prefer the alternative?

Can

Design Quality & Packaging
1. What supports, such as online resources, marketing materials, or a toolkit, are available
to help you implement and use the intervention?
o How do you access these materials?
2. How will available materials affect implementation in your setting?
Cost
1. What costs will be incurred to implement the intervention?
Outer Setting
•
•
•
•
•
•
•
•
•
•

Tell me about the area your organization is in – is it a high prevalence area, low prevalence?
Describe the type of clients you normally see – high income, low income, men, women,
LGBT populations? What type of people do you generally serve?
What types of HIV prevention methods do people in your community prefer?
Has anyone ever talked to you about using PrEP?
What do you personally think about PrEP? Is it a worthwhile prevention option, or not so
great?
Is PrEP better or worse than other prevention methods?
Has administration, or anyone in your org, ever said what they think about PrEP?
Does your organization have any trainings, etc. about HIV testing? What about PrEP?
Tell me about what your community thinks of PrEP? What about other organizations
outside of the one you work for?
Are you aware of any policies surrounding PrEP – in the government, etc.?
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Patient Needs & Resources
1. To what extent is staff aware of the needs and preferences of the individuals being
served by your organization?
o How "in touch" are staff and leadership with the individuals served by your
organization?
2. To what extent were the needs and preferences of the individuals served by your
organization considered when deciding to implement the intervention?
o Can you describe specific examples?
o Will the intervention be altered to meet their needs and preferences?
3. How well do you think the intervention will meet the needs of the individuals served by
your organization?
o In what ways will the intervention meet their needs? E.g. improved access to
services? Reduced wait times? Help with self-management? Reduced travel time
and expense?
4. How do you think the individuals served by your organization will respond to the
intervention?
5. What barriers will the individuals served by your organization face to participating in the
intervention?
6. Have you elicited information from participants regarding their experiences with the
intervention?
o What are their perceptions of the intervention?
o Can you describe what kind of specific information you have heard?
7. Have you heard stories about the experiences of participants with the intervention?
o Can you describe a specific story?
Cosmopolitanism
1. To what extent do you network with colleagues or people in similar professions/positions
outside your setting?
o What are the venues?
2. What kind of information exchange do you have with others outside your setting, either
related to the intervention, or more generally about your profession?
o What professional networking do you engage in? Listservs? Local or national
conferences? Trainings?
Peer Pressure
1. Can you tell me what you know about any other organizations that have implemented
the intervention or other similar programs?
o How has this information influenced the decision to implement the intervention?
2. To what extent are other organizations implementing the intervention?
o How does this affect support for implementing the intervention in your setting?
3. To what extent would implementing the intervention provide an advantage for your
organization compared to other organizations in your area?
o Is there a competitive advantage?
o Is there something about the intervention that would bring more individuals into
your organization, instead of another one in your area?
o

191

External Policies & Incentives
1. What kind of local, state, or national performance measures, policies, regulations, or
guidelines influenced the decision to implement the intervention?
o How will the intervention affect your organization's ability to meet these
measures, policies, regulations, or guidelines?
2. What kind of financial or other incentives influenced the decision to implement the
intervention?
o How will the intervention affect your organization's ability to receive these
incentives?
o How will the new intervention affect payment or revenue for your organization?
Inner Setting
Structural Characteristics How big is your organization? Do you have any policies in place
about whether or not staff can talk about PrEP during HIV testing?
1. How will the infrastructure of your organization (social architecture, age, maturity, size,
or physical layout) affect the implementation of the intervention?
o How will the infrastructure facilitate/hinder implementation of the intervention?
o How will you work around structural challenges?
2. What kinds of infrastructure changes will be needed to accommodate the intervention?
o Changes in scope of practice? Changes in formal policies? Changes in
information systems or electronic records systems? Other?
o What kind of approvals will be needed? Who will need to be involved?
o Can you describe the process that will be needed to make these changes?
Networks & Communications How do you typically find out about new information, such as
new initiatives, accomplishments, issues, new staff, staff departures? When you need to get
something done or to solve a problem, who are your "go-to" people?
Implementation Climate How do people in your organization feel about PrEP? What about
talking about PrEP during HIV testing?
1. This question is likely to uncover topics to explore more within other sub-constructs, but
be attentive to other themes that may not be included in your assessment.
What is the general level of receptivity in your organization to implementing the
intervention?
o

Why?

Compatibility How well does the intervention fit with your values and norms and the values
and norms within the organization? Can you describe how the intervention will be integrated
into current processes? How will it interact or conflict with current programs or processes?
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Leadership Engagement
1. What level of involvement has leadership at your organization had so far with the
intervention?
o Do they know about the intention to implement the intervention?
o Who are these leaders? How do attitudes of different leaders vary?
o What kind of support have they given you? Can you provide specific examples?
2. What kind of support or actions can you expect from leaders in your organization to help
make implementation successful?
o Who are these leaders? How do attitudes of different leaders vary?
o Do they know about the intention to implement the intervention?
o What kind of support can you expect going forward? Can you provide specific
examples?
o What types of barriers might they create?
Access to Knowledge & Information
1. What kind of training is planned for you? For colleagues?
o Do you feel the training will prepare you to carry out the roles and responsibilities
expected of you? Can you explain?
o What are the positive aspects of planned training?
o What is missing?
o What kind of continued training is planned?
2. What kinds of information and materials about the intervention have already been made
available to you? What types of things would you need?
o Copies of materials?
o Personal contact?
o Internal information sharing; e.g., staff meetings?
o Has it been timely? Relevant? Sufficient?
3. Who do you ask if you have questions about the intervention or its implementation?
o How available are these individuals?
Characteristics of Individuals
•
•

What do you, personally, know about PrEP? What makes it easy for you to talk about PrEP
during HIV testing?
What makes it hard? How confident are you in your knowledge to navigate the system – and
help a client to navigate the system to end up talking to someone about a PrEP referral?

Knowledge & Beliefs about the Intervention
1. What do you know about the intervention or its implementation?
2. Do you think the intervention will be effective in your setting?
o Why or why not?
3. At what stage of implementation is the intervention at in your organization?
o How do you think the program is going?
o Why do you say that?
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Self-efficacy
1. How confident are you that you will be able to successfully implement the intervention?
o What gives you that level of confidence (or lack of confidence)?
2. How confident are you that you will be able to use the intervention?
o What gives you that level of confidence (or lack of confidence)?
3. How confident do you think your colleagues feel about implementing the intervention?
o What gives them that level of confidence (or lack of confidence)?
4. How confident do you think your colleagues feel about using the intervention?
o What gives them that level of confidence (or lack of confidence)?

194

APPENDIX G: USF IRB APPROVAL LETTER

February 13, 2018
DeAnne Turner
Community and Family Health
Tampa, FL 33612
RE:
IRB#:
Title:

Expedited Approval for Initial Review
Pro00030102
Views of Staff Performing HIV Testing and Counseling

Study Approval Period: 2/13/2018 to 2/13/2019
Dear Ms. Turner:
On 2/13/2018, the Institutional Review Board (IRB) reviewed and APPROVED the
above application and all documents contained within, including those outlined
below.
Approved Item(s):
Protocol Document(s):
Study Protocol V1

Consent/Assent Document(s)*:
Online Survey & Interview V1 2.9.18.docx
Verbal Survey & Interview V1 2.9.18.docx
*Please use only the official IRB stamped informed consent/assent document(s) found
under the "Attachments" tab. Please note, these consent/assent documents are valid until
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the consent document is amended and approved. The Online and Verbal consents are not
stamped forms.
It was the determination of the IRB that your study qualified for expedited review which
includes activities that (1) present no more than minimal risk to human subjects, and (2)
involve only procedures listed in one or more of the categories outlined below. The IRB
may review research through the expedited review procedure authorized by 45CFR46.110.
The research proposed in this study is categorized under the following expedited review
category:
(6) Collection of data from voice, video, digital, or image recordings made for research
purposes.
(7) Research on individual or group characteristics or behavior (including, but not limited to,
research on perception, cognition, motivation, identity, language, communication, cultural
beliefs or practices, and social behavior) or research employing survey, interview, oral history,
focus group, program evaluation, human factors evaluation, or quality assurance
methodologies.
Your study qualifies for a waiver of the requirements for the documentation of informed
consent as outlined in the federal regulations at 45CFR46.117(c) which states that an IRB may
waive the requirement for the investigator to obtain a signed consent form for some or all
subjects if it finds either: (1) That the only record linking the subject and the research would
be the consent document and the principal risk would be potential harm resulting from a
breach of confidentiality. Each subject will be asked whether the subject wants documentation
linking the subject with the research, and the subject's wishes will govern; or (2) That the
research presents no more than minimal risk of harm to subjects and involves no procedures
for which written consent is normally required outside of the research context. (Online and
Verbal consents).
As the principal investigator of this study, it is your responsibility to conduct this study in
accordance with IRB policies and procedures and as approved by the IRB. Any changes to
the approved research must be submitted to the IRB for review and approval via an
amendment. Additionally, all unanticipated problems must be reported to the USF IRB
within five (5) calendar days.
We appreciate your dedication to the ethical conduct of human subject research at the
University of South Florida and your continued commitment to human research protections. If
you have any questions regarding this matter, please call 813-974-5638.
Sincerely,
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John Schinka, Ph.D.,
Chairperson USF Institutional
Review Board
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